| 1,4-DIHYDROPYRIDINE BINDING ACTIVITY | 1 |
| 12-HETE SYNTHESIS INHIBITION | 16 |
| 12-HETE SYNTHESIS STIMULATION | 15 |
| 12-HHT SYNTHESIS INHIBITION | 1 |
| 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE INHIBITION | 2 |
| 17-BETA-HYDROXYSTEROID OXIDOREDUCTASE INHIBITION | 55 |
| 2'-3'-CYCLIC NUCLEOTIDE 3'-PHOSPHOHYDROLASE STIMULATION | 2 |
| 2-CHLORODEOXYADENOSIDE INFLUX STIMULATION | 1 |
| 25-HYDROXY-VITAMIN D3-24-HYDROXYLASE INHIBITION | 1 |
| 3-HYDROXYACETYL-COA-DEHYDROGENASE INHIBITION | 2 |
| 3-HYDROXYBENZO[A]PYRENE INHIBITION | 2 |
| 5-ADENOSYLHOMOCYSTEINE HYDROLASE INHIBITION | 1 |
| 5-ALPHA-ANDROSTANE-3-ALPHA-17-BETA-DIOL FORMATION | 1 |
| 5-AMINOLEUVULINATE DEHYDRATASE INHIBITION | 1 |
| 5-HETE SYNTHESIS INHIBITION | 26 |
| 5-HYDROXYINDOLE-3-ACETALDEHYDE STIMULATION | 4 |
| 5-HYDROXYINDOLE-3-ACETIC ACID INHIBITION | 4 |
| 8-HETE SYNTHESIS INHIBITION | 1 |
| [14-C]-GLUCOSE INCORPORATION INTO HEPATIC GLYCOGEN INCREASE | 2 |
| ABERRANT CRYPT FOCI SUPPRESSION | 3 |
| ABORTIFACIENT EFFECT | 5054 |
| ABSORPTION DECREASE EFFECT | 19 |
| ABSORPTION EFFECTS(CUTANEOUS) | 93 |
| ABSORPTION ENHANCEMENT EFFECT | 64 |
| AC-AC-CO-A LIGASE STIMULATION | 2 |
| AC-AC-CO-A THIOLASE STIMULATION | 2 |
| ACANTHOLYSIS ACTIVITY | 1 |
| ACARICIDAL ACTIVITY | 68 |
| ACETANILIDE 4-HYDROXYLASE INHIBITION | 11 |
| ACETANILIDE 4-HYDROXYLASE STIMULATION | 4 |
| ACETOHEXAMIDE REDUCTASE INHIBITION | 3 |
| ACETOLACTATE SYNTHASE INHIBITION | 1 |
| ACETYL CO-A CARBOXYLASE INHIBITION | 25 |
| ACETYL CO-A CARBOXYLASE STIMULATION | 5 |
| ACETYL CO-A SYNTHASE INHIBITION | 12 |
| ACETYLATION INHIBITION | 2 |
| ACETYLCHOLINE ANTAGONIST ACTIVITY | 18 |
| ACETYLCHOLINE RECEPTOR BINDING | 3 |
| ACETYLCHOLINESTERASE INDUCTION | 14 |
| ACETYLCHOLINESTERASE INHIBITION | 744 |
| ACETYLCHOLINESTERASE MATURATION INDUCTION | 1 |
| ACETYLGLUCOSAMINIDASE STIMULATION | 1 |
| ACETYLGLUCOSEAMINIDASE INHIBITION | 15 |
| ACETYLTRANSFERASE(CHLORAMPHENICOL) STIMULATION | 1 |
| ACETYLTRANSFERASE(CHLORAMPHENICOL)INHIBITION | 3 |
| ACETYLTRANSFERASE(PAF) INHIBITION | 15 |
| ACH ESTERASE INDUCTION | 4 |
| ACH LEVEL DECREASE | 5 |
| ACH LEVEL INCREASE | 5 |
| ACH RECEPTOR BINDING INHIBITION | 10 |
| ACH RECEPTOR BLOCKING EFFECT | 47 |
| ACH RECEPTOR CLUSTER INHIBITION | 4 |
| ACH RECEPTOR DESENSITIZING EFFECT | 1 |
| ACH RELEASE INHIBITION | 19 |
| ACH RELEASE STIMULATION | 24 |
| ACH SYNTHESIS INHIBITION | 0 |
| ACH SYNTHESIS STIMULATION | 0 |
| ACID CATHEPSIN INHIBITION | 1 |
| ACID DEOXYRIBONUCLEASE INHIBITION | 2 |
| ACID DEOXYRIBONUCLEASE STIMULATION | 4 |
| ACID NEUTRALIZATION ACTIVITY | 9 |
| ACID PHOSPHATASE INHIBITION | 157 |
| ACID PHOSPHATASE STIMULATION | 89 |
| ACID PRODUCTION DECREASE | 5 |
| ACID RIBONUCLEASE INHIBITION | 67 |
| ACID RIBONUCLEASE STIMULATION | 2 |
| ACIDIFYING ACTIVITY | 14 |
| ACROSIN INHIBITION | 90 |
| ACROSOME REACTION ENHANCEMENT | 9 |
| ACROSOME REACTION INHIBITION | 2 |
| ACTH LEVEL DECREASE | 10 |
| ACTH LEVEL INCREASE | 10 |
| ACTH-INDUCTION | 44 |
| ACTIN DISTRIBUTION ALTERATION | 8 |
| ACTIN POLYMERIZATION INHIBITION | 32 |
| ACTIN POLYMERIZATION STIMULANT | 13 |
| ACTIN-BINDING EFFECT | 5 |
| ACTION POTENTIAL DURATION INCREASE | 19 |
| ACTIVATOR PROTEIN 1 INHIBITION | 35 |
| ACTIVATOR PROTEIN 1 STIMULATION | 14 |
| ACTIVATOR PROTEIN-1 BINDING INHIBITION | 1 |
| ACTOMYOSIN INHIBITION | 1 |
| ACYL COA:CHOLESTEROL ACYL TRANSFERASE INHIBITION | 45 |
| ACYL COA:CHOLESTEROL ACYL TRANSFERASE STIMULATION | 1 |
| ACYL-CO-A:CHOLESTEROL ACYLTRANSERASE INHIBITION | 122 |
| ACYL-COA OXIDASE STIMULATION | 3 |
| ACYL-T-RNA-SYNTHETASE INHIBITION | 1 |
| ACYL-T-RNA-SYNTHETASE STIMULATION | 3 |
| ACYLATED HOMOSERINE LACTONE(AHL) INDUCTION | 1 |
| ADAPTOGENIC ACTIVITY | 67 |
| ADENINE NUCLEOTIDE TRANSLOCASE INHIBITION | 4 |
| ADENINE NUCLEOTIDE TRANSLOCASE STIMULATION | 3 |
| ADENINE RELEASE STIMULATION | 2 |
| ADENOSIDE LEVEL DECREASE | 1 |
| ADENOSINE A-1 RECEPTOR BINDING INHIBITION | 54 |
| ADENOSINE A1 RECEPTOR AGONIST ACTIVITY | 12 |
| ADENOSINE A2 RECEPTOR BINDING INHIBITION | 9 |
| ADENOSINE DEAMINASE INHIBITION | 75 |
| ADENOSINE DEAMINASE STIMULATION | 3 |
| ADENOSINE KINASE INHIBITION | 4 |
| ADENOSINE NUCLEOTIDE RELEASE INHIBITION | 7 |
| ADENOSINE NUCLEOTIDE RELEASE STIMULATION | 2 |
| ADENOSINE RECEPTOR ANTAGONIST | 14 |
| ADENOSINE RECEPTOR BINDING ENHANCEMENT | 4 |
| ADENOSINE RECEPTOR BINDING INHIBITION | 84 |
| ADENOSINE RELEASE STIMULATION | 1 |
| ADENOSINE TRIPHOSPHATASE STIMULATION | 3 |
| ADENOSINE UPTAKE INHIBITION | 9 |
| ADENOSINE-TRIPHOSPHATE-CITRATE LYASE INHIBITION | 6 |
| ADENOSYL METHIONINE DECARBOXYLASE INHIBITION | 8 |
| ADENOSYL METHIONINE TRANSFERASE INHIBITION | 2 |
| ADENOSYL METHIONINE TRANSFERASE STIMULATION | 1 |
| ADENYL CYCLASE INHIBITION | 84 |
| ADENYL CYCLASE STIMULATION | 88 |
| ADENYLATE KINASE INHIBITION | 4 |
| ADHERENCE INHIBITION (BACTERIA TO GLASS) | 2 |
| ADHERENCE INHIBITION(BACTERIA TO HOST CELLS) | 74 |
| ADHESIVE ACTIVITY | 2 |
| ADIPOCYTE CONVERSION INHIBITION | 14 |
| ADIPOGENESIS INHIBITION | 3 |
| ADIPOKINETIC ACTIVITY | 15 |
| ADIPONECTIN MODULATORY EFFECT | 1 |
| ADIPONECTIN SECRETION INHIBITION | 4 |
| ADIPSIC EFFECT | 2 |
| ADJUVANT ACTIVITY | 21 |
| ADP-ATP EXCHANGE ACTIVITY INHIBITION | 1 |
| ADP-RIBOSYLATION STIMULATION | 1 |
| ADP/ATP TRANSPORT INHIBITION | 1 |
| ADRENAL HYPERTROPHY EFFECT | 13 |
| ADRENERGIC AGONIST(ALPHA) | 11 |
| ADRENERGIC AGONIST(ALPHA-1) ACTIVITY | 5 |
| ADRENERGIC AGONIST(ALPHA-2) ACTIVITY | 10 |
| ADRENERGIC AGONIST(BETA) | 20 |
| ADRENERGIC RECEPTOR BLOCKER(ALPHA) | 39 |
| ADRENERGIC RECEPTOR BLOCKER(ALPHA-1) | 86 |
| ADRENERGIC RECEPTOR BLOCKER(ALPHA-2) | 189 |
| ADRENERGIC RECEPTOR BLOCKER(BETA) | 58 |
| ADRENERGIC RECEPTOR(ALPHA-1) RECEPTOR BINDING INHIBITION | 10 |
| ADRENERGIC RECEPTOR(ALPHA-1-A) RECEPTOR STIMULATION | 4 |
| ADRENERGIC RECEPTOR(ALPHA-2) RECEPTOR BINDING INHIBITION | 8 |
| ADRENERGIC RECEPTOR(BETA) DOWN REGULATION INHIBITION | 4 |
| ADRENERGIC RECEPTOR(BETA) RECEPTOR BINDING INHIBITION | 3 |
| ADRENERGIC RECEPTOR(BETA-3) RECEPTOR STIMULATION | 3 |
| ADRENERGIC(ALPHA-2) RECEPTOR BINDING ACTIVITY | 51 |
| ADRENERGIC(BETA) RECEPTOR DOWN-REGULATION STIMULATION | 9 |
| ADRENOLYTIC(UNSPEC) | 30 |
| ADULT RESPIRATORY DISTRESS SYNDROME(ARDS) INDUCTION | 1 |
| AFLATOXIN ACTIVATION | 6 |
| AFLATOXIN B-1 OXIDATION INHIBITION | 2 |
| AFLATOXIN B1 METABOLISM INHIBITION | 3 |
| AFLATOXIN B1-DNA ADDUCT FORMATION INHIBITION | 11 |
| AFLATOXIN INACTIVATION | 47 |
| AFLATOXIN PRODUCTION INHIBITION | 49 |
| AGGLUTININ ACTIVITY | 342 |
| AGGRESSIVE BEHAVIOR INCREASE | 6 |
| AIDS THERAPEUTIC EFFECTS | 62 |
| AKT ACTIVATION INHIBITION | 2 |
| ALANINE AMINOTRANSFERASE INHIBITION | 147 |
| ALANINE AMINOTRANSFERASE STIMULATION | 75 |
| ALANINE RACEMASE INHIBITION | 26 |
| ALANINE TRANSAMINASE INHIBITION | 12 |
| ALANINE TRANSAMINASE LEVEL DECREASE | 11 |
| ALANINE TRANSAMINASE LEVEL INCREASE | 11 |
| ALANYL AMINOPEPTIDASE INHIBITION | 2 |
| ALANYL AMINOPEPTIDASE STIMULATION | 0 |
| ALBUMIN LEVEL INCREASE | 7 |
| ALCOHOL DEHYDROGENASE INHIBITION | 122 |
| ALCOHOL DEHYDROGENASE STIMULATION | 34 |
| ALCOHOL INTAKE DECREASE | 1 |
| ALCOHOL WITHDRAWAL SYMPTOMS INHIBITION | 11 |
| ALDEHYDE DEHYDROGENASE INHIBITION | 105 |
| ALDEHYDE DEHYDROGENASE STIMULATION | 20 |
| ALDEHYDE OXIDASE INHIBITION | 21 |
| ALDEHYDE REDUCTASE I INHIBITION | 24 |
| ALDOL REDUCTASE(LENS) INHIBITION | 253 |
| ALDOL REDUCTASE(LENS) STIMULATION | 2 |
| ALDOLASE INHIBITION | 39 |
| ALDOLASE STIMULATION | 5 |
| ALDOSE REDUCTASE INHIBITION | 811 |
| ALDOSE REDUCTASE STIMULATION | 1 |
| ALDOSTERONE AGONIST ACTIVITY | 19 |
| ALDOSTERONE ANTAGONIST | 16 |
| ALDOSTERONE DECREASE | 10 |
| ALDOSTERONE LEVEL INCREASE | 1 |
| ALDOSTERONE SYNTHESIS STIMULATION | 1 |
| ALDRIN EPOXIDASE INHIBITION | 6 |
| ALDRIN EPOXIDASE STIMULATION | 10 |
| ALGESIC ACTIVITY | 3 |
| ALGICIDAL ACTIVITY | 41 |
| ALKALINE PHOSPHATASE INHIBITION | 397 |
| ALKALINE PHOSPHATASE STIMULATION | 245 |
| ALKALINE RNASE INDUCTION | 1 |
| ALKALINE RNASE INHIBITION | 0 |
| ALKALINIZING ACTIVITY | 11 |
| ALKYLASE INHIBITION | 9 |
| ALKYLASE STIMULATION | 0 |
| ALKYLATING ACTIVITY REDUCTION | 20 |
| ALLELOPATHIC ACTIVITY | 10 |
| ALLERGENIC ACTIVITY | 861 |
| ALLOGRAFT REJECTION INHIBITION | 46 |
| ALLOSTERIC EFFECT | 1 |
| ALPHA-1-ANTIPROTEINASE INACTIVATION INHIBITION | 19 |
| ALPHA-1-ANTITRYPSIN STIMULATION | 1 |
| ALPHA-2 MACROGLOBULIN INHIBITION | 4 |
| ALPHA-ACID OXIDASE INDUCTION | 0 |
| ALPHA-ACID OXIDASE INHIBITION | 1 |
| ALPHA-AMYLASE INHIBITION | 202 |
| ALPHA-AMYLASE STIMULATION | 13 |
| ALPHA-CHYMOTRYPSIN INHIBITION | 27 |
| ALPHA-FUCOSIDASE INHIBITION | 13 |
| ALPHA-FUCOSIDASE STIMULATION | 7 |
| ALPHA-GALACTOSIDASE INHIBITION | 73 |
| ALPHA-GLUCOSIDASE INHIBITION | 400 |
| ALPHA-GLUCOSIDASE INHIBITION(LYSOSOMAL ACID) | 1 |
| ALPHA-GLUCOSIDASE STIMULATION | 4 |
| ALPHA-GLYCEROLPHOSPHATE DEHYDROGENASE INHIBITION | 7 |
| ALPHA-HYDROXY ACID DEHYDROGENASE INHIBITION | 1 |
| ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3) | 23 |
| ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4) | 22 |
| ALPHA-KETOGLUTARIC DEHYDROGENASE INHIBITION | 6 |
| ALPHA-KETOGLUTARIC DEHYDROGENASE STIMULATION | 4 |
| ALPHA-KETOGLUTARIC OXIDASE INHIBITION | 6 |
| ALPHA-KETOGLUTARIC OXIDASE STIMULATION | 0 |
| ALPHA-KETOISOCAPROATE INHIBITION | 1 |
| ALPHA-L-FUCOSIDASE INHIBITION | 25 |
| ALPHA-L-RHAMNOSIDASE INHIBITION | 7 |
| ALPHA-MANNOSIDASE INHIBITION | 139 |
| ALPHA-MANNOSIDASE STIMULATION | 6 |
| ALPHA-NAPHTHYL BUTYRATE ESTERASE STIMULATION | 2 |
| ALPHA-TOCOPHEROL DEPLETION PREVENTION | 5 |
| ALPHA-TOCOPHEROL LEVEL DECREASED | 8 |
| ALPHA-TOCOPHEROL LEVEL INCREASE | 7 |
| ALT VALUE DECREASED | 27 |
| ALT(ALANINE AMINOTRANSAMINASE) LEVEL INCREASE | 12 |
| AMBULATORY BEHAVIOR STIMULATION | 2 |
| AMIDASE ACTIVITY | 5 |
| AMINE TETRAZOLIUM REDUCTASE INHIBITION | 2 |
| AMINE UPTAKE INHIBITION | 1 |
| AMINO ACID ANTAGONIST EFFECT | 3 |
| AMINO ACID LEVEL ALTERATION | 4 |
| AMINO ACID LEVEL INCREASE | 1 |
| AMINO ACID OXIDASE ACTIVITY | 29 |
| AMINO ACID OXIDASE INHIBITION | 4 |
| AMINO ACID TRANSPORT INHIBITION | 6 |
| AMINO ACID TRANSPORT STIMULATION | 1 |
| AMINO ACID(AROMATIC)DECARBOXYLASE INHIBITION | 7 |
| AMINOACYL-T-RNA HYDROLYSIS EFFECT | 1 |
| AMINOACYL-T-RNA SYNTHETASE INHIBITION | 1 |
| AMINOACYL-T-RNA SYNTHETASE STIMULATION | 0 |
| AMINOGLYCOSIDE-2''-O-ADENYLTRANSFERASE INHIBITION | 2 |
| AMINOGUANIDINE INHIBITION | 1 |
| AMINOLEVULINATE(DELTA)SYNTHETASE INDUCTION INHIBITION | 5 |
| AMINOLEVULINIC(DELTA) ACID DEHYDRASE INHIBITION | 5 |
| AMINOLEVULINIC(DELTA) ACID SYNTHASE INDUCTION | 4 |
| AMINOPEPTIDASE A INHIBITION | 17 |
| AMINOPEPTIDASE B INHIBITION | 60 |
| AMINOPEPTIDASE I INHIBITION | 3 |
| AMINOPEPTIDASE II INHIBITION | 2 |
| AMINOPEPTIDASE M INHIBITION | 22 |
| AMINOPEPTIDASE N INHIBITION | 16 |
| AMINOPEPTIDASE W INHIBITION | 3 |
| AMINOPYRINE-N-DEMETHYLASE INDUCTION | 124 |
| AMINOPYRINE-N-DEMETHYLASE INHIBITION | 116 |
| AMINOTRANSFERASE (ALT) INHIBITION | 4 |
| AMINOTRANSFERASE (AST) INHIBITION | 5 |
| AMP DEAMINASE STIMULATION | 1 |
| AMPHETAMINE-LIKE RELEASING EFFECT | 13 |
| AMYLASE ACTIVITY ENHANCED | 10 |
| AMYLASE INHIBITION | 68 |
| AMYLASE RELEASE INHIBITION | 3 |
| AMYLASE RELEASE STIMULATION | 17 |
| AMYLOGLUCOSIDASE INHIBITION | 36 |
| AMYLOGLUCOSIDASE STIMULATION | 0 |
| AMYLOID-BETA AGGREGATION INHIBITION | 2 |
| AMYOTROPHIC LATERAL SCLEROSIS DISEASE TREATMENT | 1 |
| ANABOLIC ACTIVITY | 56 |
| ANABOLIC STEROID ACTIVITY | 1 |
| ANALEPTIC ACTIVITY | 17 |
| ANALGESIC ACTIVITY | 12299 |
| ANANDAMIDE BIOSYNTHESIS STIMULATION | 1 |
| ANAPHRODISIAC EFFECTS | 82 |
| ANAPHYLACTIC RESPONSE | 45 |
| ANDROGEN RECEPTOR INHIBITION | 3 |
| ANDROGENIC EFFECT | 139 |
| ANDROGENIC RECEPTOR BINDING ACTIVITY | 36 |
| ANDROSTENEDIONE 6-BETA-HYDROXYLASE INHIBITION | 5 |
| ANEMIA PRODUCING ACTIVITY | 7 |
| ANESTHETIC ACTIVITY(GENERAL) | 20 |
| ANESTHETIC ACTIVITY(LOCAL) | 378 |
| ANESTHETIC ACTIVITY(UNSPEC) | 35 |
| ANEUPLOIDY INHIBITION | 0 |
| ANGIOGENESIS INDUCTION | 18 |
| ANGIOGENESIS INHIBITION | 269 |
| ANGIOPROTECTIVE ACTIVITY | 14 |
| ANGIOTENSIN CONVERTING ENZYME INHIBITION | 1 |
| ANGIOTENSIN CONVERTING ENZYME STIMULATION | 4 |
| ANGIOTENSIN I INCREASE | 1 |
| ANGIOTENSIN II RECEPTOR BINDING ACTIVITY | 4 |
| ANGIOTENSIN II RECEPTOR BINDING INHIBITION | 21 |
| ANGIOTENSIN-CONVERTING ENZYME INHIBITION | 1110 |
| ANGIOTENSIN-II INHIBITION | 306 |
| ANILINE HYDRASE INHIBITION | 38 |
| ANILINE HYDROXYLASE INDUCTION | 97 |
| ANILINE HYDROXYLASE INHIBITION | 63 |
| ANIMOCYCLOPROPANE-1-CARBOXYLIC ACID SYNTHASE ACTIVITY INHIB | 1 |
| ANOREXIC ACTIVITY | 90 |
| ANOXIA TOLERANCE DECREASED | 0 |
| ANOXIA TOLERANCE INCREASED | 16 |
| ANTACID ACTIVITY | 59 |
| ANTHELMINTIC ACTIVITY | 2734 |
| ANTHERIDIA INDUCTION | 4 |
| ANTHOCYANIN PRODUCTION INHIBITION | 3 |
| ANTHRANILATE SYNTHASE ACTIVITY | 0 |
| ANTI-HB-E-AG ACTIVITY | 5 |
| ANTI-HB-S-AG ACTIVITY | 8 |
| ANTI-MOTION SICKNESS EFFECT | 6 |
| ANTI-OCCLUSIVE ARTERIAL DISEASE | 1 |
| ANTI-PREGNANT MARE SERUM GONADOTROPIN ACTIVITY | 101 |
| ANTI-QUORUM SENSING ACTIVITY | 1 |
| ANTI-RHINITIC EFFECT | 5 |
| ANTI-STROKE ACTIVITY | 10 |
| ANTIACNE ACTIVITY | 81 |
| ANTIACTIN DEPOLYMERIZATION ACTIVITY | 5 |
| ANTIACTIN DESTABILIZATION ACTIVITY | 2 |
| ANTIACTIN PROTEOLYSIS ACTIVITY | 2 |
| ANTIADHESION EFFECT | 276 |
| ANTIAGGLUTININ ACTIVITY | 16 |
| ANTIAGGRESSION EFFECT | 34 |
| ANTIAGING ACTIVITY | 67 |
| ANTIALCOHOLIC ACTIVITY | 99 |
| ANTIALGAL ACTIVITY | 674 |
| ANTIALLERGENIC ACTIVITY | 756 |
| ANTIALLERGIC ENCEPHALOMYELOCYTIC ACTIVITY | 3 |
| ANTIALTITUDE SICKNESS ACTIVITY | 7 |
| ANTIALZHEIMER'S ACTIVITY | 48 |
| ANTIAMEBIC ACTIVITY | 1252 |
| ANTIAMNESIC ACTIVITY | 81 |
| ANTIAMPHETAMINE ACTIVITY | 44 |
| ANTIAMYLOIDOGENIC ACTIVITY | 3 |
| ANTIAMYLOIDOSIS ACTIVITY | 7 |
| ANTIANALGESIC ACTIVITY | 47 |
| ANTIANAPHYLACTIC ACTIVITY | 377 |
| ANTIANCYLOSTOMIASIS ACTIVITY | 110 |
| ANTIANDROGENIC EFFECT | 196 |
| ANTIANESTHETIC EFFECT | 7 |
| ANTIANGINAL ACTIVITY | 233 |
| ANTIANGIOGENIC ACTIVITY | 96 |
| ANTIANNELID ACTIVITY | 0 |
| ANTIANOPHELES ACTIVITY | 14 |
| ANTIANOREXIC ACTIVITY | 9 |
| ANTIANXIETY EFFECT | 51 |
| ANTIAPLASTIC ANEMIA ACTIVITY | 14 |
| ANTIARACHNID ACTIVITY | 1 |
| ANTIARRHYTHMIC ACTIVITY | 624 |
| ANTIASCARIASIS ACTIVITY | 134 |
| ANTIASTHMATIC ACTIVITY | 1289 |
| ANTIATHEROGENIC ACTIVITY | 8 |
| ANTIATHEROSCLEROTIC ACTIVITY | 185 |
| ANTIATOPIC DERMATITIS ACTIVITY | 10 |
| ANTIAUXIN-LIKE ACTIVITY | 10 |
| ANTIBACTERIAL ACTIVITY | 132462 |
| ANTIBACTERIAL ACTIVITY(PLANT PATHOGEN) | 566 |
| ANTIBACTERIAL ANTAGONIST EFFECT | 6 |
| ANTIBACTERIOPHAGE ACTIVITY | 282 |
| ANTIBACTERIURIA ACTIVITY | 2 |
| ANTIBIOTIC INDUCING ACTIVITY | 10 |
| ANTIBODY ACTIVITY ENHANCEMENT | 31 |
| ANTIBODY BINDING INHIBITION | 9 |
| ANTIBODY CONJUGATION ACTIVITY | 1 |
| ANTIBODY FORMATION ENHANCEMENT | 75 |
| ANTIBODY FORMATION SUPPRESSION | 78 |
| ANTIBOTULISM ACTIVITY | 2 |
| ANTIBRADYCARDIA ACTIVITY | 9 |
| ANTIBRADYKININ ACTIVITY | 24 |
| ANTIBURN EFFECT | 310 |
| ANTICARDIOTOXIC EFFECT | 21 |
| ANTICARIES ACTIVITY | 106 |
| ANTICATALEPTIC ACTIVITY | 13 |
| ANTICATARACT ACTIVITY | 85 |
| ANTICELLULITE EFFECT | 18 |
| ANTICERCARIAL ACTIVITY | 79 |
| ANTICEREBRAL EDEMA ACTIVITY | 9 |
| ANTICESTODAL ACTIVITY | 91 |
| ANTICHOLERETIC ACTIVITY | 18 |
| ANTICHOLESTATIC ACTIVITY | 21 |
| ANTICHOLINERGIC ACTIVITY | 240 |
| ANTICIRRHOTIC ACTIVITY | 7 |
| ANTICLASTOGENIC ACTIVITY | 319 |
| ANTICOAGULANT ACTIVITY | 751 |
| ANTICOCCIDIAL ACTIVITY | 151 |
| ANTICOMPLEMENT ACTIVITY | 547 |
| ANTICONDYLOMATA ACUMINATA | 9 |
| ANTICONVULSANT ACTIVITY | 2937 |
| ANTICRUSTACEAN ACTIVITY | 4208 |
| ANTICURARIFORM ACTIVITY | 7 |
| ANTICYTOLYTIC ACTIVITY | 18 |
| ANTICYTOTOXIC ACTIVITY | 432 |
| ANTIDANDRUFF EFFECT | 69 |
| ANTIDEAFNESS ACTIVITY | 4 |
| ANTIDEHYDRATION ACTIVITY | 8 |
| ANTIDEMENTIA ACTIVITY | 76 |
| ANTIDEPRESSANT ACTIVITY | 460 |
| ANTIDERMATITIS ACTIVITY | 12 |
| ANTIDIARRHEAL ACTIVITY | 3695 |
| ANTIDIPSETIC ACTIVITY | 13 |
| ANTIDIURETIC ACTIVITY | 123 |
| ANTIDIURETIC HORMONE DECREASE | 1 |
| ANTIDRUG-RESISTANCE ACTIVITY | 12 |
| ANTIECZEMA EFFECT | 306 |
| ANTIEDEMA ACTIVITY | 119 |
| ANTIEMBRYOTOXIC ACTIVITY | 4 |
| ANTIEMETIC ACTIVITY | 636 |
| ANTIEMPHYSEMA ACTIVITY | 2 |
| ANTIENDOTOXIC ACTIVITY | 15 |
| ANTIEPILEPTIFORM ACTIVITY | 17 |
| ANTIESTROGENIC EFFECT | 345 |
| ANTIFATIGUE ACTIVITY | 232 |
| ANTIFERTILITY ACTIVITY(MALE) | 38 |
| ANTIFERTILITY EFFECT(UNSPECIFIED) | 2119 |
| ANTIFIBRILLATORY ACTIVITY | 30 |
| ANTIFIBRINOLYTIC ACTIVITY | 74 |
| ANTIFIBROTIC ACTIVITY | 4 |
| ANTIFILARIAL ACTIVITY | 390 |
| ANTIFLUKE ACTIVITY | 33 |
| ANTIFOLIC ACID EFFECT | 8 |
| ANTIFOULING ACTIVITY | 180 |
| ANTIFSH ACTIVITY | 25 |
| ANTIFUNGAL ACTIVITY | 36103 |
| ANTIFUNGAL ACTIVITY(PLANT PATHOGENS) | 4601 |
| ANTIGALACTAGOGUE EFFECT | 113 |
| ANTIGASTRITIS ACTIVITY | 68 |
| ANTIGEN ACTIVATION INHIBITION | 19 |
| ANTIGEN EXPRESSION ENHANCEMENT | 14 |
| ANTIGEN EXPRESSION INHIBITION | 65 |
| ANTIGEN PRESENTATION INHIBITION | 22 |
| ANTIGENIC ACTIVITY | 75 |
| ANTIGIARDIASIS ACTIVITY | 112 |
| ANTIGIBBERELLIN-LIKE ACTIVITY | 6 |
| ANTIGLAUCOMIC ACTIVITY | 9 |
| ANTIGNAWING ACTIVITY | 7 |
| ANTIGONADAL ACTIVITY(INSECT) | 13 |
| ANTIGONADOTROPIN EFFECT(UNSPECIFIED) | 155 |
| ANTIGOUT ACTIVITY | 241 |
| ANTIHALITOSIS EFFECT | 21 |
| ANTIHALLUCINOGENIC ACTIVITY | 0 |
| ANTIHCG ACTIVITY | 55 |
| ANTIHEMATOPOIETIC ACTIVITY | 33 |
| ANTIHEMOLYTIC ACTIVITY | 194 |
| ANTIHEMORRHAGIC ACTIVITY | 422 |
| ANTIHEMORRHAGIC SHOCK EFFECT | 14 |
| ANTIHEMORRHOIDAL ACTIVITY | 490 |
| ANTIHEMOSTATIC ACTIVITY | 13 |
| ANTIHEMOTOXIC ACTIVITY | 6 |
| ANTIHEPATOTOXIC ACTIVITY | 4049 |
| ANTIHISTAMINE ACTIVITY | 589 |
| ANTIHYPERAZOTEMIC ACTIVITY | 2 |
| ANTIHYPERBILIRUBINEMIC ACTIVITY | 13 |
| ANTIHYPERCHOLESTEROLEMIC ACTIVITY | 1015 |
| ANTIHYPERGLYCEMIC(ANTIDIABETIC) ACTIVITY | 5832 |
| ANTIHYPERHIDROSIS ACTIVITY | 2 |
| ANTIHYPERIMMUNOGLOBULINEMIC EFFECT | 2 |
| ANTIHYPERINSULINEMIC ACTIVITY | 8 |
| ANTIHYPERKALEMIC ACTIVITY | 1 |
| ANTIHYPERKERATOSIS ACTIVITY | 6 |
| ANTIHYPERLACTACIDAEMIA ACTIVITY | 1 |
| ANTIHYPERLIPEMIC ACTIVITY | 448 |
| ANTIHYPERPLASIA ACTIVITY | 8 |
| ANTIHYPERSULPHOBROMOPHTHALEINEMIC ACTIVITY | 1 |
| ANTIHYPERTENSIVE ACTIVITY | 1539 |
| ANTIHYPERTHYROID EFFECT | 1 |
| ANTIHYPERTRIGLYCERIDEMIA EFFECT | 244 |
| ANTIHYPERTROPHIC ACTIVITY | 5 |
| ANTIHYPERURICEMIC ACITIVIY | 19 |
| ANTIHYPOACUSIS ACTIVITY | 1 |
| ANTIHYPOGLYCEMIC ACTIVITY | 16 |
| ANTIHYPOPROTEINEMIA ACTIVITY | 2 |
| ANTIHYPOTENSIVE ACTIVITY | 148 |
| ANTIHYPOTHERMIC ACTIVITY | 24 |
| ANTIHYPOTHYROID EFFECT | 5 |
| ANTIHYPOXIC EFFECT | 113 |
| ANTIIMMUNOTOXIC ACTIVITY | 1 |
| ANTIIMPLANTATION EFFECT | 1965 |
| ANTIINEBRIANT ACTIVITY | 2 |
| ANTIINFLAMMATORY ACTIVITY | 16751 |
| ANTIINVASIVE ACTIVITY | 34 |
| ANTIISCHEMIC EFFECT | 503 |
| ANTIJAUNDICE EFFECT | 163 |
| ANTIJUVENILE HORMONE ACTIVITY | 15 |
| ANTIKININ-LIKE ACTIVITY | 1 |
| ANTILEECH ACTIVITY | 14 |
| ANTILEISHMANIASIS ACTIVITY | 2631 |
| ANTILEPROTIC ACTIVITY | 489 |
| ANTILEUCORRHEA ACTIVITY | 173 |
| ANTILEUKOPENIC ACTIVITY | 89 |
| ANTILH ACTIVITY | 58 |
| ANTILIPASE ACTIVITY | 6 |
| ANTILIPOGENIC ACTIVITY | 13 |
| ANTILIPOLYTIC ACTIVITY | 105 |
| ANTILITHIC ACTIVITY | 171 |
| ANTILUPUS ACTIVITY | 19 |
| ANTIMALARIAL ACTIVITY | 9509 |
| ANTIMANIC ACTIVITY | 2 |
| ANTIMETABOLITE ACTIVITY | 4 |
| ANTIMICROBIAL ACTIVITY(UNSPECIFIED) | 224 |
| ANTIMIGRAINE EFFECT | 87 |
| ANTIMITE ACTIVITY | 29 |
| ANTIMITOGENIC ACTIVITY | 201 |
| ANTIMITOTIC ACTIVITY | 782 |
| ANTIMITOTIC ACTIVITY(PLANT CELLS) | 124 |
| ANTIMULTIPLE SCLEROSIS EFFECT | 6 |
| ANTIMUSCULAR DYSTROPHIC EFFECT | 1 |
| ANTIMUTAGENIC ACTIVITY | 5142 |
| ANTIMYASTHENIC ACTIVITY | 3 |
| ANTIMYCOBACTERIAL ACTIVITY | 7682 |
| ANTIMYCOPLASMAL ACTIVITY | 330 |
| ANTINAUSEANT EFFECT | 83 |
| ANTINEMATODAL ACTIVITY | 601 |
| ANTINEPHRITIC EFFECT | 162 |
| ANTINEPHROPTOSIS ACTIVITY | 10 |
| ANTINEPHROTOXIC | 155 |
| ANTINEUROTOXIC ACTIVITY | 136 |
| ANTINICOTINIC ACTIVITY | 14 |
| ANTINUTRITIONAL VALUE | 15 |
| ANTIOBESITY ACTIVITY | 48 |
| ANTIOSTEOPOROSIS ACTIVITY | 95 |
| ANTIOTOTOXICITY ACTIVITY | 5 |
| ANTIOXALURIA | 10 |
| ANTIOXIDANT ACTIVITY | 7338 |
| ANTIOXURIASIS ACTIVITY | 2 |
| ANTIOXYTOCIC EFFECT | 331 |
| ANTIPANCREATITIS ACTIVITY | 4 |
| ANTIPANCREATOTOXIC ACTIVITY | 16 |
| ANTIPARASITIC ACTIVITY | 427 |
| ANTIPARKINSON ACTIVITY | 25 |
| ANTIPENTYLENETETRAZOL ACTIVITY(IN VITRO) | 2 |
| ANTIPEPTIC ACTIVITY | 30 |
| ANTIPEPTIDE ACTIVITY | 1 |
| ANTIPERSPIRANT EFFECT | 18 |
| ANTIPHAGE ACTIVITY | 1640 |
| ANTIPHYTOTOXIC ACTIVITY | 5 |
| ANTIPLASMIN INHIBITION | 25 |
| ANTIPLATELET ACTIVITY | 167 |
| ANTIPLEURISY ACTIVITY | 10 |
| ANTIPOLYDIPSIA ACTIVITY | 1 |
| ANTIPRESBYACUSIS EFFECT | 1 |
| ANTIPROGESTERONE EFFECT | 109 |
| ANTIPROLIFERATION ACTIVITY | 3075 |
| ANTIPROTEASE INHIBITION | 6 |
| ANTIPROTEOLYTIC ACTIVITY | 22 |
| ANTIPROTOPLAST REGENERATION | 43 |
| ANTIPROTOZOAN ACTIVITY | 852 |
| ANTIPRURITIC ACTIVITY | 323 |
| ANTIPSORIATIC ACTIVITY | 78 |
| ANTIPSYCHOTIC ACTIVITY | 39 |
| ANTIPYRETIC ACTIVITY | 4715 |
| ANTIRADIATION EFFECT | 206 |
| ANTIRESERPINE ACTIVITY | 9 |
| ANTIRICKETTSIAL ACTIVITY | 24 |
| ANTISCHISTOSOMAL ACTIVITY | 594 |
| ANTISCIATICA ACTIVITY | 5 |
| ANTISCLERODERMA ACTIVITY | 12 |
| ANTISECRETORY EFFECT | 56 |
| ANTISEPTICEMIA ACTIVITY | 16 |
| ANTISHOCK EFFECT | 55 |
| ANTISIALAGOGUE EFFECT | 8 |
| ANTISICKLING ACTIVITY | 95 |
| ANTISILICOSIS ACTIVITY | 6 |
| ANTISNORING EFFECT | 5 |
| ANTISPASMODIC ACTIVITY(UNSPECIFIED TYPE) | 6545 |
| ANTISPASMOLYTIC ACTIVITY | 136 |
| ANTISPECK EFFECT | 1 |
| ANTISPERMATOGENIC EFFECT | 840 |
| ANTISPERMATORRHEA ACTIVITY | 1 |
| ANTISTEREOTYPIC BEHAVIOR EFFECT | 5 |
| ANTISTERNUTATORY EFFECT | 2 |
| ANTISTREPTOLYSIN ACTIVITY | 9 |
| ANTISTRESS ACTIVITY | 295 |
| ANTISWEET ACTIVITY | 79 |
| ANTITACHYCARDIA ACTIVITY | 30 |
| ANTITERATOGENIC ACTIVITY | 5 |
| ANTITHIAMINE ACTIVITY | 38 |
| ANTITHROMBIN III STIMULATION | 2 |
| ANTITHROMBIN TIME INCREASED | 2 |
| ANTITHROMBOCYTOPENIC PURPURA ACTIVITY | 8 |
| ANTITHROMBOTIC EFFECT | 303 |
| ANTITHYROID ACTIVITY | 90 |
| ANTITHYROTROPIC ACTIVITY | 30 |
| ANTITINNITUS ACTIVITY | 20 |
| ANTITOXIC ACTIVITY | 819 |
| ANTITREMATODAL ACTIVITY | 8 |
| ANTITREMORGENIC ACTIVITY | 17 |
| ANTITREPONEMAL ACTIVITY | 469 |
| ANTITRICHOMONAL ACTIVITY | 860 |
| ANTITRYPANOSOMAL ACTIVITY | 3036 |
| ANTITUBULIN ACTIVITY | 37 |
| ANTITUMOR ACTIVITY | 22404 |
| ANTITUMOR ANTAGONIST | 3 |
| ANTITUMOR ANTIVIRAL ACTIVITY | 4 |
| ANTITUMOR-PROMOTING ACTIVITY | 1175 |
| ANTITUSSIVE ACTIVITY | 2192 |
| ANTIULCER ACTIVITY | 3682 |
| ANTIULCERATIVE COLITIS ACTIVITY | 35 |
| ANTIUREMIC ACTIVITY | 31 |
| ANTIUROLITHIASIS ACTIVITY | 38 |
| ANTIURTICARIANT ACTIVITY | 3 |
| ANTIVENIN EFFECT | 2032 |
| ANTIVERTIGO EFFECT | 102 |
| ANTIVIRAL ACTIVITY | 19225 |
| ANTIVIRAL ACTIVITY(PLANT PATHOGENS) | 668 |
| ANTIVITILIGO EFFECT | 13 |
| ANTIWRINKLING ACTIVITY | 7 |
| ANTIYEAST ACTIVITY | 24172 |
| ANTIYEAST ACTIVITY(PLANT PATHOGENS) | 26 |
| ANXIETY INDUCTION | 45 |
| ANXIOLYTIC EFFECT | 270 |
| APHRODISIAC ACTIVITY | 1896 |
| APOLIPOPROTEIN B INHIBITION | 4 |
| APOPTOSIS INDUCTION | 1652 |
| APOPTOSIS INHIBITION | 299 |
| APPETITE STIMULANT | 1653 |
| APPETITE SUPPRESSANT | 15 |
| APRESSORIUM FORMATION INHIBITION | 5 |
| APUDOCYTE NUMBER DECREASE | 1 |
| AQUEOUS FLARE INHIBITION | 5 |
| ARACHIDONATE METABOLISM INHIBITION | 141 |
| ARACHIDONATE METABOLISM STIMULATION | 15 |
| ARACHIDONATE-12-LIPOXYGENASE INHIBITION | 3 |
| ARACHIDONATE-5-LIPOXYGENASE INHIBITION | 14 |
| ARACHIDONIC ACID BINDING INHIBITION | 4 |
| ARACHIDONIC ACID RELEASE INHIBITION | 59 |
| ARACHIDONIC ACID RELEASE STIMULATION | 25 |
| ARACHIDONOYL COA LYSOPHOSPHATIDE ACYLTRANSFERASE INACTIVATION | 1 |
| ARACHIDONOYL COA SYNTHASE INACTIVATION | 1 |
| ARACHNID GROWTH INHIBITION | 1 |
| ARG-GINGIPAIN INHIBITION | 1 |
| ARGINASE INHIBITION ACTIVITY | 6 |
| ARGININE ARYLAMIDASE INHIBITION | 5 |
| ARGININE ESTERASE INHIBITION | 0 |
| ARGININE ESTERASE STIMULATION | 1 |
| ARGININE SYNTHETASE INHIBITION | 1 |
| ARGININE SYNTHETASE STIMULATION | 1 |
| ARGINYL T-RNA INHIBITION | 1 |
| AROMATASE INHIBITION | 294 |
| AROMATASE STIMULATION | 1 |
| ARRHYTHMOGENIC EFFECT | 153 |
| ARROW POISON | 213 |
| ARTERIAL STIFFNESS INCREASE | 1 |
| ARYL HYDROCARBON HYDROXYLASE INDUCTION | 66 |
| ARYL HYDROCARBON HYDROXYLASE INHIBITION | 61 |
| ARYL HYDROCARBON HYDROXYLASE(AHH) STIMULATION | 4 |
| ARYL HYDROCARBON RECEPTOR BINDING INHIBITION | 23 |
| ARYLAMINE N-ACETYLTRANSFERASE INHIBITION | 37 |
| ARYLSULFATASE INHIBITION | 3 |
| ARYLSULPHOTRANSFERASE STIMULATION | 2 |
| ASCARICIDAL ACTIVITY | 130 |
| ASCORBATE OXIDASE INHIBITION | 3 |
| ASCORBATE OXIDASE STIMULATION | 2 |
| ASCORBATE OXIDATION STIMULATION | 3 |
| ASCORBATE PEROXIDASE INDUCTION | 1 |
| ASCORBIC ACID LEVEL DECREASE | 12 |
| ASCORBIC ACID LEVEL INCREASE | 8 |
| ASCORBIC ACID TRANSPORT STIMULATION | 1 |
| ASCORBIC ACID(ADRENAL)LOWERING EFFECT | 19 |
| ASPARAGINE SYNTHETASE INHIBITION | 1 |
| ASPARTATE AMINOTRANSFERASE INDUCTION | 99 |
| ASPARTATE AMINOTRANSFERASE INHIBITION | 114 |
| ASPARTATE CARBAMATE TRANSFERASE INHIBITION | 6 |
| ASPARTATE CARBAMATE TRANSFERASE STIMULATION | 1 |
| ASPARTATE KINASE INHIBITION | 1 |
| ASPARTATE SEMIALDEHYDE DEHYDROGENASE INHIBITION | 2 |
| ASPARTATE TRANSAMINASE LEVEL DECREASE | 16 |
| ASPARTATE TRANSAMINASE LEVEL INCREASED | 20 |
| ASPARTATE TRANSCARBOXAMYLASE INHIBITION | 7 |
| ASPARTYL-AMINOPEPTIDASE INHIBITION | 2 |
| ASPARTYL-AMINOPEPTIDASE STIMULATION | 3 |
| AST VALUE DECREASED | 14 |
| ASTRINGENT EFFECT | 862 |
| ASTROCYTE/GLIA TOXICITY | 1 |
| AT-1 RECEPTOR INHIBITION | 111 |
| ATAXIA | 54 |
| ATHEROGENIC EFFECT | 2 |
| ATHEROSCLEROTIC EFFECT | 7 |
| ATP LEVELS DECREASED | 69 |
| ATP LEVELS INCREASED | 39 |
| ATP RELEASE INHIBITION | 8 |
| ATP SYNTHESIS INHIBITION | 18 |
| ATP-ASE (NA+/K+) BINDING ACTIVITY | 32 |
| ATP-ASE ACTIVITY PROTECTION | 2 |
| ATP-ASE INHIBITION | 272 |
| ATP-ASE STIMULATION | 132 |
| ATP-ASE(CA++) INHIBITION | 118 |
| ATP-ASE(CA++) STIMULATION | 33 |
| ATP-ASE(CA++/MG++) INHIBITION | 7 |
| ATP-ASE(CA++/MG++) STIMULATION | 5 |
| ATP-ASE(CA++/NA+) INHIBITION | 1 |
| ATP-ASE(CANALICULAR) INHIBITION | 0 |
| ATP-ASE(CANALICULAR) STIMULATION | 1 |
| ATP-ASE(DYNEIN) INHIBITION | 2 |
| ATP-ASE(H+) INHIBITION | 19 |
| ATP-ASE(H+) STIMULATION | 7 |
| ATP-ASE(H+/K+) INHIBITION | 39 |
| ATP-ASE(H+/K+) STIMULATION | 2 |
| ATP-ASE(MG++) INHIBITION | 102 |
| ATP-ASE(MG++) STIMULATION | 18 |
| ATP-ASE(MG++/NA+/K+) INHIBITION | 1 |
| ATP-ASE(NA+) INHIBITION | 2 |
| ATP-ASE(NA+/CA++) STIMULATION | 29 |
| ATP-ASE(NA+/K+) INHIBITION | 555 |
| ATP-ASE(NA+/K+) RECEPTOR BINDING INHIBITION | 0 |
| ATP-ASE(NA+/K+) STIMULATION | 23 |
| ATP-ASE(VACUOLAR) INHIBITION | 6 |
| ATP-CITRATE LYASE INHIBITION | 11 |
| ATP-P EXCHANGE ACTIVITY INDUCTION | 1 |
| ATP-P EXCHANGE INHIBITION | 2 |
| ATP-SENSITIVE K+ CHANNEL BLOCKER | 4 |
| ATRIAL NATRIURETIC PEPTIDE DECREASE | 1 |
| ATRIAL NATRIURETIC PEPTIDE INCREASE | 6 |
| ATRIAL NATRIURETIC PEPTIDE RECEPTOR INHIBITION | 24 |
| ATTENTION DEFICIT IMPROVEMENT | 11 |
| ATTENUATION OF BEHAVIORAL EFFECTS | 10 |
| AUDITORY DAMAGE PREVENTION | 4 |
| AUDITORY-EVOKED POTENTIAL STIMULATION | 1 |
| AUTOMATOTROPIC EFFECT,NEGATIVE | 9 |
| AUTOMATOTROPIC EFFECT,POSITIVE | 0 |
| AUTONOMIC EFFECTS(UNSPECIFIED) | 150 |
| AUTOPHAGY STIMULATION | 2 |
| AUTOPHOSPHORYLATION INHIBITION | 12 |
| AUXIN-LIKE ACTIVITY | 24 |
| AVITAMINOSIS EFFECT | 2 |
| AZOCOLL PROTEINASE INHIBITION | 1 |
| B-FIBROBLAST GROWTH FACTOR EXPRESSION INHIBITION | 2 |
| B2 RECEPTOR BINDING | 1 |
| BACTERIAL AGGREGATION INHIBITION | 1 |
| BACTERIAL AGGREGATION STIMULATION | 3 |
| BACTERIAL BIOFILM FORMATION INHIBITION | 6 |
| BACTERIAL INHIBITION-INDUCTION-PHAGE INHIBITION | 322 |
| BACTERIAL MOTILITY INHIBITION | 1 |
| BACTERIAL STIMULANT ACTIVITY | 169 |
| BACTERIAL STIMULANT ACTIVITY(PLANT PATHOGEN) | 3 |
| BACTERIOPHAGE INDUCTION | 4 |
| BARBITURATE EFFECT | 1 |
| BARBITURATE POTENTIATION | 1273 |
| BARBITURATE SLEEPING TIME DECREASED | 409 |
| BASIC ELECTRON TRANSPORT STIMULATED | 2 |
| BCL (ANTI-APOPTOTIC) PROTEIN BINDING INHIBITION | 9 |
| BEHCET'S SYNDROME IMPROVEMENT | 1 |
| BENIGN PROSTATIC HYPERPLASIA IMPROVEMENT | 394 |
| BENZO(A)PYRENE HYDROXYLATION INHIBITION | 2 |
| BENZODIAZEPINE BINDING INHIBITION | 137 |
| BENZODIAZEPINE BINDING STIMULATION | 45 |
| BENZOPYRENE HYDROXYLASE INDUCTION | 28 |
| BENZOPYRENE HYDROXYLASE INHIBITION | 12 |
| BENZOPYRENE METABOLISM INHIBITION | 50 |
| BENZOPYRENE METABOLISM STIMULATION | 8 |
| BENZOPYRENE MONOOXYGENASE INHIBITION | 1 |
| BENZOPYRENE-DNA BINDING INHIBITION | 16 |
| BENZOPYRENE-PROTEIN BINDING INHIBITION | 44 |
| BENZOXYRESORUFIN-O-DEBENZYLASE(BROD) INHIBITION | 14 |
| BENZOXYRESORUFIN-O-DEBENZYLASE(BROD) STIMULATION | 4 |
| BENZPHETAMINE DEMETHYLASE STIMULATION | 9 |
| BENZPHETAMINE N-DEMETHYLASE INHIBITION | 4 |
| BENZPHETAMINE N-DEMETHYLATION INHIBITION | 2 |
| BENZPYRENE HYDROXYLASE INHIBITION | 22 |
| BENZYLOXYRESORUFIN O-DEBENZYLASE INHIBITION | 2 |
| BENZYLOXYRESORUFIN-O-DEALKYLASE STIMULATION | 0 |
| BETA-1,3-GLUCANASE STIMULATION | 3 |
| BETA-2-MICROGLOBULIN STIMULATION | 6 |
| BETA-ADRENERGIC RECEPTOR DENSITY DECREASE | 4 |
| BETA-AMYLASE INHIBITION | 22 |
| BETA-CAROTENE DEPLETION PREVENTION | 1 |
| BETA-CASEIN CONTENT DECREASED | 1 |
| BETA-CASEIN CONTENT INCREASED | 7 |
| BETA-CHYMOTRYPSIN INHIBITION | 2 |
| BETA-ENDORPHIN RELEASE | 2 |
| BETA-ENDORPHIN RELEASE INHIBITION | 1 |
| BETA-FACTOR IIA INHIBITION | 2 |
| BETA-FACTOR IIA STIMULATION | 0 |
| BETA-GALACTOSIDASE INHIBITION | 158 |
| BETA-GALACTOSIDASE STIMULATION | 11 |
| BETA-GLUCAN RECEPTOR ANTAGONIST ACTIVITY | 1 |
| BETA-GLUCAN SYNTHETASE INHIBITION | 24 |
| BETA-GLUCOCEREBROSIDASE INHIBITION | 4 |
| BETA-GLUCOSIDASE ACTIVITY ENHANCEMENT | 16 |
| BETA-GLUCOSIDASE INHIBITION | 197 |
| BETA-GLUCURONIDASE INHIBITION | 329 |
| BETA-GLUCURONIDASE STIMULATION | 26 |
| BETA-HEXOAMIDASE INHIBITION | 22 |
| BETA-HYDROXYBUTYRATE LEVEL INHIBITION | 1 |
| BETA-HYDROXYBUTYRATE OXIDASE INHIBITION | 1 |
| BETA-LACTAMASE INHIBITION | 55 |
| BETA-MANNOSIDASE INHIBITION | 68 |
| BETA-N-ACETYLGLUCOSAMINIDASE INHIBITION | 10 |
| BETA-N-ACETYLGLUCOSAMINIDASE STIMULATION | 11 |
| BETA-N-ACETYLHEXOSAMINIDASE INHIBITION | 1 |
| BETA-SECRETASE ENZYME INHIBITION | 4 |
| BETA-SECRETASE INHIBITION | 1 |
| BETA-XYLOSIDASE INHIBITION | 10 |
| BEVERAGE USE | 75 |
| BILE ACID EXCRETION INHIBITION | 2 |
| BILE ACID EXCRETION STIMULATION | 5 |
| BILE ACID LEVEL DECREASE | 5 |
| BILE ACID LEVEL INCREASE | 0 |
| BILE ACID RESORPTION INHIBITION | 3 |
| BILE ACID SYNTHESIS STIMULATION | 16 |
| BILE ACID:COA LIGASE INHIBITION | 1 |
| BILE ACID:GLY/TAU N-ACYLTRANSFERASE INHIBITION | 1 |
| BILE COMPOSITION ALTERATION | 2 |
| BILE LITHOGENIC SUPPRESSION | 6 |
| BILE SECRETION DECREASE | 6 |
| BILE SECRETION INCREASE | 76 |
| BILIRUBIN OXIDASE INHIBITION | 2 |
| BINDING EFFECT | 402 |
| BINDING TO HUMAN PERIPHERAL BLOOD LYMPHOCYTES | 2 |
| BINDING(MITRENDIPINE) INHIBITION | 1 |
| BIOAVAILABILITY OF | 60 |
| BIODIASTASE INHIBITION | 31 |
| BIOGENIC AMINE METABOLISM EFFECTS | 3 |
| BIOLUMINESCENCE AUTOINDUCTION EFFECT | 5 |
| BIOLUMINESCENCE INDUCTION | 1 |
| BIOSURFACTANT ACTIVITY | 3 |
| BITTER TASTING EFFECT | 394 |
| BLADDER STONE FORMATION INHIBITION | 0 |
| BLADDER STONE FORMATION STIMULATION | 1 |
| BLASTULATION INHIBITION | 1 |
| BLEB FORMATION INHIBITION | 1 |
| BLOOD ALCOHOL LEVEL DECREASE | 18 |
| BLOOD DETECTION(REAGENT) | 3 |
| BLOOD FLOW DECREASE | 15 |
| BLOOD FLOW INCREASE | 94 |
| BLOOD PRESSURE EFFECT BIPHASIC | 44 |
| BLOOD SYSTEM EFFECTS(UNSPECIFIED) | 313 |
| BLOOD VISCOSITY DECREASED | 40 |
| BLOOD VISCOSITY INCREASED | 4 |
| BODY WEIGHT LOSS INHIBITION | 44 |
| BONE DISORDER EFFECTS | 143 |
| BONE FORMATION STIMULATION | 9 |
| BONE MARROW CELL STIMULATION | 4 |
| BONE MARROW DEPRESSANT EFFECT | 20 |
| BONE METABOLISM INHIBITION | 6 |
| BONE RESORPTION INHIBITION | 77 |
| BONE RESORPTION STIMULATION | 19 |
| BONE WEAKENING EFFECT | 2 |
| BRADYCARDIA ACTIVITY | 150 |
| BRADYKININ AGONIST ACTIVITY | 3 |
| BRADYKININ ANTAGONIST ACTIVITY | 54 |
| BRADYKININ DEGRADATION INHIBITION | 1 |
| BRADYKININ RECEPTOR BINDING EFFECT | 11 |
| BRASSINOLIDE INHIBITION | 3 |
| BRASSINOSTEROID INHIBITION | 2 |
| BRASSINOSTEROID STIMULATION | 0 |
| BROMELAIN INHIBITION | 8 |
| BRONCHOCONSTRICTOR ACTIVITY | 53 |
| BRONCHOCONSTRICTOR ACTIVITY(AUTONOMIC) | 2 |
| BRONCHODILATOR ACTIVITY | 847 |
| BRONCHODILATOR ACTIVITY(AUTONOMIC) | 34 |
| BUN LOWERING EFFECT | 27 |
| BUN RAISING EFFECT | 8 |
| BUSH TEA USE | 10 |
| BUTYRYL-CO-A DEHYDROGENASE STIMULATION | 2 |
| BUTYRYLCHOLINESTERASE INHIBITION | 113 |
| C-14 FORMATE INCORPORATION INTO PURINES INHIBITION | 8 |
| C-FOS EXPRESSION INHIBITION | 1 |
| C-FOS EXPRESSION STIMULATION | 2 |
| C-JUN N-TERMINAL KINASE PHOSPHORYLATION INHIBITION | 2 |
| C-JUN-N-TERMINAL KINASE INHIBITION | 5 |
| C-JUN-N-TERMINAL KINASE STIMULATION | 2 |
| CA PUMP INHIBITION | 6 |
| CALCIFICATION INHIBITION | 3 |
| CALCIFICATION STIMULATION | 1 |
| CALCINEURIN INHIBITION | 4 |
| CALCINOGENIC ACTIVITY | 38 |
| CALCITONIN GENE-RELATED PEPTIDE LEVEL DECREASE | 2 |
| CALCITONIN GENE-RELATED PEPTIDE STIMULATION | 1 |
| CALCITONIN GENE-RELATED PROTEIN RECEPTOR BINDING ACTIVITY | 14 |
| CALCITONIN INDUCTION | 5 |
| CALCITRIOL ACTIVITY(CALBINDIN STIMULATION) | 9 |
| CALCIUM AGONIST ACTIVITY | 21 |
| CALCIUM ANTAGONIST EFFECT | 83 |
| CALCIUM BINDING EFFECT | 1 |
| CALCIUM BINDING PROTEIN INHIBITION | 1 |
| CALCIUM CHANNEL AGONIST | 34 |
| CALCIUM CHANNEL BINDING EFFECT | 49 |
| CALCIUM CHANNEL BLOCKER | 360 |
| CALCIUM CHANNEL MODULATOR ACTIVITY | 7 |
| CALCIUM CHANNEL RECEPTOR BINDING INHIBITION | 0 |
| CALCIUM EXCRETION DECREASE | 5 |
| CALCIUM ION RELEASE INHIBITION | 111 |
| CALCIUM ION UPTAKE INHIBITION | 244 |
| CALCIUM ION UPTAKE STIMULATION | 85 |
| CALCIUM LEVEL DECREASE(EXTRACELLULAR) | 19 |
| CALCIUM LEVEL DECREASE(INTRACELLULAR) | 155 |
| CALCIUM LEVEL INCREASE(EXTRACELLULAR) | 14 |
| CALCIUM LEVEL INCREASE(INTRACELLULAR) | 170 |
| CALCIUM PUMP STIMULATION | 1 |
| CALCIUM RELEASE STIMULATION | 44 |
| CALCIUM SENSITIVITY INHIBITION | 2 |
| CALCIUM SENSITIVITY STIMULATION | 1 |
| CALCIUM TRANSIENT INDUCTION | 2 |
| CALCIUM TRANSIENT INHIBITION | 8 |
| CALCIUM TRANSPORT INHIBITION | 61 |
| CALCIUM TRANSPORT STIMULATION | 28 |
| CALCIUM-DEPENDENT PROTEIN KINASE INHIBITION | 1 |
| CALCIURIA DECREASE | 4 |
| CALLUS GROWTH INHIBITION | 1 |
| CALMODULIN INDUCTION | 4 |
| CALMODULIN INHIBITION | 20 |
| CALPAIN INHIBITION | 7 |
| CALPAIN(M) INHIBITION | 4 |
| CALPAIN(MU) INHIBITION | 4 |
| CAMK-III PROTEIN KINASE INHIBITION | 1 |
| CANALICULAR-5'-NUCLEOTIDASE INHIBITION | 2 |
| CANALICULAR-5'-NUCLEOTIDASE STIMULATION | 1 |
| CANCER CHEMOPREVENTION | 7 |
| CANCER-ASSOCIATED RISK FACTOR | 12 |
| CANNABINOID RECEPTOR BINDING | 6 |
| CAPILLARY ANTIHEMORRHAGIC ACTIVITY | 48 |
| CAPILLARY PERMEABILITY DECREASED | 176 |
| CAPILLARY PERMEABILITY INCREASED | 53 |
| CAPILLARY RESISTANCE INCREASE | 5 |
| CAPSAICIN INHIBITION | 2 |
| CAPSAICIN-HYDROLYZING ENZYME ACTIVITY INCREASE | 1 |
| CARBAMYL PHOSPHATE SYNTHETASE INHIBITION | 16 |
| CARBAMYL PHOSPHATE SYNTHETASE STIMULATION | 3 |
| CARBOHYDRATE ABSORPTION INHIBITION | 1 |
| CARBOLINE,BETA: AGONIST | 6 |
| CARBON DIOXIDE PRODUCTION INHIBITION | 1 |
| CARBONIC ANHYDRASE DOWNREGULATION | 1 |
| CARBONIC ANHYDRASE INHIBITION | 27 |
| CARBONIC ANHYDRASE UPREGULATION | 1 |
| CARBONYL REDUCTASE INHIBITIION | 6 |
| CARBOXAMIDE UTILIZATION INHIBITION | 2 |
| CARBOXYL METHYLATION INHIBITION | 2 |
| CARBOXYLESTERASE INHIBITION | 3 |
| CARBOXYLIC PROTEINASE INHIBITION | 4 |
| CARBOXYLIC PROTEINASE STIMULATION | 0 |
| CARBOXYMETHYLCELLULASE INHIBITION | 6 |
| CARBOXYPEPTIDASE A INDUCTION | 0 |
| CARBOXYPEPTIDASE A INHIBITION | 60 |
| CARBOXYPEPTIDASE B INDUCTION | 9 |
| CARBOXYPEPTIDASE B INHIBITION | 26 |
| CARBOXYPEPTIDASE INHIBITION | 17 |
| CARBOXYPEPTIDASE Y INHIBITION | 3 |
| CARCINOGENESIS INHIBITION | 1641 |
| CARCINOGENIC ACTIVITY | 1075 |
| CARCINOSTATIC ACTIVITY | 73 |
| CARDIAC ANTIACCELERATOR ACTIVITY | 13 |
| CARDIAC CONDUCTION IMPROVEMENT | 4 |
| CARDIAC DEPRESSANT ACTIVITY | 406 |
| CARDIAC HYPERTROPHY INHIBITION | 2 |
| CARDIAC OUTPUT DECREASED | 14 |
| CARDIAC OUTPUT INCREASED | 30 |
| CARDIOEXCITATORY ACTIVITY | 35 |
| CARDIOPROTECTIVE ACTIVITY | 54 |
| CARDIOTONIC ACTIVITY | 1039 |
| CARDIOTOXIC ACTIVITY | 324 |
| CARDIOVASCULAR EFFECTS(UNSPECIFIED) | 583 |
| CARIOGENIC EFFECT | 5 |
| CARIOSTATIC EFFECT | 12 |
| CARMINATIVE ACTIVITY | 494 |
| CARNITINE ACETYL-COENZYME A TRANSFERASE INDUCTION | 1 |
| CARNITINE ACETYLTRANSFERASE INHIBITION | 17 |
| CARNITINE ACETYLTRANSFERASE STIMULATION | 2 |
| CARNITINE OCTANOYLTRANSFERASE STIMULATION | 2 |
| CARNITINE PALMITOYL TRANSFERASE STIMULATION | 3 |
| CARNITINE PALMITOYL TRANSFERASE-I INHIBITION | 2 |
| CARNOSINASE INHIBITION | 1 |
| CASEIN KINASE INHIBITION | 21 |
| CASEIN KINASE STIMULATION | 1 |
| CASEIN-KINASE TYPE PHOSPHORYLATION INHIBITION | 1 |
| CASEINOLYTIC ACTIVITY | 13 |
| CASPASE STIMULATION | 8 |
| CASPASE-1 STIMULATION | 4 |
| CASPASE-2 INHIBITION | 3 |
| CASPASE-3 INHIBITION | 30 |
| CASPASE-3 STIMULATION | 71 |
| CASPASE-7 STIMULATION | 2 |
| CASPASE-8 INHIBITION | 5 |
| CASPASE-8 STIMULATION | 17 |
| CASPASE-9 INHIBITION | 4 |
| CASPASE-9 STIMULATION | 24 |
| CAT ATTRACTANT EFFECT | 2 |
| CATALASE INHIBITION | 58 |
| CATALASE STIMULATION | 244 |
| CATALEPTIC EFFECT | 83 |
| CATALYSIS INHIBITION | 1 |
| CATARACT DEVELOPMENT INHIBITION | 15 |
| CATECHIN OXIDASE INHIBITION | 1 |
| CATECHOL-O-METHYL TRANSFERASE INHIBITION | 23 |
| CATECHOL-O-METHYL TRANSFERASE STIMULATION | 3 |
| CATECHOLAMINE INHIBITORY EFFECT | 33 |
| CATECHOLAMINE RELEASE INHIBITION | 43 |
| CATECHOLAMINE-RELEASING EFFECT | 39 |
| CATHEPSIN A INHIBITION | 7 |
| CATHEPSIN B INDUCTION | 43 |
| CATHEPSIN B INHIBITION | 91 |
| CATHEPSIN C INHIBITION | 6 |
| CATHEPSIN D INDUCTION | 8 |
| CATHEPSIN D INHIBITION | 35 |
| CATHEPSIN G INHIBITION | 38 |
| CATHEPSIN H INHIBITION | 4 |
| CATHEPSIN INHIBITION | 23 |
| CATHEPSIN L INDUCTION | 7 |
| CATHEPSIN L INHIBITION | 9 |
| CATHEPSIN STIMULATION | 1 |
| CAUSTIC EFFECT | 17 |
| CAUTERIZING EFFECT | 17 |
| CDC2 KINASE INHIBITION | 1 |
| CDC2/CYCLIN B KINASE INHIBITION | 4 |
| CDC25 PHOSPHATASE INHIBITION | 2 |
| CELL ADHESION INHIBITION | 204 |
| CELL ADHESION STIMULATION | 67 |
| CELL AGGREGATION ENHANCEMENT | 83 |
| CELL AGGREGATION INHIBITION | 22 |
| CELL ATTACHMENT ENHANCEMENT EFFECT | 55 |
| CELL ATTACHMENT ENHANCEMENT INHIBITION | 23 |
| CELL BINDING ACTIVITY | 12 |
| CELL BINDING INHIBITION | 0 |
| CELL CLEAVAGE INHIBITION | 10 |
| CELL CONTACT INHIBITION INDUCTION | 3 |
| CELL CONTENT RELEASE INHIBITION | 3 |
| CELL CONTRACTION INHIBITION | 5 |
| CELL CYCLE BLOCKING EFFECT | 103 |
| CELL CYCLE CHECKPOINT INHIBITION(G2 PHASE) | 2 |
| CELL CYCLE CYTOTOXICITY(G1 PHASE) | 146 |
| CELL CYCLE CYTOTOXICITY(G2 + M PHASE) | 123 |
| CELL CYCLE CYTOTOXICITY(G2 PHASE) | 63 |
| CELL CYCLE CYTOTOXICITY(M PHASE) | 23 |
| CELL CYCLE CYTOTOXICITY(S PHASE) | 61 |
| CELL CYCLE SYNCHRONIZATION | 2 |
| CELL DIFFERENTIATION INDUCTION | 799 |
| CELL DIFFERENTIATION INHIBITION | 126 |
| CELL FUSION INHIBITION | 1 |
| CELL GROWTH ENHANCEMENT EFFECT | 290 |
| CELL HARVEST ENHANCEMENT | 1 |
| CELL INVASION INHIBITION | 42 |
| CELL LYSIS EFFECT | 15 |
| CELL MEDIATED CYTOTOXICITY ENHANCEMENT | 2 |
| CELL MEDIATED IMMUNE RESPONSE STIMULATION | 15 |
| CELL MEMBRANE PERMEATION | 15 |
| CELL MEMBRANE STABILIZER | 33 |
| CELL MEMBRANE TOXICITY | 19 |
| CELL METABOLISM STUDY | 52 |
| CELL MIGRATION EFFECT | 15 |
| CELL MIGRATION INHIBITION | 64 |
| CELL MORPHOLOGICAL ALTERATION | 141 |
| CELL MOTILITY INHIBITION | 21 |
| CELL PROLIFERATION INHIBITION | 1673 |
| CELL PROLIFERATION STIMULATION | 459 |
| CELL SURFACE HYDROPHOBICITY DECREASE | 1 |
| CELL SURVIVAL INCREASED | 1 |
| CELL SYNCHRONIZATION EFFECT | 10 |
| CELL TRANSFORMATION INDUCTION | 45 |
| CELL TRANSFORMATION INHIBITION | 120 |
| CELL TRANSFORMATION REVERSAL INDUCTION | 5 |
| CELL TRANSPORT EFFECTS | 65 |
| CELL WALL SYNTHESIS INHIBITION | 18 |
| CELL-CELL COMMUNICATION ENHANCEMENT | 15 |
| CELL-CELL COMMUNICATION INHIBITION | 25 |
| CELLULAR IMMUNITY INHIBITION | 41 |
| CELLULAR IMMUNITY STIMULATION | 7 |
| CELLULASE INHIBITION | 11 |
| CELLULASE STIMULATION | 1 |
| CELLULOSE BIOSYNTHESIS INHIBITION | 16 |
| CEPHALOSPORINASE INHIBITION | 15 |
| CERAMIDE SYNTHASE INHIBITION | 2 |
| CERCARIAL PENETRATION EFFECT | 3 |
| CERCARIAL PENETRATION INHIBITION | 89 |
| CERCARIAL PENETRATION STIMULANT | 15 |
| CERCARICIDAL EFFECT | 56 |
| CEREBRAL ARTERIOSCLEROSIS SYMPTOMS DECREASED | 17 |
| CEREBRAL BLOOD FLOW INCREASED | 45 |
| CEREBRAL EDEMA DECREASED | 26 |
| CEREBRAL INSUFFICIENCY IMPROVEMENT | 19 |
| CEREBRAL OXYGENATION INCREASE | 2 |
| CHALCONE ISOMERASE INHIBITION | 1 |
| CHALCONE SYNTHASE INHIBITION | 1 |
| CHECKPOINT KINASE STIMULATION | 1 |
| CHELATING EFFECT(IRON) | 44 |
| CHELATION EFFECT | 15 |
| CHEMILUMINESCENCE INHIBITION | 66 |
| CHEMOKINE CINC-1 INDUCTION INHIBITION | 17 |
| CHEMOKINE PRODUCTION INHIBITION | 11 |
| CHEMOKINE RECEPTOR-1 BINDING INHIBITION | 0 |
| CHEMORECEPTION INHIBITION | 2 |
| CHEMORECEPTOR STIMULANT | 7 |
| CHEMOSENSITIVITY EFFECT | 6 |
| CHEMOSTERILANT ACTIVITY | 3 |
| CHEMOTAXIS FACTOR STIMULATION | 5 |
| CHEMOTAXIS INHIBITION | 88 |
| CHEMOTAXIS STIMULATION | 36 |
| CHEWING GUM USE | 4 |
| CHEWING MOVEMENT INHIBITION | 1 |
| CHEWING STICK USE | 203 |
| CHITIN BINDING ACTIVITY | 1 |
| CHITIN SYNTHASE INHIBITION | 56 |
| CHITIN SYNTHASE STIMULATION | 1 |
| CHITIN SYNTHESIS INHIBITION | 8 |
| CHITINASE ACTIVITY | 2 |
| CHITINASE INHIBITION | 39 |
| CHITINASE STIMULATION | 1 |
| CHITOSAN SYNTHESIS INHIBITION | 2 |
| CHITOSANASE STIMULATION | 1 |
| CHITOTRIOSIDASE STIMULATION | 0 |
| CHLORIDE CHANNEL ACTIVATION | 2 |
| CHLORIDE CHANNEL INHIBITION | 12 |
| CHLORIDE SECRETION INHIBITION | 9 |
| CHLORIDE SECRETION STIMULATION | 4 |
| CHLORIDE TRANSPORT INHIBITION | 1 |
| CHLORIDE TRANSPORT STIMULATION | 2 |
| CHLOROPHYLL SYNTHESIS INHIBITION | 42 |
| CHLORZOXAZONE INHIBITION | 13 |
| CHOLAGOGUE ACTIVITY | 152 |
| CHOLECYSTOKININ ANTAGONIST | 10 |
| CHOLECYSTOKININ RECEPTOR BINDING EFFECT | 98 |
| CHOLECYSTOKININ RELEASE STIMULATION | 2 |
| CHOLERETIC ACTIVITY | 629 |
| CHOLESTASE INDUCTION | 1 |
| CHOLESTASE INHIBITION | 2 |
| CHOLESTATIC LIVER DISEASE TREATMENT | 1 |
| CHOLESTEROL ABSORBTION EFFECT | 1 |
| CHOLESTEROL ABSORPTION INHIBITION | 48 |
| CHOLESTEROL ACYLTRANSFERASE INHIBITION | 69 |
| CHOLESTEROL ACYLTRANSFERASE STIMULATION | 7 |
| CHOLESTEROL ESTER FORMATION INHIBITION | 28 |
| CHOLESTEROL ESTER HYDROLASE ACTIVITY INCREASE | 7 |
| CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITION | 15 |
| CHOLESTEROL ESTERASE STIMULATION | 4 |
| CHOLESTEROL ESTERASE(PANCREATIC) INHIBITION | 1 |
| CHOLESTEROL INHIBITION | 100 |
| CHOLESTEROL LEVEL DECREASE | 361 |
| CHOLESTEROL LEVEL INCREASE | 48 |
| CHOLESTEROL SYNTHESIS INHIBITION | 160 |
| CHOLESTEROL SYNTHESIS STIMULATION | 17 |
| CHOLESTEROL-7-ALPHA-HYDROXYLASE INHIBITION | 14 |
| CHOLESTEROL-7-ALPHA-HYDROXYLASE STIMULATION | 15 |
| CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION | 8 |
| CHOLINE ACETYLTRANSFERASE INDUCTION | 81 |
| CHOLINE ACETYLTRANSFERASE INHIBITION | 5 |
| CHOLINE RELEASE INHIBITION | 4 |
| CHOLINE UPTAKE INCREASE | 1 |
| CHOLINERGIC ACTIVITY | 21 |
| CHOLINESTERASE INHIBITION | 215 |
| CHOLINESTERASE STIMULATION | 6 |
| CHONDROGENESIS INHIBITION | 4 |
| CHORISMATE MUTASE ACTIVITY | 0 |
| CHROMATIN CONDENSATION INDUCTION | 2 |
| CHROMOSOME ABERRATION INHIBITION | 124 |
| CHROMOSOME ABERRATIONS INDUCED | 478 |
| CHRONOTROPIC EFFECT NEGATIVE | 637 |
| CHRONOTROPIC EFFECT POSITIVE | 375 |
| CHYMASE INHIBITION | 3 |
| CHYMOSIN INHIBITION | 4 |
| CHYMOTRYPSIN INHIBITION | 346 |
| CILIA REGENERATION INHIBITION | 17 |
| CILIOTOXICITY | 5 |
| CIRCADIAN RHYTHM EFFECT | 10 |
| CIRCULATION STIMULATION | 263 |
| CITRATE LYASE INHIBITION | 17 |
| CITRATE LYASE STIMULATION | 0 |
| CITRATE SYNTHASE INHIBITION | 17 |
| CITRATURIA DECREASE | 1 |
| CITRIC ACID LEVEL DECREASE | 2 |
| CLASTOGENIC ACTIVITY | 363 |
| CLEFT PALATE INDUCTION | 2 |
| CLONOGENIC INHIBITION ACTIVITY | 8 |
| CLONOGENICITY STIMULATION ACTIVITY | 4 |
| CM-CSF EXPRESSION INHIBITION | 2 |
| CNS DEPRESSANT ACTIVITY | 3292 |
| CNS EFFECTS(GENERAL) | 574 |
| CNS STIMULANT ACTIVITY | 1184 |
| COAGULANT ACTIVITY | 211 |
| COAGULASE ACTIVITY | 9 |
| COCARCINOGENIC ACTIVITY | 186 |
| COELIAC DISEASE EXACERBATION | 1 |
| COENZYME A DESATURASE STIMULATION | 1 |
| COENZYME A HYDROXYLASE STIMULATION | 1 |
| COENZYME A REDUCTASE(3-OH-3-METHYLGLUTARYL)-INHIBITION | 10 |
| COENZYME Q SYNTHESIS INHIBITION | 2 |
| COGNITIVE ENHANCEMENT EFFECT | 126 |
| COLLAGEN BIOSYNTHESIS INHIBITION | 12 |
| COLLAGEN CONTRACTION STIMULATION | 2 |
| COLLAGEN CROSSLINKING INHIBITION | 2 |
| COLLAGEN DEGRADATION ACTIVITY | 1 |
| COLLAGEN FIBRIL(TYPE I)RETICULATION STIMULATION | 12 |
| COLLAGEN FIBRIL(TYPE II)RETICULATION STIMULATION | 2 |
| COLLAGEN GLYCOSYLATION INHIBITION | 2 |
| COLLAGEN NETWORK FORMATION STIMULATION | 2 |
| COLLAGEN RESORPTION INHIBITION | 2 |
| COLLAGEN STABILIZING EFFECT | 6 |
| COLLAGEN SYNTHESIS INHIBITION | 34 |
| COLLAGEN SYNTHESIS STIMULATION | 45 |
| COLLAGENASE INHIBITION | 139 |
| COLLAGENASE STIMULATION | 5 |
| COLLAGENOLYTIC INHIBITION | 2 |
| COLLAGENOUS COLITIS IMPROVEMENT | 1 |
| COLONY FORMATION EFFICIENCY STIMULATION | 5 |
| COLONY FORMATION ENHANCEMENT | 41 |
| COLONY FORMATION INHIBITION | 150 |
| COLONY FORMING UNIT-GRANULOCYTE MACROPHAGE INHIBITIION | 1 |
| COLONY FORMING UNIT-GRANULOCYTE MACROPHAGE STIMULATION | 1 |
| COLONY STIMULATING FACTOR INHIBITION | 3 |
| COLONY-STIMULATING FACTOR PRODUCTION STIMULATION | 46 |
| COLORECTAL PROLIFERATIVE LESION INHIBITION | 1 |
| COMEDOGENIC ACTIVITY | 2 |
| COMITOGENIC ACTIVITY | 8 |
| COMMON COLD RELIEF | 518 |
| COMPLEMENT ALTERNATIVE PATHWAY INHIBITION | 166 |
| COMPLEMENT C-3 CONVERTASE INHIBITION | 5 |
| COMPLEMENT C1Q BINDING INHIBITION | 1 |
| COMPLEMENT C5 CONVERTASE INHIBITION | 2 |
| COMPLEMENT C5-A BINDING INHIBITION | 3 |
| COMPLEMENT CLASSICAL PATHWAY INHIBITION | 265 |
| COMPLEMENT CONSUMPTION ENHANCEMENT | 0 |
| COMPLEMENT INDUCTION EFFECT | 23 |
| COMPLEMENT(GENERAL) ENZYME INHIBITION | 46 |
| COMPLEMENT-ALTERNATE PATHWAY STIMULATION | 23 |
| COMPLEMENT-CLASSICAL PATHWAY STIMULATION | 9 |
| COMPLEMENT-DEPENDENT CYTOTOXICITY ENHANCEMENT | 1 |
| COMPLEX FORMATION | 6 |
| COMPLEX SPHINGOLIPID SYNTHESIS INHIBITION | 6 |
| COMUTAGENIC ACTIVITY | 69 |
| CONDIMENT | 84 |
| CONDITIONAL PREFERENCE INHIBITION | 1 |
| CONDITIONED AVOIDANCE RESPONSE DECREASED | 83 |
| CONDITIONED AVOIDANCE RESPONSE INCREASED | 33 |
| CONDITIONED PLACE PREFERENCE INHIBITION | 5 |
| CONDITIONED PLACE PREFERENCE STIMULATION | 2 |
| CONDITIONED PREFERENCE ACTIVITY | 5 |
| CONDITIONED TASTE AVERSION | 51 |
| CONGESTIVE EDEMA REDUCTION | 61 |
| CONJUGATION TUBE INDUCTION | 6 |
| CONTRACEPTIVE AND/OR INTERCEPTIVE EFFECT | 588 |
| CONTRACTING EFFECT(NON-SPECIFIC) | 88 |
| CONVULSANT ACTIVITY | 468 |
| COPOLYMERIZATION EFFECT | 1 |
| COPPER METABOLISM ENHANCEMENT | 4 |
| COPPER METABOLISM INHIBITION | 2 |
| COPULATORY RESPONSE LATENCY INDUCER | 9 |
| CORONA PENETRATING ENZYME(CPE)INHIBITION | 1 |
| CORONARY BLOOD FLOW DECREASED | 18 |
| CORONARY BLOOD FLOW INCREASED | 128 |
| CORONARY RESISTANCE DECREASED | 13 |
| CORONARY RESISTANCE INCREASED | 0 |
| CORONARY VASODILATOR ACTIVITY | 148 |
| CORONARY VASODILATOR ACTIVITY(AUTONOMIC) | 4 |
| CORTICOID 5-BETA REDUCTASE INHIBITION | 13 |
| CORTICOSTEROID 11-BETA-DEHYDROGENASE INHIBITION | 6 |
| CORTICOSTEROID LEVEL INCREASE | 3 |
| CORTICOSTEROID SYNTHESIS STIMULATION | 2 |
| CORTICOSTEROID TYPE ACTIVITY | 64 |
| CORTICOSTERONE LEVEL DECREASE | 19 |
| CORTICOSTERONE-INDUCTION | 168 |
| CORTICOTROPIN RELEASING HORMONE RECEPTOR BINDING INHIBITION | 7 |
| CORTISOL DECREASE | 19 |
| CORTISOL INCREASE | 13 |
| COSMETIC EFFECTS | 175 |
| COUMARIN 7-HYDROXYLASE INHIBITION | 1 |
| COX-1 HYDROPEROXIDASE INHIBITION | 22 |
| COX-2 HYDROPEROXIDASE INHIBITION | 5 |
| CREATIN KINASE INHIBITION | 8 |
| CREATIN KINASE STIMULATION | 13 |
| CREATINE PHOSPHOKINASE ENHANCEMENT | 11 |
| CREATINE PHOSPHOKINASE INHIBITION | 1 |
| CREATININE LEVEL DECREASE | 29 |
| CREATININE LEVEL INCREASE | 8 |
| CREATININE PHOSPHOKINASE INHIBITION | 19 |
| CREATININE PHOSPHOKINASE LEVEL INCREASE | 1 |
| CROHN'S DISEASE TREATMENT | 1 |
| CROWN GALL TUMOR INHIBITION | 407 |
| CRYOGLOBULINEMIA TREATMENT | 1 |
| CRYOPROTECTIVE ACTIVITY | 3 |
| CSF RECEPTOR DOWNREGULATION | 2 |
| CULTIVATION OF ECONOMICALLY USEFUL PLANTS | 59 |
| CURARIMIMETIC ACTIVITY | 87 |
| CURRENT INHIBITION(LARGE CATION) | 3 |
| CUTINASE INHIBITION | 5 |
| CYCLIC AMP ACCUMULATION | 20 |
| CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITION | 55 |
| CYCLIC AMP DEPENDENT PROTEIN KINASE STIMULATION | 1 |
| CYCLIC AMP INDEPENDENT TYROSINE KINASE STIMULATION | 1 |
| CYCLIC AMP INHIBITION | 147 |
| CYCLIC AMP LEVEL DECREASE | 24 |
| CYCLIC AMP PHOSPHODIESTERASE INHIBITION | 450 |
| CYCLIC AMP PHOSPHODIESTERASE STIMULATION | 7 |
| CYCLIC AMP STIMULATION | 234 |
| CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITION | 14 |
| CYCLIC GMP FORMATION INDUCTION | 4 |
| CYCLIC GMP FORMATION INHIBITION | 1 |
| CYCLIC GMP INHIBITION | 51 |
| CYCLIC GMP LEVEL DECREASE | 2 |
| CYCLIC GMP LEVEL INCREASE | 8 |
| CYCLIC GMP PHOSPHODIESTERASE INHIBITION | 1 |
| CYCLIC GMP PHOSPHODIESTERASE STIMULATION | 1 |
| CYCLIC GMP STIMULATION | 52 |
| CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITION | 105 |
| CYCLIC NUCLEOTIDE PHOSPHORYLASE INHIBITION | 2 |
| CYCLIN A EXPRESSION INHIBITION | 3 |
| CYCLIN A KINASE INHIBITION | 1 |
| CYCLIN A LEVEL INCREASE | 3 |
| CYCLIN B STIMULATIION | 3 |
| CYCLIN B-1 EXPRESSION INHIBITION | 2 |
| CYCLIN D LEVEL INCREASE | 1 |
| CYCLIN D1 EXPRESSION INHIBITION | 20 |
| CYCLIN D1-CDK4 INHIBITION ACTIVITY | 13 |
| CYCLIN D3 INHIBITION | 2 |
| CYCLIN DEPENDENT KINASE 1 INHIBITION | 18 |
| CYCLIN DEPENDENT KINASE 1 STIMULATION | 1 |
| CYCLIN DEPENDENT KINASE 2 INHIBITION | 28 |
| CYCLIN DEPENDENT KINASE 2 STIMULATION | 2 |
| CYCLIN E EXPRESSION INHIBITION | 8 |
| CYCLIN E KINASE INHIBITION | 2 |
| CYCLIN E LEVEL INCREASE | 1 |
| CYCLIN E-DEPENDENT KINASE 6 INHIBITION | 1 |
| CYCLIN E-DEPENDENT KINASE INHIBITION | 2 |
| CYCLIN E-DEPENDENT KINASE STIMULATION | 5 |
| CYCLOOXYGENASE 1 INHIBITION | 509 |
| CYCLOOXYGENASE 2 INHIBITION | 572 |
| CYCLOOXYGENASE INHIBITION | 1108 |
| CYCLOOXYGENASE STIMULATION | 67 |
| CYCLOOXYGENASE(PLATELET)INHIBITION | 75 |
| CYCLOPHORASE INHIBITION | 3 |
| CYCLOPLEGIC ACTIVITY | 0 |
| CYSTATIN C STIMULATION | 0 |
| CYSTEINE PROTEASE ACTIVATION | 1 |
| CYSTEINE PROTEASE INHIBITION | 28 |
| CYSTIC FIBROSIS TREATMENT | 1 |
| CYTIDINE TRIPHOSPHATE SYNTHETASE INHIBITION | 2 |
| CYTIDINE TRIPHOSPHATE SYNTHETASE STIMULATION | 0 |
| CYTIDYLTRANSFERASE FORMATION INHIBITION | 2 |
| CYTOCHROME 1A2 INDUCTION | 4 |
| CYTOCHROME 2E1 INDUCTION | 4 |
| CYTOCHROME B-5 INCREASE | 40 |
| CYTOCHROME B-5 INHIBITION | 21 |
| CYTOCHROME B-5 REDUCTASE INHIBITION | 8 |
| CYTOCHROME B-5 REDUCTASE STIMULATION | 11 |
| CYTOCHROME C REDUCTASE INHIBITION | 30 |
| CYTOCHROME C REDUCTION EFFECT | 53 |
| CYTOCHROME C RELEASE INHIBITION | 8 |
| CYTOCHROME C RELEASE STIMULATION | 30 |
| CYTOCHROME LEVEL DECREASE | 8 |
| CYTOCHROME OXIDASE INDUCTION | 63 |
| CYTOCHROME OXIDASE INHIBITION | 41 |
| CYTOCHROME P-448 INDUCTION | 10 |
| CYTOCHROME P-448 INHIBITION | 4 |
| CYTOCHROME P3A INDUCTION | 4 |
| CYTOCHROME P450 1A1 MONOOXYGENASE INHIBITION | 12 |
| CYTOCHROME P450 1A1 MONOOXYGENASE STIMULATION | 1 |
| CYTOCHROME P450 1B1 MONOOXYGENASE INHIBITION | 1 |
| CYTOCHROME P450 3A4 INDUCTION | 1 |
| CYTOCHROME P450 3A4 INHIBITION | 30 |
| CYTOCHROME P450 3A4 MONOOXYGENASE STIMULATION | 0 |
| CYTOCHROME P450 BINDING | 20 |
| CYTOCHROME P450 INDUCTION | 252 |
| CYTOCHROME P450 INHIBITION | 795 |
| CYTOCHROME P450 LEVEL INCREASE | 21 |
| CYTOCHROME P450 STIMULATION | 71 |
| CYTOCHROME P45O 1A2 MONOOXYGENASE INHIBITION | 7 |
| CYTOKINE ENHANCEMENT | 27 |
| CYTOKINE INHIBITION | 50 |
| CYTOKINE TRANSCRIPTION INHIBITION | 3 |
| CYTOKINE TRANSCRIPTION STIMULATION | 0 |
| CYTOKININ ANTAGONIST ACTIVITY | 34 |
| CYTOKININ-LIKE ACTIVITY | 10 |
| CYTOLYTIC ACTIVITY | 65 |
| CYTOPENIC EFFECT | 1 |
| CYTOPROTECTIVE ACTIVITY | 184 |
| CYTOSKELETAL DISRUPTION INHIBITION | 1 |
| CYTOSKELETON DISORGANIZATION ACTIVITY | 8 |
| CYTOTOXIC ACTIVITY | 70594 |
| CYTOTOXIC CELL INHIBITION | 9 |
| CYTOTOXIC FACTOR ACTIVITY INCREASE | 1 |
| CYTOTOXICITY ENHANCEMENT | 70 |
| CYTOTOXICITY INHIBITION | 116 |
| CYTOTOXIN INDUCTION | 2 |
| DAUNOMYCIN EFFLUX INHIBITION | 10 |
| DEATH | 1157 |
| DEBRIDING AGENT | 2 |
| DECIDUAL RESPONSE INHIBITION | 9 |
| DECONGESTANT EFFECT | 43 |
| DEFENSIVE TOXIN | 2 |
| DEFIBRINOGENATING EFFECT | 30 |
| DEFLEECING EFFECT | 3 |
| DEFORMATION INDUCTION | 9 |
| DEGRANULATION INHIBITION | 160 |
| DEGRANULATION STIMULATION | 10 |
| DEHYDROASCORBIC ACID UPTAKE INHIBITION | 15 |
| DEHYDROFOLATE REDUCTASE INHIBITION | 2 |
| DEHYDROGENASE ACTIVITY STIMULATION | 1 |
| DEHYDROGENASE,ALPHA-HYDROXY-ACID- INHIBITION | 2 |
| DEHYDROPEPTIDASE INHIBITION | 4 |
| DEHYDROTESTOSTERONE FORMATION REDUCTION | 4 |
| DEHYDROTESTOSTERONE INDUCTION | 1 |
| DEHYDROXYPEPTIDASE INHIBITION | 4 |
| DELAYED TYPE CUTANEOUS HYPERSENSITIVITY INHIBITION | 107 |
| DELAYED TYPE CUTANEOUS HYPERSENSITIVITY STIMULATION | 63 |
| DELAYED TYPE HYPERSENSITIVITY INHIBITION | 24 |
| DELAYED TYPE HYPERSENSITIVITY STIMULATION | 11 |
| DELTA RECEPTOR ANTAGONIST ACTIVITY | 1 |
| DELTA RECEPTOR BINDING ACTIVITY | 1 |
| DELTA-CHYMOTRYPSIN INHIBITION | 1 |
| DEMETHYLASE INHIBITION | 31 |
| DEMULCENT EFFECT | 93 |
| DEMYELINATING ACTIVITY | 10 |
| DENATURATION OF | 1 |
| DENERVATING ACTIVITY | 10 |
| DENSE ERYTHROCYTE FORMATION INHIBITION | 1 |
| DENTAL PLAQUE FORMATION INHIBITION | 11 |
| DENTIFRICE ACTIVITY | 22 |
| DEODORIZING EFFECT | 84 |
| DEOXYNUCLEOTIDYLTRANSFERASE INHIBITION | 8 |
| DEOXYRIBONUCLEASE INHIBITION | 12 |
| DEOXYRIBOSE DEGRADATION INHIBITION | 30 |
| DEOXYRIBOSE DEGRADATION STIMULATION | 1 |
| DEPIGMENTATION EFFECT | 26 |
| DEPILATORY ACTIVITY | 6 |
| DEPOLARIZING AGENT | 47 |
| DEPURATIVE EFFECT | 143 |
| DERMAL PENETRATION ENHANCER | 19 |
| DERMATITIS IMPROVEMENT | 177 |
| DERMATITIS PRODUCING EFFECT | 452 |
| DERMATOLOGICAL STUDIES | 6 |
| DESATURASE DELTA-5 ACTIVITY INCREASE | 2 |
| DESATURASE-DELTA 6 INHIBITION | 3 |
| DESATURASE-DELTA-5 INHIBITION | 25 |
| DESCRIPTION OF PATHOLOGICAL STATE OF A PLANT | 4 |
| DESENSITIZATION EFFECT | 15 |
| DESMUTAGENIC ACTIVITY | 255 |
| DETERGENT EFFECT | 5 |
| DETOXIFYING EFFECT(NON-IMMUNOLOGIC) | 39 |
| DEVELOPMENTAL DELAY ACTIVITY | 7 |
| DEXTRANASE INHIBITION | 3 |
| DEXTRANSUCRASE INHIBITION | 21 |
| DIABETES-INHIBITION OF DEVELOPMENT | 23 |
| DIABETIC ANGIOPATHY IMPROVEMENT | 4 |
| DIABETIC CATARACT INHIBITION | 3 |
| DIABETIC NEPHROPATHY IMPROVEMENT | 8 |
| DIABETIC NEUROPATHY IMPROVEMENT | 20 |
| DIABETIC RETINOPATHY IMPROVEMENT | 7 |
| DIABETIC VASCULOPATHY IMPROVEMENT | 2 |
| DIABETOGENIC ACTIVITY | 29 |
| DIACYLGLYCEROL ACYLTRANSFERASE INHIBITION | 23 |
| DIACYLGLYCEROL KINASE INHIBITION | 6 |
| DIACYLGLYCEROL LEVEL DECREASE | 6 |
| DIACYLGLYCEROL LEVEL INCREASE | 2 |
| DIAMINE OXIDASE INHIBITION | 10 |
| DIAMINE OXIDASE STIMULATION | 0 |
| DIAPHORASE INDUCING ACTIVITY | 5 |
| DIAPHORASE INHIBITION | 16 |
| DIAPHORETIC ACTIVITY | 501 |
| DIASTASE INHIBITION | 32 |
| DIASTOLIC DYSFUNCTION IMPROVEMENT | 1 |
| DIGESTANT ACTION | 1563 |
| DIGLYCERIDE FORMATION INHIBITION | 1 |
| DIHYDROFOLATE REDUCTASE INHIBITION | 44 |
| DIHYDROOROTATE DEHYDROGENASE INHIBITION | 4 |
| DIHYDROPTEROATE SYNTHETASE INHIBITION | 4 |
| DIHYDROTESTOSTERONE INHIBITION | 1 |
| DIHYDROTESTOSTERONE STIMULATION | 1 |
| DIHYDROXYPHENYLACETIC ACID(DOPAC) INHIBITION | 3 |
| DIHYDROXYPHENYLACETIC ACID(DOPAC) STIMULATION | 5 |
| DILTIAZEM BINDING INHIBITION | 4 |
| DIPEPTIDE SYNTHETASE INHIBITION | 5 |
| DIPEPTIDYL AMINOPEPTIDASE IV INHIBITION | 2 |
| DIPEPTIDYL PEPTIDASE III INHIBITION | 2 |
| DIPEPTIDYL PEPTIDASE INHIBITION | 5 |
| DIPSOGENIC EFFECT | 2 |
| DISACCHARIDASE INHIBITION | 1 |
| DISSOLUTION OF ACTIVE PRINCIPLE FROM PLANT DURING EXTRACTION | 1 |
| DISULFIRAM-LIKE ACTIVITY | 3 |
| DIURETIC ACTIVITY | 4576 |
| DNA ADDUCT FORMATION ENHANCEMENT | 10 |
| DNA ADDUCT FORMATION INDUCTION | 10 |
| DNA ADDUCT FORMATION INHIBITION | 53 |
| DNA AGGREGATION ENHANCEMENT | 2 |
| DNA BINDING EFFECT | 533 |
| DNA CLEAVAGE INHIBITION | 30 |
| DNA COMPLEX FORMATION INHIBITION | 5 |
| DNA COMPLEXING STIMULATION | 1 |
| DNA CROSS-LINK FORMATION INHIBITION | 1 |
| DNA CROSS-LINK FORMATION STIMULATION | 35 |
| DNA DAMAGE PREVENTION ACTIVITY | 137 |
| DNA DEPENDENT DNA POLYMERASE ALPHA INHIBITION | 12 |
| DNA DEPENDENT RNA POLYMERASE I INHIBITION | 9 |
| DNA DEPENDENT RNA POLYMERASE INHIBITION | 44 |
| DNA DEPENDENT RNA POLYMERASE STIMULATION | 1 |
| DNA DISRUPTION EFFECT | 103 |
| DNA FRAGMENTATION FACTOR-45 DEGRADATION INDUCTION | 2 |
| DNA FRAGMENTATION INHIBITION | 21 |
| DNA FRAGMENTATION STIMULATION | 21 |
| DNA GYRASE INHIBITION | 51 |
| DNA HELICASE INHIBITION | 2 |
| DNA INTERCALATING EFFECT | 98 |
| DNA INTERSTRAND CROSS-LINK INHIBITION | 1 |
| DNA LADDER FORMATION STIMULATION | 11 |
| DNA LIGASE INHIBITION | 44 |
| DNA METHYLASE INHIBITION | 9 |
| DNA METHYLASE STIMULATION | 5 |
| DNA METHYLATION INHIBITION | 22 |
| DNA METHYLATION STIMULATION | 2 |
| DNA NICKING ACTIVITY | 208 |
| DNA POLYMERASE ALPHA INHIBITION | 222 |
| DNA POLYMERASE BETA INHIBITION | 162 |
| DNA POLYMERASE GAMMA INHIBITION | 40 |
| DNA POLYMERASE I INHIBITION | 82 |
| DNA POLYMERASE II INHIBITION | 17 |
| DNA POLYMERASE III INHIBITION | 3 |
| DNA POLYMERASE INDUCTION | 6 |
| DNA POLYMERASE INHIBITION | 332 |
| DNA PRIMASE INHIBITION | 4 |
| DNA REPAIR INDUCTION | 98 |
| DNA REPAIR INHIBITION | 36 |
| DNA REPAIR INHIBITION(GAMMA RADIATION-INDUCED) | 3 |
| DNA REPAIR INHIBITION(UV-INDUCED) | 24 |
| DNA REPAIR INHIBITION(X-RAY-INDUCED) | 10 |
| DNA REPAIR SYNTHESIS STIMULATION | 70 |
| DNA SCISSION EFFECT | 342 |
| DNA SCISSION INHIBITION | 40 |
| DNA STIMULATION | 123 |
| DNA SYNTHESIS INHIBITION | 2010 |
| DNA SYNTHESIS STIMULATION | 111 |
| DNA TRANSCRIPTION INITIATION | 19 |
| DNA UNCOILING STIMULATION | 1 |
| DNA-BINDING INHIBITION | 111 |
| DNA-PROTEIN CROSS-LINK INHIBITION | 1 |
| DNASE ACTIVITY | 17 |
| DOPA DECARBOXYLASE INHIBITION | 17 |
| DOPAMINE BETA-HYDROXYLASE INHIBITION | 44 |
| DOPAMINE DEPLETION | 38 |
| DOPAMINE INCREASE | 49 |
| DOPAMINE METABOLISM ALTERATION | 13 |
| DOPAMINE RECEPTOR BINDING INHIBITION | 8 |
| DOPAMINE RECEPTOR BLOCKING EFFECT | 197 |
| DOPAMINE RECEPTOR SUPERSENSITIZATION INHIBITION | 7 |
| DOPAMINE RECEPTOR UPREGULATION | 2 |
| DOPAMINE RELEASE INHIBITION | 24 |
| DOPAMINE SYNTHESIS INHIBITION | 9 |
| DOPAMINE TURNOVER STIMULATION | 1 |
| DOPAMINE UPTAKE INHIBITION | 84 |
| DOPAMINE-BETA-HYDROXYLASE STIMULATION | 5 |
| DOPAMINE-RELEASING ACTIVITY | 37 |
| DOPAMINERGIC EFFECT | 45 |
| DOPAMINERGIC(D1) RECEPTOR BINDING ACTIVITY | 10 |
| DOPAMINERGIC(D2) RECEPTOR BINDING ACTIVITY | 17 |
| DPN-CYTOCHROME C REDUCTASE INHIBITION | 1 |
| DPN-CYTOCHROME C REDUCTASE STIMULATION | 0 |
| DROMOTROPIC EFFECT,NEGATIVE | 11 |
| DROMOTROPIC EFFECT,POSITIVE | 1 |
| DROUGHT RESISTANCE INCREASE | 2 |
| DRUG ACCUMULATION INHIBITION | 6 |
| DRUG ACCUMULATION STIMULATION | 4 |
| DRUG ADDICTION | 9 |
| DRUG ADDICTION INHIBITION | 72 |
| DRUG DELIVERY VEHICLE USE | 2 |
| DRUG DISCRIMINATION EFFECT | 20 |
| DRUG EFFLUX INHIBITION | 11 |
| DRUG INTERACTION | 170 |
| DRUG METABOLIZING ENZYME INHIBITION | 4 |
| DRUG NEUTRALIZING EFFECT | 1 |
| DRUG RESISTANCE REVERSAL INDUCTION | 88 |
| DRUG(AMPHETAMINE) DISCRIMINATION EFFECT | 2 |
| DRUG(COCAINE) DISCRIMINATION EFFECT | 2 |
| DT DIAPHORASE LEVEL INCREASE | 11 |
| DYE-CONTAINING PLANT | 87 |
| DYSSPERMATOGENIC ACTIVITY | 2 |
| E-SELECTIN EXPRESSION INHIBITION | 4 |
| E-SELECTIN EXPRESSION STIMULATION | 1 |
| E-SELECTIN TRANSCRIPTION STIMULATION | 1 |
| EARLY ANTIGEN VIRAL INDUCTION INHIBITION | 133 |
| EARLY ANTIGEN VIRAL INDUCTION STIMULATION | 19 |
| ECDYSONE,20-HYDROXY: ANTAGONIST ACTIVITY | 0 |
| ECDYSONE-20-MONOOXYGENASE INHIBITION | 6 |
| ECDYSTEROID ACTIVITY | 2 |
| ECDYSTEROID AGONIST ACTIVITY | 32 |
| ECDYSTEROID ANTAGONIST ACTIVITY | 54 |
| ECONOMIC ASPECTS OF | 5 |
| ECONOMIC ASPECTS OF PLANT DRUGS | 7 |
| ECONOMIC ASPECTS OF PLANT-DERIVED CHEMICAL CMPDS | 1 |
| ECTOPIC PREGNANCY TREATMENT | 1 |
| EEF-2 KINASE INHIBITION | 9 |
| EFFECT OF AMOUNT OF LIGHT ON PLANTS | 4 |
| EFFECT OF FERTILIZERS ON PLANTS | 8 |
| EFFECT OF FUNGICIDES ON PLANT | 0 |
| EFFECT OF HARVEST TIME ON PLANT AND CONSTITUENT YIELD | 1 |
| EFFECT OF INFECTION ON PLANTS AND THEIR CONSTITUENTS | 1 |
| EFFECT OF PLANT EXTRACT ON FERMENTATION | 1 |
| EFFECT OF SOIL FUMIGATION ON PLANT | 2 |
| EFFECT OF SPACING ON PLANTS | 4 |
| EFFECT OF STERILIZATION PROCEDURES ON A PURE COMPOUND | 1 |
| EFFECT OF TEMPERATURE ON PLANT GROWTH AND CONSTITUENTS | 1 |
| EFFECT OF WATER SUPPLY ON PLANT GROWTH | 1 |
| EFFECT OF WEEDING ON PLANTS | 2 |
| EFFECT ON TEETH | 6 |
| EFFECTIVE REFRACTORY PERIOD INCREASE | 5 |
| EFFECTS OF ENVIRONMENTAL POLLUTION ON PLANT GROWTH | 1 |
| EFFECTS OF HERBICIDES AND GROWTH REGULATORS ON PLANTS | 13 |
| EFFECTS OF STERILIZATION ON PLANT MATERIAL | 1 |
| EGG PRODUCTION INCREASED | 5 |
| EJACULATION RETARDANT | 19 |
| EJACULATION STIMULANT | 19 |
| ELAM-1 EXPRESSION INHIBITION | 2 |
| ELASTASE INHIBITION | 504 |
| ELASTASE RELEASE INHIBITION | 3 |
| ELECTROLYTE EXCRETION EFFECT | 11 |
| ELECTROLYTE TRANSPORT INHIBITION | 5 |
| ELECTROLYTE TRANSPORT MODULATION | 1 |
| ELECTRON TRANSPORT INHIBITION | 32 |
| ELECTROPHYSIOLOGICAL EFFECTS | 46 |
| EMBRYONIC CELL DIVISION INHIBITION | 1 |
| EMBRYOTOXIC EFFECT(RELATED TO FERTILITY REGULATION) | 1074 |
| EMBRYOTOXIC EFFECT(RELATED TO GENERAL TOXIC EFFECTS) | 134 |
| EMETIC ACTIVITY | 704 |
| EMOLLIENT EFFECT | 304 |
| ENDOCYTOSIS INHIBITION | 8 |
| ENDOGENOUS BETA-AMYLOID LEVELS DECREASED | 3 |
| ENDOGLUCONASE INHIBITION | 5 |
| ENDONUCLEASE INHIBITION | 5 |
| ENDONUCLEASE STIMULATION | 0 |
| ENDOPEPTIDASE INHIBITION | 44 |
| ENDOPEPTIDASE STIMULATION | 6 |
| ENDORPHIN BINDING INHIBITION | 34 |
| ENDOTHELIAL CELL TUBE FORMATION INHIBITION | 24 |
| ENDOTHELIAL CELL-LEUKOCYTE ADHESION INHIBITION | 10 |
| ENDOTHELIAL CELL-LEUKOCYTE ADHESION STIMULATION | 2 |
| ENDOTHELIN A RECEPTOR BINDING | 29 |
| ENDOTHELIN A RECEPTOR BINDING INHIBITION | 14 |
| ENDOTHELIN B RECEPTOR BINDING | 31 |
| ENDOTHELIN CONVERTING ENZYME INHIBITION | 13 |
| ENDOTHELIN INHIBITION | 30 |
| ENDOTHELIN-1 ACTIVATION INHIBITION | 2 |
| ENDOTHELIN-1 PRODUCTION STIMULATION | 2 |
| ENDOTHELIN-1 RECEPTOR BINDING | 28 |
| ENDOTHELIN-1 RECEPTOR BINDING INHIBITION | 5 |
| ENDOTHELIN-2 RECEPTOR BINDING | 10 |
| ENDURANCE EFFECT | 20 |
| ENERGY EXPENDITURE STIMULATION | 5 |
| ENKEPHALINASE A-I INHIBITION | 2 |
| ENKEPHALINASE A-II INHIBITION | 2 |
| ENKEPHALINASE B INHIBITION | 2 |
| ENOPHTHALMIC EFFECT | 2 |
| ENZYME DEBRIDEMENT ACTIVITY | 2 |
| ENZYME EFFECTS(UNSPECIFIED) | 98 |
| EOSINOPENIC EFFECT | 12 |
| EOSINOPHIL CATIONIC PROTEIN RELEASE INHIBITION | 3 |
| EOSINOPHIL PEROXIDASE INHIBITION | 1 |
| EOSINOPHILA EFFECT | 3 |
| EOTAXIN (CHEMOKINE) PRODUCTION INHIBITION | 11 |
| EPIDERMAL BARRIER ACTIVITY | 2 |
| EPIDERMAL GROWTH FACTOR BINDING INHIBITION | 13 |
| EPIDERMAL GROWTH FACTOR BINDING STIMULATION | 7 |
| EPIDERMAL GROWTH FACTOR INHIBITION | 14 |
| EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITION | 43 |
| EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITION | 28 |
| EPIDERMAL GROWTH FACTOR RECEPTOR SIALYLATION | 1 |
| EPINEPHRINE LEVEL INCREASE | 6 |
| EPOXIDASE INHIBITION | 30 |
| EPOXIDE HYDRASE INDUCTION | 35 |
| EPOXIDE HYDRASE INHIBITION | 3 |
| EPOXIDE HYDRATASE INHIBITION | 2 |
| EPOXIDE HYDRATASE STIMULATION | 8 |
| EPOXIDE HYDROLASE ACTIVITY INCREASE | 39 |
| EPOXIDE HYDROLASE INHIBITION | 15 |
| EPSTEIN-BARR VIRUS ACTIVATION | 143 |
| EPSTEIN-BARR VIRUS EARLY ANTIGEN ACTIVATION INHIBITION | 966 |
| EPSTEIN-BARR VIRUS EARLY ANTIGEN INDUCTION | 136 |
| ERB B-2 RECEPTOR KINASE INHIBITION | 1 |
| ERECTILE DYSFUNCTION TREATMENT | 24 |
| ERGOGENIC ACTIVITY | 47 |
| ERGOSTEROL SYNTHESIS INHIBITION | 2 |
| ERK 1/2 ACTIVATION INHIBITION | 17 |
| ERK 1/2 ACTIVATION STIMULATION | 3 |
| ERK1 ACTIVATION STIMULATION | 1 |
| EROD INHIBITION | 8 |
| ERYTHROCYTE AGGLUTINATION STIMULATION | 4 |
| ERYTHROMYCIN N-DEMETHYLASE INHIBITION | 29 |
| ERYTHROMYCIN N-DEMETHYLASE STIMULATION | 8 |
| ERYTHROMYCIN N-DEMETHYLATION INHIBITIION | 2 |
| ERYTHROMYCIN RESISTANCE-INDUCING EFFECT | 7 |
| ERYTHROPOIESIS INHIBITION | 6 |
| ERYTHROPOIESIS STIMULATION | 3 |
| ERYTHROPOIETIN INDUCTION | 10 |
| ERYTHROPOIETIN INHIBITION | 0 |
| ESCHAROTIC EFFECT | 79 |
| ESTERASE ACTIVITY | 16 |
| ESTERASE INHIBITION | 13 |
| ESTERIFICATION STIMULATION | 1 |
| ESTRADIOL LEVEL DECREASE | 3 |
| ESTRADIOL SECRETION STIMULATION | 15 |
| ESTRADIOL-2-HYDROXYLASE INHIBITION | 5 |
| ESTRADIOL-INDUCED MRNA EXPRESSION INHIBITION | 2 |
| ESTRADIOL-INDUCED MRNA EXPRESSION STIMULATION | 2 |
| ESTROGEN BINDING INHIBITION | 42 |
| ESTROGEN BINDING SITE-TYPE II BINDING EFFECT | 22 |
| ESTROGEN METABOLISM STIMULATION | 18 |
| ESTROGEN RECEPTOR BINDING EFFECT | 276 |
| ESTROGEN RECEPTOR LEVEL INCREASE | 1 |
| ESTROGEN RECEPTOR MODULATION | 3 |
| ESTROGEN RECEPTOR TRANSCRIPTION STIMULATION | 15 |
| ESTROGEN RECEPTOR(ALPHA) BINDING EFFECT | 72 |
| ESTROGEN RECEPTOR(ALPHA) INHIBITION | 8 |
| ESTROGEN RECEPTOR(ALPHA) STIMULATION | 8 |
| ESTROGEN RECEPTOR(BETA) BINDING EFFECT | 68 |
| ESTROGEN RECEPTOR(BETA) EXPRESSION INHIBITION | 2 |
| ESTROGEN RECEPTOR-ALPHA TRANSCRIPTION INHIBITION | 5 |
| ESTROGEN SYNTHESIS STIMULATION | 2 |
| ESTROGEN SYNTHETASE INHIBITION | 10 |
| ESTROGENIC EFFECT | 2478 |
| ESTRONE SULFATASE INHIBITION | 7 |
| ESTROUS CYCLE DISRUPTION EFFECT | 321 |
| ET-A RECEPTOR INHIBITION | 26 |
| ETHANOL ABSORPTION DECREASED | 122 |
| ETHANOL ABSORPTION INCREASED | 1 |
| ETHANOL ELIMINATION INCREASED | 11 |
| ETHANOL OXIDATION ENHANCED | 29 |
| ETHANOL POTENTIATION EFFECT | 4 |
| ETHANOL PREFERENCE DECREASED | 25 |
| ETHOXYCOUMARIN DEETHYLASE INHIBITION | 88 |
| ETHOXYCOUMARIN DEETHYLASE STIMULATION | 19 |
| ETHOXYRESORUFIN DEETHYLASE INDUCTION | 16 |
| ETHOXYRESORUFIN DEETHYLASE INHIBITION | 30 |
| ETHOXYRESORUFIN O-DEMETHYLASE INHIBITION | 5 |
| ETHOXYRESORUFIN-O-DEALKYLASE STIMULATION | 6 |
| ETHOXYRESORUFIN-O-DEALKYLASE(EROD) INHIBITION | 53 |
| ETHOXYRESORUFIN-O-DEETHYLASE INHIBITION | 54 |
| ETHOXYRESORUFIN-O-DEETHYLASE(EROD) STIMULATION | 17 |
| ETHYLENE BIOSYNTHESIS INHIBITION | 7 |
| ETHYLMORPHINE-N-DEMETHYLASE INDUCTION | 1 |
| ETHYLMORPHINE-N-DEMETHYLASE INHIBITION | 9 |
| ETHYNYLBICYCLOORTHOBENZOATE BINDING INHIBITION | 1 |
| EUGLOBULIN LYSIS TIME SHORTENING | 3 |
| EUKARYOTIC INITIATION FACTOR-2 INHIBITION | 1 |
| EUPHORIANT ACTIVITY | 63 |
| EXO-BETA-1,3-GLUCANASE INHIBITION | 1 |
| EXOCYTOSIS INHIBITION | 40 |
| EXOCYTOSIS STIMULATION | 8 |
| EXONUCLEASE III INHIBITION | 2 |
| EXPECTORANT ACTIVITY | 1103 |
| EXPLORATORY BEHAVIOR DECREASED | 29 |
| EXPLORATORY BEHAVIOR INCREASED | 3 |
| EXTRACELLULAR REGULATED KINASE-2 INHIBITION | 2 |
| EXTRACELLULAR SIGNAL-REGULATED KINASE 2 STIMULATION | 2 |
| EXTRAVASATION ACTIVITY | 1 |
| EYE PROBLEMS(UNSPECIFIED) | 530 |
| F-ACTIN FORMATION INHIBITION | 1 |
| FACTOR X LEVEL DECREASED | 2 |
| FACTOR-XA INHIBITION | 13 |
| FARNESOIC ACID METHYLTRANSFERASE INHIBITION | 1 |
| FARNESOID X RECEPTOR ANTAGONIST | 2 |
| FARNESYL-PROTEIN TRANSFERASE INHIBITION | 142 |
| FARNESYLTRANSFERASE INHIBITION | 29 |
| FATTY ACID BINDING PROTEIN INHIBITION | 0 |
| FATTY ACID COMPOSITION CHANGE | 27 |
| FATTY ACID CONTENT DECREASE | 42 |
| FATTY ACID CONTENT INCREASE | 40 |
| FATTY ACID OXIDATION INHIBITION | 3 |
| FATTY ACID OXIDATION STIMULATION | 4 |
| FATTY ACID RELEASE INHIBITION | 12 |
| FATTY ACID RELEASE STIMULATION | 17 |
| FATTY ACID SYNTHASE INHIBITION | 28 |
| FATTY ACID SYNTHASE STIMULATION | 5 |
| FATTY ACID SYNTHESIS INHIBITION | 10 |
| FATTY ACID SYNTHESIS STIMULATION | 2 |
| FECUNDITY PROMOTION EFFECT | 10 |
| FEED EFFICIENCY IMPROVEMENT | 4 |
| FEEDING ATTRACTANT(FISH) | 12 |
| FEEDING DETERRENT | 8 |
| FEEDING DETERRENT(ANIMAL) | 106 |
| FEEDING DETERRENT(FISH) | 134 |
| FEEDING DETERRENT(INSECT) | 3465 |
| FEEDING STIMULANT | 16 |
| FEEDING STIMULANT(INSECT) | 141 |
| FELINE IMMUNODEFICIENCY VIRUS INTEGRASE INHIBITION | 1 |
| FEMALE DISORDERS(UNSPECIFIED) | 753 |
| FERMENTATION INHIBITION | 2 |
| FERMENTATION STIMULATION | 12 |
| FERRITIN EXPRESSION STIMULATION | 2 |
| FERRITIN IRON RELEASE STIMULATION | 4 |
| FERRITIN LEVEL DECREASE | 0 |
| FERTILITY PROMOTION EFFECT | 646 |
| FERTILIZATION INHIBITION | 90 |
| FERTILIZATION INHIBITION(NON-MAMMALIAN) | 33 |
| FERTILIZATION STIMULANT | 33 |
| FETAL OSSIFICATION REDUCTION | 9 |
| FIBRIN DEPOSITION INCREASE | 1 |
| FIBRINOGEN BINDING INHIBITION | 8 |
| FIBRINOGEN CONVERSION INHIBITION | 21 |
| FIBRINOGEN LEVEL DECREASED | 17 |
| FIBRINOGEN LEVEL INCREASE | 5 |
| FIBRINOGENOLYTIC ACITIVTY | 1 |
| FIBRINOLYTIC ACTIVITY | 279 |
| FIBRINOLYTIC POTENTIAL INHIBITION | 1 |
| FIBROBLAST GROWTH FACTOR EXPRESSION | 2 |
| FIBROBLAST GROWTH FACTOR RELEASE INHIBITION | 8 |
| FIBROMECTIN SYNTHESIS INHIBITION | 2 |
| FIBROMECTIN SYNTHESIS STIMULATION | 1 |
| FIBRONECTIN DEPOSITION STIMULATION | 2 |
| FIBRONECTIN PHOSPHORYLATION INHIBITION | 0 |
| FIBRONECTIN PRODUCTION INHIBITION | 2 |
| FICIN INHIBITION | 3 |
| FISH POISON | 1504 |
| FKBP12(FK506 BINDING PROTEIN) BINDING ACTIVITY | 2 |
| FLAVOR ENHANCING EFFECT | 5 |
| FLAVORING EFFECT | 74 |
| FLUORESCENCE REACTION | 9 |
| FOAM CELL FORMATION INHIBITION | 1 |
| FOCAL ADHESION KINASE ACTIVATION | 1 |
| FOOD COLORING AGENT | 5 |
| FOOD CONSUMPTION REDUCTION | 86 |
| FOOD PRESERVATIVE | 14 |
| FOOD USE | 2190 |
| FOOD-DRUG INTERACTION | 18 |
| FOOT PROBLEM TREATMENT(UNSPEC) | 2 |
| FORMIC ACID INCORPORATION INTO PURINES INHIBITION | 24 |
| FORMYLMETHIONINE AMINOPEPTIDASE INHIBITION | 1 |
| FORMYLTETRAHYDROFOLATE SYNTHETASE INHIBITION | 3 |
| FRACTURE HEALING ACCELERATION | 78 |
| FRAGRANCE USE | 54 |
| FREE RADICAL FORMATION INHIBITION | 71 |
| FREE RADICAL FORMATION STIMULATION | 2 |
| FRUCTOSAMINE LEVEL DECREASE | 1 |
| FRUCTOSE DIPHOSPHATASE INHIBITION | 8 |
| FRUCTOSE DIPHOSPHATASE STIMULATION | 6 |
| FRUCTOSE DIPHOSPHATE ALDOLASE INHIBITION | 1 |
| FRUCTOSE LEVEL DECREASE | 2 |
| FRUCTOSE UTILIZATION INHIBITION | 2 |
| FRUCTOSE-1-6-BIPHOSPHATASE INHIBITION | 2 |
| FRUIT GROWTH STIMULANT | 3 |
| FRUIT SPOILAGE INHIBITION | 4 |
| FRUITING BODY INDUCTION | 3 |
| FSH LEVELS DECREASED | 7 |
| FSH RELEASE INHIBITION | 51 |
| FSH RELEASE STIMULATION EFFECT | 38 |
| FSH SYNTHESIS INHIBITION | 11 |
| FSH SYNTHESIS STIMULATION | 27 |
| FUCOSIDASE INHIBITION | 39 |
| FUCOSYLTRANSFERASE INHIBITION | 1 |
| FUMARASE INHIBITION | 15 |
| FUMIGANT ACTIVITY | 8 |
| FUNCTION COORDINATION EFFECTS | 2 |
| FUNGAL ATTRACTANT ACTIVITY | 2 |
| FUNGAL HORMONE ACTIVITY | 2 |
| FUNGAL HYPHAL SPHERICAL ENLARGEMENT | 4 |
| FUNGAL STIMULANT | 152 |
| FUNGAL STIMULANT(PLANT PATHOGENS) | 28 |
| FURIN INHIBITION | 0 |
| G PROTEIN RECEPTOR BINDING | 1 |
| G-PROTEIN ACTIVATION STIMULATION | 2 |
| GABA INHIBITION | 36 |
| GABA LEVEL INCREASE | 20 |
| GABA RECEPTOR BINDING INHIBITION | 62 |
| GABA RECEPTOR BINDING STIMULATION | 19 |
| GABA RECEPTOR BLOCKING EFFECT | 143 |
| GABA RECEPTOR MODULATORY EFFECT | 35 |
| GABA RELEASE INHIBITION | 14 |
| GABA RELEASE STIMULATION | 14 |
| GABA TRANSAMINASE ACTIVITY INCREASE | 1 |
| GABA TRANSAMINASE ACTIVITY INHIBITION | 23 |
| GABA UPTAKE INHIBITION | 1 |
| GALACTAGOGUE EFFECT | 852 |
| GALACTITOL ACCUMULATION INHIBITION | 4 |
| GALACTOSIDASE INHIBITION | 36 |
| GALACTOSYLTRANSFERASE INHIBITION | 1 |
| GALANIN RECEPTOR BINDING ACTIVITY | 6 |
| GALL BLADDER EFFECT(UNSPECIFIED) | 56 |
| GALL BLADDER PARALYSIS | 3 |
| GALLSTONE FORMATION INHIBITION | 13 |
| GALLSTONE SOLUBILIZING EFFECT | 31 |
| GAMETOCYTOCIDAL ACTIVITY | 5 |
| GAMMA CARBOXYLASE INHIBITION | 1 |
| GAMMA-CHYMOTRYPSIN INHIBITION | 1 |
| GAMMA-GLUTAMYL CYSTEINE SYNTHETASE INDUCTION | 2 |
| GAMMA-GLUTAMYL TRANSFERASE INDUCTION | 16 |
| GAMMA-GLUTAMYL TRANSFERASE INHIBITION | 20 |
| GAMMA-GLUTAMYL TRANSPEPTIDASE INHIBITION | 53 |
| GAMMA-GLUTAMYL TRANSPEPTIDASE STIMULATION | 35 |
| GANGLIONIC BLOCKING EFFECT | 32 |
| GANGLIONIC STIMULANT EFFECT | 4 |
| GANGLIOSIDE SYNTHESIS INHIBITION | 3 |
| GAP JUNCTION CHANNEL BLOCKING ACTIVITY | 2 |
| GAP JUNCTIONAL INTERCELLULAR COMMUNICATION PROTECTION | 9 |
| GAP JUNCTIONAL INTERCELLULAR COMMUNICATION STIMULATION | 6 |
| GASTRIC ANTISECRETORY ACTIVITY | 172 |
| GASTRIC EMPTYING TIME DECREASED | 25 |
| GASTRIC EMPTYING TIME INCREASED | 69 |
| GASTRIC INHIBITORY PEPTIDE SECRETION INHIBITION | 4 |
| GASTRIC INHIBITORY POLYPEPTIDE INHIBITION | 2 |
| GASTRIC INHIBITORY POLYPEPTIDE STIMULATION | 12 |
| GASTRIC MOTILITY REDUCTION | 73 |
| GASTRIC MOTILITY STIMULANT | 64 |
| GASTRIC MUCOSAL EXFOLIANT ACTIVITY | 6 |
| GASTRIC MUCUS INCREASE | 20 |
| GASTRIC SECRETORY INHIBITION | 164 |
| GASTRIC SECRETORY STIMULATION | 65 |
| GASTRIN LEVEL DECREASE | 2 |
| GASTRIN RELEASING PEPTIDE RECEPTOR BINDING INHIBITION | 6 |
| GASTROINTESTINAL DISORDERS(UNSPECIFIED) | 506 |
| GASTRULATION INHIBITION | 5 |
| GDP INHIBITION | 1 |
| GELATINASE INHIBITION | 5 |
| GELATINASE STIMULATION | 1 |
| GELATINOLYTIC ACTIVITY | 1 |
| GENE CONVERSION EFFECT | 9 |
| GENE EXPRESSION INDUCTION | 256 |
| GENE EXPRESSION INHIBITION | 244 |
| GENE INDUCTION | 33 |
| GENE TRANSCRIPTION INHIBITION | 3 |
| GENETIC IMPROVEMENT OF MEDICINAL PLANTS | 6 |
| GENITAL DISORDERS(UNSPECIFIED) | 183 |
| GENITOURINARY EFFECT(UNSPECIFIED) | 586 |
| GENOTOXICITY ACTIVITY | 501 |
| GENOTOXICITY INHIBITION | 155 |
| GERANYLGERANYL-PROTEIN TRANSFERASE INHIBITION | 23 |
| GERANYLGERANYLTRANSFERASE INHIBITION | 3 |
| GERM TUBE GROWTH INHIBITION | 25 |
| GERMINATION STIMULANT(POLLEN) | 3 |
| GIANT CELL FORMATION INHIBITION | 78 |
| GIBBERELLIN-LIKE ACTIVITY | 27 |
| GLAUCOMIC EFFECT | 1 |
| GLOMERULAR FILTRATION RATE DECREASE | 1 |
| GLOMERULAR FILTRATION RATE INCREASE | 1 |
| GLUCAGON INDUCTION | 35 |
| GLUCAGON RECEPTOR BINDING | 0 |
| GLUCAGON RELEASE STIMULATION | 3 |
| GLUCAGON SYNTHESIS INHIBITION | 4 |
| GLUCAGON-LIKE PEPTIDE BINDING | 0 |
| GLUCAGON-LIKE PEPTIDE SECRETION INHIBITION | 1 |
| GLUCAGON-LIKE PEPTIDE SECRETION STIMULATION | 1 |
| GLUCAN FORMATION INHIBITION | 16 |
| GLUCAN SYNTHASE,(1-3)-BETA ACTIVATION | 1 |
| GLUCAN SYNTHASE,(1-3)BETA INHIBITION | 2 |
| GLUCAN SYNTHETASE INDUCTION | 1 |
| GLUCAN SYNTHETASE INHIBITION(1-3)-BETA-D | 27 |
| GLUCANASE INHIBITION | 12 |
| GLUCANASE(BETA-1,3) ACTIVITY | 1 |
| GLUCOAMYLASE IMMOBILIZATION | 1 |
| GLUCOAMYLASE INHIBITION | 25 |
| GLUCOCORTICOID BINDING INHIBITION | 1 |
| GLUCOCORTICOID GENE DOWN-REGULATION | 2 |
| GLUCOCORTICOID INTERACTING RECEPTOR PROTEIN INHIBITION | 2 |
| GLUCOCORTICOID LIKE ACTIVITY | 1 |
| GLUCOCORTICOID MEDIATED SIGNAL TRANSDUCTION INHIBITION | 3 |
| GLUCOCORTICOID RECEPTOR BINDING | 14 |
| GLUCOCORTICOID RECEPTOR LEVEL INCREASE | 3 |
| GLUCOCORTICOID RELEASE INHIBITION | 1 |
| GLUCOKINASE INHIBITION | 1 |
| GLUCOKINASE STIMULATION | 16 |
| GLUCONEOGENESIS INHIBITION | 19 |
| GLUCONEOGENESIS STIMULATION | 23 |
| GLUCOSAMINE SYNTHETASE INHIBITION | 8 |
| GLUCOSE ABSORPTION INHIBITION | 79 |
| GLUCOSE METABOLISM INHIBITION | 1 |
| GLUCOSE METABOLISM STIMULATION | 31 |
| GLUCOSE OXIDASE INDUCTION | 4 |
| GLUCOSE OXIDASE INHIBITION | 6 |
| GLUCOSE RELEASE INHIBITION | 5 |
| GLUCOSE TRANSPORT INHIBITION | 70 |
| GLUCOSE TRANSPORT STIMULATION | 76 |
| GLUCOSE UPTAKE INDUCTION | 99 |
| GLUCOSE UPTAKE INHIBITION | 102 |
| GLUCOSE UTILIZATION INHIBITION | 8 |
| GLUCOSE UTILIZATION STIMULATION | 22 |
| GLUCOSE-1-PHOSPHATE URIDYL TRANSFERASE STIMULATION | 1 |
| GLUCOSE-6-PHOSPHATASE INHIBITION | 96 |
| GLUCOSE-6-PHOSPHATASE STIMULATION | 38 |
| GLUCOSE-6-PHOSPHATE DEHYDROGENASE INHIBITION | 60 |
| GLUCOSE-6-PHOSPHATE DEHYDROGENASE STIMULATION | 91 |
| GLUCOSE-6-PHOSPHATE GLYCOGEN SYNTHETASE INHIBITION | 0 |
| GLUCOSE-6-PHOSPHATE PHOSPHORYLASE A INHIBITION | 0 |
| GLUCOSE-6-PHOSPHATE TRANSLOCASE INHIBITION | 1 |
| GLUCOSIDASE I INHIBITION | 74 |
| GLUCOSIDASE II INHIBITION | 33 |
| GLUCOSIDASE INHIBITION | 195 |
| GLUCOSYLTRANSFERASE INHIBITION | 92 |
| GLUCOSYLTRANSFERASE STIMULATION | 4 |
| GLUCURONIDATION INHIBITION | 11 |
| GLUCURONIDATION STIMULATION | 0 |
| GLUCURONIDE PRODUCTION EFFECT | 4 |
| GLUCURONYL TRANSFERASE INHIBITION | 4 |
| GLUCURONYL TRANSFERASE STIMULATION | 22 |
| GLUT-4 EXPRESSION INHIBITION | 1 |
| GLUTAMATE DECARBOXYLASE ACTIVITY INCREASE | 1 |
| GLUTAMATE DECARBOXYLASE INHIBITION | 10 |
| GLUTAMATE DEHYDROGENASE INHIBITION | 32 |
| GLUTAMATE DEHYDROGENASE STIMULATION | 27 |
| GLUTAMATE OXIDASE INHIBITION | 1 |
| GLUTAMATE OXIDASE STIMULATION | 5 |
| GLUTAMATE RECEPTOR AGONIST | 5 |
| GLUTAMATE RECEPTOR BLOCKER | 38 |
| GLUTAMATE RELEASE INHIBITION | 12 |
| GLUTAMATE UPTAKE INHIBITION | 24 |
| GLUTAMATE-OXALOACETATE INHIBITION | 34 |
| GLUTAMATE-OXALOACETATE STIMULATION | 29 |
| GLUTAMATE-OXALOACETATE-TRANSAMINASE INHIBITION | 594 |
| GLUTAMATE-OXALOACETATE-TRANSAMINASE STIMULATION | 190 |
| GLUTAMATE-PYRUVATE INHIBITION | 37 |
| GLUTAMATE-PYRUVATE STIMULATION | 25 |
| GLUTAMATE-PYRUVATE-TRANSAMINASE INHIBITION | 1533 |
| GLUTAMATE-PYRUVATE-TRANSAMINASE STIMULATION | 246 |
| GLUTAMATE-TRANSFERASE INHIBITION | 6 |
| GLUTAMATE-TRANSFERASE STIMULATION | 2 |
| GLUTAMIC ACID DECARBOXYLASE STIMULATION | 5 |
| GLUTAMIC ACID RELEASE STIMULATION | 10 |
| GLUTAMINASE INHIBITION | 2 |
| GLUTAMINASE STIMULATION | 1 |
| GLUTAMINE SYNTHETASE INDUCTION | 4 |
| GLUTAMINE SYNTHETASE INHIBITION | 2 |
| GLUTAMYL-AMINOPEPTIDASE INHIBITION | 1 |
| GLUTARYL CO-A REDUCTASE INHIBITION | 12 |
| GLUTARYL CO-A REDUCTASE(BETA-HYDROXY-BETA-METHYL)INHIBITION | 12 |
| GLUTATHIONE DEPLETION | 72 |
| GLUTATHIONE DEPLETION INHIBITION | 101 |
| GLUTATHIONE DISULFIDE LEVEL DECREASE | 1 |
| GLUTATHIONE DISULFIDE REDUCTASE STIMULATION | 1 |
| GLUTATHIONE FORMATION INDUCTION | 232 |
| GLUTATHIONE FORMATION INHIBITION | 66 |
| GLUTATHIONE OXIDATION ACTIVITY | 14 |
| GLUTATHIONE PEROXIDASE INHIBITION | 58 |
| GLUTATHIONE PEROXIDASE STIMULATION | 260 |
| GLUTATHIONE REDUCTASE INHIBITION | 111 |
| GLUTATHIONE REDUCTASE STIMULATION | 106 |
| GLUTATHIONE-S-TRANSFERASE INDUCTION | 914 |
| GLUTATHIONE-S-TRANSFERASE INHIBITION | 263 |
| GLYCERALDEHYDE PHOSPHATE DEHYDROGENASE INHIBITION | 30 |
| GLYCERALDEHYDE PHOSPHODEHYDROGENASE STIMULATION | 4 |
| GLYCERO-3-PHOSPHATE ACYL TRANSFERASE INHIBITION | 3 |
| GLYCERO-3-PHOSPHATE DEHYDROGENASE STIMULATION | 2 |
| GLYCEROL-3-PHOSPHATE DEHYDROGENASE INHIBITION | 21 |
| GLYCEROLPHOSPHATE ACYLTRANSFERASE STIMULATION | 7 |
| GLYCINE RECEPTOR BINDING ACTIVITY | 4 |
| GLYCINE RECEPTOR INHIBITION | 4 |
| GLYCOAMINOGLYCAN SYNTHESIS STIMULATION | 1 |
| GLYCOGEN CONTENT DECREASED | 59 |
| GLYCOGEN CONTENT INCREASED | 59 |
| GLYCOGEN PHOSPHORYLASE INHIBITION | 5 |
| GLYCOGEN PHOSPHORYLASE STIMULATION | 4 |
| GLYCOGEN SYNTHASE KINASE INHIBITION | 3 |
| GLYCOGEN SYNTHESIS INHIBITION | 18 |
| GLYCOGEN SYNTHESIS STIMULATION | 21 |
| GLYCOGEN SYNTHETASE INHIBITION | 11 |
| GLYCOGEN SYNTHETASE STIMULATION | 7 |
| GLYCOGENESIS STIMULATION | 1 |
| GLYCOHYDROLASE INHIBITION | 1 |
| GLYCOLATE DEHYDROGENASE INHIBITION | 1 |
| GLYCOLATE OXIDASE INHIBITION | 4 |
| GLYCOLIC ACID OXIDASE INHIBITION | 2 |
| GLYCOLYSIS INHIBITION | 43 |
| GLYCOLYSIS STIMULATION | 8 |
| GLYCOPROTEIN IIB-IIIA ANTAGONIST ACTIVITY | 6 |
| GLYCOPROTEIN IV REDISTRIBUTION INHIBITION | 1 |
| GLYCOPROTEIN LEVEL DECREASE | 5 |
| GLYCOPROTEIN METABOLISM EFFECT | 1 |
| GLYCOPROTEIN PRECIPITATION | 3 |
| GLYCOPROTEIN PROCESSING INHIBITION | 61 |
| GLYCOPROTEIN SECRETION INHIBITION | 4 |
| GLYCOSAMINOGLYCAN SYNTHESIS INHIBITION | 3 |
| GLYCOSAMINOGLYCAN SYNTHESIS STIMULATION | 14 |
| GLYCOSIDASE ACTIVITY | 11 |
| GLYCOSIDASE INHIBITION | 89 |
| GLYCOSYLATED HEMOGLOBIN INHIBITION | 2 |
| GLYCOSYLATION INHIBITION | 4 |
| GLYCOSYLPHOSPHATIDYLINOSITOL INHIBITION | 0 |
| GLYCYL-N-ACYL-TRANSFERASE INHIBITION | 4 |
| GLYCYRRHETINATE DEHYDROGENASE ACTIVITY | 1 |
| GLYOXALASE I STIMULATION | 2 |
| GLYOXALASE II INHIBITION | 2 |
| GLYOXYLASE I INHIBITION | 68 |
| GM-CSF EXPRESSION STIMULATION | 1 |
| GM-CSF INHIBITION | 6 |
| GM-CSF SECRETION STIMULATION | 3 |
| GMP RELEASE INHIBITION | 2 |
| GMP RELEASE STIMULATION | 4 |
| GOITROGENIC ACTIVITY | 24 |
| GOLGI COMPLEX DISASSEMBLY | 7 |
| GOLGI MANNOSIDASE I-A INHIBITION | 1 |
| GOLGI MANNOSIDASE I-B INHIBITION | 1 |
| GOLGI MANNOSIDASE II INHIBITION | 2 |
| GONADAL TOXICITY | 21 |
| GONADOTROPIN RELEASE INHIBITION(UNSPECIFIED) | 55 |
| GONADOTROPIN RELEASE STIMULATION(UNSPECIFIED) | 27 |
| GONADOTROPIN RELEASING HORMONE RELEASE INHIBITION | 2 |
| GONADOTROPIN SYNTHESIS INHIBITION(UNSPECIFIED) | 58 |
| GONADOTROPIN SYNTHESIS STIMULATION(UNSPECIFIED) | 60 |
| GP120 BINDING TO CD4+ CELLS INHIBITION | 48 |
| GRANULOCYTE COLONY STIMULATING FACTOR RELEASE STIMULATION | 2 |
| GRANULOCYTIC CELL IODINATION INHIBITION | 85 |
| GRANULOCYTIC CELL IODINATION STIMULATION | 35 |
| GRANULOCYTOPENIA ACTIVITY | 1 |
| GRANULOMA FORMATION INHIBITION | 17 |
| GRANULOMA POTENTIATION EFFECT | 50 |
| GRAS STATUS | 157 |
| GROWTH HORMONE INHIBITION | 12 |
| GROWTH HORMONE STIMULATION | 29 |
| GROWTH INHIBITOR ACTIVITY | 183 |
| GROWTH PROMOTER ACTIVITY | 87 |
| GROWTH REGULATOR(INSECT) | 6 |
| GTP HYDROLYSIS INHIBITION | 0 |
| GTP HYDROLYSIS STIMULATION | 0 |
| GTP LEVELS DECREASED | 1 |
| GTP-ASE INHIBITION | 9 |
| GTP-ASE STIMULATION | 23 |
| GUANASE INDUCTION | 3 |
| GUANASE INHIBITION | 1 |
| GUANIDINOACETIC ACID LEVEL INCREASE | 1 |
| GUANOSINE MONOPHOSPHATE SYNTHETASE INHIBITION | 7 |
| GUANOSINE TRIPHOSPHATE SYNTHETASE INHIBITION | 1 |
| GUANOSINE TRIPHOSPHATE SYNTHETASE STIMULATION | 2 |
| GUANYLATE CYCLASE INHIBITION | 27 |
| GUANYLATE CYCLASE STIMULATION | 20 |
| GUSTATORY EFFECTS | 26 |
| H+ CONDUCTION STIMULATION | 2 |
| H+/K+ EXCHANGE STIMULATION | 5 |
| HAEMATIN FORMATION INHIBITION | 1 |
| HAGEMAN FACTOR INHIBITION | 31 |
| HAIR CLEANING ACTIVITY | 4 |
| HAIR CONDITIONER | 92 |
| HAIR DYEING EFFECT | 43 |
| HAIR INHIBITION EFFECT | 26 |
| HAIR LOSS INHIBITION | 38 |
| HAIR STIMULANT EFFECT | 394 |
| HALLUCINOGENIC ACTIVITY | 365 |
| HARMONIZING EFFECT | 1 |
| HATCHING INHIBITION | 3 |
| HATCHING STIMULANT | 2 |
| HATCHING STIMULANT(MOLLUSC) | 2 |
| HDL RECEPTOR ACTIVITY INCREASE | 3 |
| HEARING IMPROVEMENT ACTIVITY | 2 |
| HEAT SENSITIZATION ACTIVITY | 1 |
| HEAT SHOCK PROTEIN INDUCTION | 10 |
| HEAT SHOCK PROTEIN SUPPRESSION | 12 |
| HEMAGGLUTININ ACTIVITY | 852 |
| HEMAGGLUTININ ACTIVITY INHIBITION | 12 |
| HEMAGGLUTININ SYNTHESIS INHIBITION | 7 |
| HEMATINIC ACTIVITY | 222 |
| HEMATOLOGICAL EFFECTS | 7 |
| HEMATOMA RESORPTION ACCELERATION | 1 |
| HEMATOPOIETIC ACTIVITY | 78 |
| HEME OXYGENASE INHIBITION | 1 |
| HEME OXYGENASE STIMULATION | 1 |
| HEME SYNTHESIS INHIBITION | 1 |
| HEMEOXYGENASE INDUCTION | 13 |
| HEMOCONCENTRATION INHIBITION | 1 |
| HEMOGLOBIN INDUCTION | 62 |
| HEMOGLOBIN LEVELS DECREASED | 21 |
| HEMOGLOBIN OXIDIZING ABILITY | 6 |
| HEMOGLOBINASE INHIBITION | 9 |
| HEMOLYSIN DECREASE | 6 |
| HEMOLYSIN INCREASE | 8 |
| HEMOLYSIS INHIBITORY ACTIVITY | 145 |
| HEMOLYTIC ACTIVITY | 958 |
| HEMOLYTIC PLAQUE FORMING CELL INDUCTION | 4 |
| HEMORRHAGIC EFFECT | 84 |
| HEMOSTATIC ACTIVITY | 745 |
| HEMOTOXIC ACTIVITY | 72 |
| HEPARANASE INHIBITION | 4 |
| HEPARIN ANTAGONIST ACTIVITY | 6 |
| HEPARIN INDUCTION | 1 |
| HEPATIC MIXED FUNCTION OXIDASE INHIBITION | 14 |
| HEPATIC UDP GLUCORONOSYLTRANSFERASE ACTIVITY DECREASED | 3 |
| HEPATIC UDP GLUCORONOSYLTRANSFERASE ACTIVITY INCREASED | 0 |
| HEPATITIS ANTIGEN EXPRESSION INHIBITION | 67 |
| HEPATITIS B ANTIGEN INACTIVATION | 1 |
| HEPATITIS B SURFACE ANTIGEN INACTIVATION | 37 |
| HEPATOPROTECTIVE ACTIVITY | 108 |
| HEPATOTOXIC ACTIVITY | 1251 |
| HERBICIDAL ACTIVITY | 164 |
| HERG CHANNEL INHIBITION | 1 |
| HETEROCYCLIC AMINE FORMATION INHIBITION | 29 |
| HEXAMINIDASE INHIBITION | 2 |
| HEXOBARBITAL HYDROXYLASE INHIBITION | 13 |
| HEXOBARBITAL HYDROXYLASE STIMULATION | 5 |
| HEXOKINASE INHIBITION | 34 |
| HEXOKINASE STIMULATION | 23 |
| HEXOSAMINE SECRETION INHIBITION | 33 |
| HEXOSAMINE SECRETION STIMULATION | 14 |
| HEXOSAMINIDASE INHIBITION | 64 |
| HEXOSAMINIDASE STIMULATION | 10 |
| HEXOSE MONOPHOSPHATE SHUNT STIMULATION | 2 |
| HEXOSE SYNTHESIS INHIBITION | 8 |
| HGPRT INHIBITION | 75 |
| HIGH-AFFINITY UPTAKE OF CHOLINE(HACU) INHIBITION | 1 |
| HISTAMINASE LEVEL DECREASE | 1 |
| HISTAMINASE LEVEL INCREASE | 1 |
| HISTAMINE ANTAGONIST ACTIVITY | 26 |
| HISTAMINE RECEPTOR BINDING ACTIVITY | 28 |
| HISTAMINE RECEPTOR BINDING INHIBITION | 28 |
| HISTAMINE RELEASE INHIBITION | 1204 |
| HISTAMINE RELEASE STIMULATION | 117 |
| HISTAMINE-1 RECEPTOR BINDING ACTIVITY | 19 |
| HISTAMINE-N-METHYLTRANSFERASE INHIBITION | 0 |
| HISTAMINERGIC EFFECT | 107 |
| HISTIDINE DECARBOXYLASE INDUCTION | 17 |
| HISTIDINE DECARBOXYLASE INHIBITION | 10 |
| HISTIDINE KINASE INHIBITION | 11 |
| HISTOLOGICAL STUDIES | 12 |
| HISTONE ACETYLATION INCREASE | 6 |
| HISTONE ACETYLATION INHIBITION | 2 |
| HISTONE DEACETYLASE INHIBITION | 14 |
| HISTONE PHOSPHORYLATION INHIBITION | 7 |
| HISTONE PHOSPHORYLATION STIMULATION | 2 |
| HIV PROMOTER GENE ACTIVATION | 4 |
| HIV PROTEASE INHIBITION | 6 |
| HIV-1 INTEGRASE INHIBITION | 260 |
| HIV-TAT PROTEIN INHIBITION | 2 |
| HMG CO-A REDUCTASE STIMULATION | 2 |
| HMG-CO-A INHIBITION | 5 |
| HMG-CO-A REDUCTASE INHIBITION | 236 |
| HMG-CO-A SYNTHASE INHIBITION | 5 |
| HMG-CO-A SYNTHASE STIMULATION | 3 |
| HOMOCYSTEINE LEVEL INCREASE | 5 |
| HOMOSERINE DEHYDROGENASE INHIBITION | 2 |
| HOMOVANILLIC ACID STIMULATION | 2 |
| HORMONAL EFFECTS(UNSPECIFIED) | 38 |
| HORSERADISH PEROXIDASE INHIBITION | 15 |
| HUMAN MICROSOMAL EPOXIDE HYDROLASE INHIBITION | 1 |
| HUMAN TUMOR STEM CELL INHIBITION | 44 |
| HUMORAL IMMUNITY INHIBITION | 24 |
| HUMORAL IMMUNITY STIMULATION | 11 |
| HYALURONIC ACID DEPOLYMERIZATION | 3 |
| HYALURONIC ACID INHIBITION | 2 |
| HYALURONIC ACID STIMULATION | 2 |
| HYALURONIDASE INDUCTION | 3 |
| HYALURONIDASE INHIBITION | 260 |
| HYDROCHOLERETIC ACTIVITY | 3 |
| HYDROGEN PEROXIDE RELEASE INHIBITION | 58 |
| HYDROGEN PEROXIDE SCAVENGER ACTIVITY | 77 |
| HYDROGEN PEROXIDE SECRETION STIMULATION | 38 |
| HYDROGENASE INHIBITION | 3 |
| HYDROLYTIC ENZYMES ACTIVITY DECREASE | 2 |
| HYDROPEROXIDE PRODUCTION INHIBITION | 9 |
| HYDROPEROXIDE PRODUCTION STIMULATION | 1 |
| HYDROXIDE RADICAL GENERATION INHIBITION | 128 |
| HYDROXY(17)-STEROID URINARY EXCRETION INCREASED | 8 |
| HYDROXYLATION INHIBITION | 6 |
| HYDROXYMETHYLGLUTARYL-CO-A REDUCTASE INDUCTION | 10 |
| HYDROXYPROLINE INHIBITION | 3 |
| HYDROXYSTEROID(11-BETA) DEHYDROGENASE INHIBITION | 73 |
| HYDROXYSTEROID(17-BETA) DEHYDROGENASE INHIBITION | 78 |
| HYDROXYSTEROID(17-BETA) INHIBITION | 8 |
| HYDROXYSTEROID(3-ALPHA) DEHYDROGENASE INHIBITION | 87 |
| HYDROXYSTEROID(3-BETA) DEHYDROGENASE INHIBITION | 18 |
| HYDROXYSTEROID(BETA) DEHYDROGENASE INHIBITION | 35 |
| HYDROXYSTEROID(BETA) DEHYDROGENASE STIMULATION | 1 |
| HYPERACTIVITY INHIBITION | 5 |
| HYPERACTIVITY STIMULATION | 1 |
| HYPERALGESIC ACTIVITY | 13 |
| HYPERCALCEMIC ACTIVITY | 4 |
| HYPERCHOLESTEROLEMIC ACTIVITY | 205 |
| HYPERGLYCEMIC ACTIVITY | 405 |
| HYPERKALEMIC ACTIVITY | 8 |
| HYPERLIPIDEMIC ACTIVITY | 92 |
| HYPERNATREMIA ACTIVITY | 7 |
| HYPEROXALURIC EFFECT | 2 |
| HYPERPHOSPHATEMIC ACTIVITY | 2 |
| HYPERPHOSPHOLIPIDEMIC ACTIVITY | 3 |
| HYPERPLASIA INDUCTION | 47 |
| HYPERPOLARIZATION EFFECT | 6 |
| HYPERPROTHROMBINEMIA EFFECT | 4 |
| HYPERREFLEXIA ACTIVITY | 1 |
| HYPERTENSIVE ACTIVITY | 779 |
| HYPERTHERMIC EFFECT | 102 |
| HYPERTREHALOSAEMIC EFFECT | 7 |
| HYPERTRIGLYCERIDEMIA ACTIVITY | 34 |
| HYPERUREMIC ACTIVITY | 5 |
| HYPOAZOTEMIC ACTIVITY | 25 |
| HYPOCALCEMIC ACTIVITY | 20 |
| HYPOCHLOROUS ACID SCAVENGER ACTIVITY | 7 |
| HYPOCHOLESTEROLEMIC ACTIVITY | 739 |
| HYPOGLYCEMIC ACTIVITY | 2741 |
| HYPOKALEMIC ACTIVITY | 49 |
| HYPOLIPEMIC ACTIVITY | 342 |
| HYPONATREMIA ACTIVITY | 6 |
| HYPOOXALURIC EFFECT | 2 |
| HYPOPHOSPHOLIPIDEMIC ACTIVITY | 18 |
| HYPOPHYSEAL-ADRENAL STIMULANT | 0 |
| HYPOPROTEINEMIA ACTIVITY | 5 |
| HYPOPROTHROMBINEMIA EFFECT | 17 |
| HYPOTENSIVE ACTIVITY | 4038 |
| HYPOTHERMIC ACTIVITY | 1338 |
| HYPOTREHALOSEMIC ACTIVITY | 3 |
| HYPOTRIGLYCERIDEMIA ACTIVITY | 273 |
| HYPOXANTHINE LEVEL DECREASE | 1 |
| HYPOXANTHINE TRANSPORT INHIBITION | 3 |
| HYPOXIA-INDUCIBLE FACTOR 1 ACTIVATION | 1 |
| HYPOXIA-INDUCIBLE FACTOR-1 INHIBITION | 25 |
| I-KAPPA-B KINASE 1 INHIBITION | 4 |
| I-KAPPA-B KINASE 2 INHIBITION | 5 |
| I-KAPPA-B KINASE INHIBITION | 3 |
| I-KAPPA-B-ALPHA DEGRADATION INHIBITION | 2 |
| ILEAL TRANSPORT INHIBITION | 3 |
| ILEAL TRANSPORT STIMULATION | 1 |
| IMMUNOCOMPLEX FORMATION INHIBITION | 1 |
| IMMUNODEPRESSIVE ACTIVITY | 15 |
| IMMUNOGLOBULIN BINDING ACTIVITY | 5 |
| IMMUNOGLOBULIN PRODUCTION INHIBITION | 66 |
| IMMUNOGLOBULIN PRODUCTION STIMULATION | 54 |
| IMMUNOGLOBULIN-A INDUCTION | 60 |
| IMMUNOGLOBULIN-E INDUCTION | 11 |
| IMMUNOGLOBULIN-G INDUCTION | 80 |
| IMMUNOGLOBULIN-M INDUCTION | 3 |
| IMMUNOGLOBULIN-SECRETING CELL GENERATION INHIBITION | 1 |
| IMMUNOLOGIC EFFECTS(UNSPECIFIED) | 107 |
| IMMUNOMODULATOR ACTIVITY | 494 |
| IMMUNOPRECIPITATION REACTION | 57 |
| IMMUNOREACTIVE PARATHORMONE RELEASE INHIBITION | 5 |
| IMMUNOREACTIVITY INHIBITION | 4 |
| IMMUNOREACTIVITY STIMULATION | 2 |
| IMMUNOSTIMULANT ACTIVITY | 1430 |
| IMMUNOSUPPRESSANT ACTIVITY | 1394 |
| IMMUNOTOXIC ACTIVITY | 3 |
| IMPAIRED DEVELOPMENT OF FERTILIZED OVA | 4 |
| IMPLANTATION AUGMENTATION | 7 |
| INDOLAMINE-2-3-DIOXYGENASE INHIBITION | 1 |
| INDOLE-3-ACETIC ACID ANTAGONIST ACTIVITY | 1 |
| INDOLEACETIC ACID OXIDASE INHIBITION | 14 |
| INDOLEACETIC ACID OXIDASE STIMULATION | 3 |
| INFLAMMATION INDUCTION | 260 |
| INHIBIN SECRETION INHIBITION | 4 |
| INHIBIT MOUSE-KILLING | 4 |
| INHIBITION OF FOLLICULAR MATURATION | 3 |
| INHIBITION OF HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1) ACTIVATION | 3 |
| INHIBITION OF OOCYTE PENETRATION BY SPERM | 16 |
| INOSINE LEVEL DECREASE | 1 |
| INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITION | 22 |
| INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE INHIBITION | 6 |
| INOSINIC ACID DEHYDROGENASE INHIBITION | 44 |
| INOSITOL PHOSPHATASE INHIBITION | 5 |
| INOSITOL PHOSPHATE FORMATION INHIBITION | 68 |
| INOSITOL PHOSPHATE FORMATION STIMULATION | 7 |
| INOSITOL UPTAKE INHIBITION | 1 |
| INOSITOL-1,4,5-TRIPHOSPHATE AGONIST ACTIVITY | 4 |
| INOTROPIC EFFECT NEGATIVE | 388 |
| INOTROPIC EFFECT POSITIVE | 840 |
| INSECT ATTRACTANT ACTIVITY | 136 |
| INSECT DEFENSIVE EFFECT | 9 |
| INSECT DEVELOPMENT INHIBITION | 251 |
| INSECT DEVELOPMENT STIMULATION | 14 |
| INSECT FOOD UTILIZATION ENHANCEMENT | 3 |
| INSECT MATING BEHAVIOR INHIBITION | 2 |
| INSECT REPELLENT ACTIVITY | 726 |
| INSECT STERILITY INDUCTION | 26 |
| INSECT SURVIVAL INHIBITION | 39 |
| INSECT SURVIVAL STIMULATION | 3 |
| INSECTICIDAL ANTAGONIST | 24 |
| INSECTICIDE ACTIVITY | 5981 |
| INSTABILITY OF | 1 |
| INSULIN ACTIVITY | 15 |
| INSULIN ANTAGONIST | 15 |
| INSULIN BINDING ACTIVITY | 5 |
| INSULIN BIOSYNTHESIS INHIBITION | 5 |
| INSULIN BIOSYNTHESIS STIMULATION | 11 |
| INSULIN DEGRADATION INHIBITION | 26 |
| INSULIN INDUCTION | 122 |
| INSULIN LEVEL DECREASE | 21 |
| INSULIN LEVEL INCREASE | 102 |
| INSULIN POTENTIATING EFFECT | 57 |
| INSULIN RECEPTOR BINDING EFFECT | 11 |
| INSULIN RECEPTOR BINDING INHIBITION | 3 |
| INSULIN RECEPTORS DECREASED | 4 |
| INSULIN RECEPTORS INCREASED | 4 |
| INSULIN RELEASE INHIBITION | 70 |
| INSULIN RELEASE STIMULATION | 106 |
| INSULIN RESISTANCE INHIBITION | 10 |
| INSULIN SENSITIVITY INCREASE | 9 |
| INSULIN-LIKE GROWTH FACTOR 1 DECREASE | 6 |
| INSULIN-LIKE GROWTH FACTOR 1 INCREASE | 7 |
| INSULIN-LIKE GROWTH FACTOR BP-3 STIMULATION | 2 |
| INSULIN-LIKE GROWTH FACTOR II RECEPTOR INCREASE | 3 |
| INTEGRIN INHIBITION | 1 |
| INTERACTION WITH DNA | 8 |
| INTERACTION WITH RNA | 1 |
| INTERCALATION EFFECT | 11 |
| INTERCELLULAR ADHESION MOLECULE-1 EXPRESSION STIMULATION | 1 |
| INTERCELLULAR ADHESION MOLECULE-1 INHIBITION | 64 |
| INTERCELLULAR ADHESION MOLECULE-1 TRANSCRIPTION STIMULATION | 1 |
| INTERCELLULAR COMMUNICATION ENHANCEMENT | 18 |
| INTERCELLULAR COMMUNICATION INHIBITION | 30 |
| INTERCHROMOSOMAL RECOMBINATION INDUCTION | 3 |
| INTERFERON ANTAGONIST | 2 |
| INTERFERON BETA SECRETION STIMULATION | 5 |
| INTERFERON INDUCTION STIMULATION | 306 |
| INTERFERON INDUCTION SUPPRESSANT | 18 |
| INTERFERON SECRETION INHIBITION | 7 |
| INTERFERON-GAMMA ELICITED ACTIVATION OF STAT1 INHIBITION | 1 |
| INTERFERON-GAMMA PRODUCTION STIMULATION | 68 |
| INTERFERON-GAMMA SECRETION INHIBITION | 84 |
| INTERLEUKIN 10 SECRETION STIMULATION | 15 |
| INTERLEUKIN 8 INDUCTION INHIBITION | 31 |
| INTERLEUKIN 8 SYNTHESIS INHIBITION | 26 |
| INTERLEUKIN BINDING SITE INHIBITION | 10 |
| INTERLEUKIN I RECEPTOR BINDING INHIBITION | 13 |
| INTERLEUKIN II RECEPTOR GENE STIMULATION | 12 |
| INTERLEUKIN INDUCTION | 46 |
| INTERLEUKIN RECEPTOR EXPRESSION INHIBITION | 27 |
| INTERLEUKIN RECEPTOR EXPRESSION STIMULATION | 2 |
| INTERLEUKIN-1 FORMATION INHIBITION | 74 |
| INTERLEUKIN-1 FORMATION STIMULATION | 116 |
| INTERLEUKIN-1 INHIBITION | 8 |
| INTERLEUKIN-1 RELEASE INHIBITION | 30 |
| INTERLEUKIN-1 RELEASE STIMULATION | 27 |
| INTERLEUKIN-1-ALPHA RELEASE INHIBITION | 86 |
| INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITION | 7 |
| INTERLEUKIN-1-BETA GENE EXPRESSION INHIBITION | 6 |
| INTERLEUKIN-1-BETA GENE EXPRESSION STIMULATION | 7 |
| INTERLEUKIN-1-BETA RELEASE INHIBITION | 155 |
| INTERLEUKIN-1-BETA RELEASE STIMULATION | 14 |
| INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION | 51 |
| INTERLEUKIN-10 SECRETION INHIBITION | 16 |
| INTERLEUKIN-12 P40 PROMOTER INHIBITION | 4 |
| INTERLEUKIN-12 PRODUCTION INHIBITION | 11 |
| INTERLEUKIN-12 STIMULATION | 7 |
| INTERLEUKIN-18 SECRETION STIMULATION | 1 |
| INTERLEUKIN-2 FORMATION INHIBITION | 132 |
| INTERLEUKIN-2 FORMATION STIMULATION | 52 |
| INTERLEUKIN-2 INDUCIBLE T-CELL KINASE INHIBITION | 5 |
| INTERLEUKIN-2 RELEASE INHIBITION | 40 |
| INTERLEUKIN-3 INHIBITION | 8 |
| INTERLEUKIN-4 FORMATION STIMULATION | 31 |
| INTERLEUKIN-4 RELEASE INHIBITION | 99 |
| INTERLEUKIN-5 EXPRESSION INHIBITION | 3 |
| INTERLEUKIN-5 EXPRESSION STIMULATION | 0 |
| INTERLEUKIN-5 INHIBITION | 28 |
| INTERLEUKIN-5 STIMULATION | 4 |
| INTERLEUKIN-6 FORMATION INHIBITION | 32 |
| INTERLEUKIN-6 FORMATION STIMULATION | 64 |
| INTERLEUKIN-6 GENE EXPRESSION INHIBITION | 2 |
| INTERLEUKIN-6 INHIBITION | 19 |
| INTERLEUKIN-6 RELEASE INHIBITION | 30 |
| INTERLEUKIN-6 RELEASE STIMULATION | 15 |
| INTERLEUKIN-6-RECEPTOR BLOCKER ACTIVITY | 12 |
| INTERLEUKIN-8 BINDING INHIBITION | 19 |
| INTERLEUKIN-8 PRODUCTION INHIBITION | 41 |
| INTERLEUKIN-8 STIMULATION | 3 |
| INTERLEUKIN-II FORMATION STIMULATION | 62 |
| INTERLEUKIN-II INHIBITION | 43 |
| INTERLEUKIN-III INDUCTION STIMULATION | 15 |
| INTERMEDIATE FILAMENT MODULATION | 1 |
| INTESTINAL ABSORPTION INHIBITION | 34 |
| INTESTINAL ABSORPTION STIMULATION | 17 |
| INTESTINAL ANTISECRETORY ACTIVITY | 24 |
| INTESTINAL FLUID RETENTION EFFECT | 5 |
| INTESTINAL MOTILITY INHIBITION | 238 |
| INTESTINAL MOTILITY STIMULATION | 168 |
| INTESTINAL SECRETORY ACTIVITY | 19 |
| INTOXICANT ACTIVITY | 11 |
| INTRACELLULAR ADHESION MOLECULE-1 INHIBITION | 40 |
| INTRACELLULAR LOCALIZATION ACTIVITY | 1 |
| INTRACHROMOSOMAL RECOMBINATION INDUCTION | 3 |
| INTRACRANIAL PRESSURE REDUCTION | 2 |
| INTRAOCULAR PRESSURE INCREASED | 25 |
| INTRAOCULAR PRESSURE REDUCTION | 101 |
| INVERTASE INHIBITION | 97 |
| INVERTASE STIMULATION | 5 |
| IODIDE TRANSPORT INHIBITION | 1 |
| IODIDE UPTAKE STIMULATION | 1 |
| IONOPHORIC ACTIVITY | 136 |
| IRON ABSORPTION DECREASED | 13 |
| IRON COMPLEXING EFFECT | 40 |
| IRON UPTAKE INCREASED | 10 |
| IRON UPTAKE INHIBITION | 1 |
| IRRITABLE BOWEL SYNDROME IMPROVEMENT | 3 |
| IRRITANT ACTIVITY | 1675 |
| ISOCITRATE DEHYDROGENASE INHIBITION | 15 |
| ISOCITRATE DEHYDROGENASE STIMULATION | 12 |
| ISOCITRATE LYASE INHIBITION | 2 |
| ISOLEUCYL T-RNA SYNTHETASE INHIBITION | 5 |
| ISOMALTASE INHIBITION | 30 |
| ISOPRENYLATION INHIBITION | 31 |
| ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE INHIBITION | 1 |
| JUVENILE HORMONE ACTIVITY | 174 |
| JUVENILE HORMONE SYNTHESIS INHIBITION | 16 |
| K PUMP INHIBITION | 3 |
| K TRANSPORT ACROSS RBC MEMBRANE DECREASED | 3 |
| K TRANSPORT ACROSS RBC MEMBRANE ENHANCED | 9 |
| K+ DEPLETION | 33 |
| K+ DEPLETION INHIBITION | 1 |
| K+ OUTWARD CURRENT INHIBITION | 15 |
| K+ OUTWARD CURRENT STIMULATION | 1 |
| K+ SECRETION INHIBITION | 2 |
| K+-P-NPPASE INHIBITION | 1 |
| KAIROMONE ACTIVITY | 1 |
| KALLIKREIN INHIBITION | 44 |
| KAPA-DAPA AMINOTRANSFERASE INHIBITION | 1 |
| KAPPA-OPIOID RECEPTOR BINDING INHIBITION | 3 |
| KERATINIZATION STIMULANT | 24 |
| KERATITIS DEVELOPMENT DELAY | 2 |
| KERATOLYTIC EFFECT | 8 |
| KERATOPLASTIC ACTIVITY | 2 |
| KETOSIS INHIBITION | 7 |
| KIDNEY STONE DEVELOPMENT INHIBITION | 7 |
| KIDNEY STONE DISSOLUTION EFFECT | 165 |
| KINASE ACTIVITY INHIBITION | 85 |
| KINASE BINDING INHIBITION | 1 |
| KINASE-INSERTED DOMAIN CONTAINING RECEPTOR INHIBITION | 1 |
| KINESIN MOTOR PROTEIN ACTIVITY INHIBITION | 2 |
| KININ ACTIVITY | 2 |
| KININ-INACTIVATION | 7 |
| KININ-LIKE ACTIVITY | 15 |
| KININASE ACTIVITY STIMULATION | 2 |
| KNOCK-DOWN EFFECT | 8 |
| LABOR INDUCTION EFFECT | 2093 |
| LACCASE INHIBITION | 5 |
| LACRIMAL GLAND SECRETION STIMULATION | 1 |
| LACRYMATION INHIBITION | 1 |
| LACRYMATION STIMULATION | 25 |
| LACTASE INHIBITION | 43 |
| LACTASE STIMULATION | 6 |
| LACTATE DEHYDROGENASE INHIBITION | 222 |
| LACTATE DEHYDROGENASE LEAKAGE INHIBITION | 38 |
| LACTATE DEHYDROGENASE LEAKAGE STIMULATION | 1 |
| LACTATE DEHYDROGENASE STIMULATION | 173 |
| LACTATE DEHYDROGENASE-A4 INHIBITION | 6 |
| LACTATE DEHYDROGENASE-B4 INHIBITION | 7 |
| LACTATE DEHYDROGENASE-C4 INHIBITION | 2 |
| LACTATE INDUCTION | 11 |
| LACTATE INHIBITION | 38 |
| LACTATE-DEHYDROGENASE-X INHIBITION | 79 |
| LACTOFERRIN RELEASE STIMULATION | 1 |
| LACTOSE SYNTHETASE INDUCTION | 0 |
| LACTOSE SYNTHETASE INHIBITION | 5 |
| LAMINARINASE INHIBITION | 4 |
| LAMINARIOBIASE INHIBITION | 4 |
| LAMININ INHIBITION | 1 |
| LARVAL GROWTH INHIBITION | 238 |
| LARVAL METAMORPHOSIS PROMOTION | 8 |
| LARVAL SETTLING EFFECT | 3 |
| LARVICIDAL ACTIVITY | 1461 |
| LARVIPOSITIONAL STIMULANT | 1 |
| LARYNGEAL REFLEX INHIBITION | 10 |
| LAURATE OMEGA-HYDROXYLASE(LAH) INHIBITION | 1 |
| LAURATE OMEGA-HYDROXYLASE(LAH) STIMULATION | 7 |
| LAXATIVE EFFECT | 2567 |
| LDH-1 INHIBITION | 6 |
| LDH-5 INHIBITION | 2 |
| LDL BINDING ACTIVITY | 1 |
| LDL OXIDATION INHIBITION | 239 |
| LDL OXIDATIVE MODIFICATION INHIBITION | 27 |
| LDL RECEPTOR ACTIVITY DECREASE | 12 |
| LDL RECEPTOR BINDING STIMULATION | 6 |
| LDL RECEPTOR UPREGULATION | 6 |
| LDL UPTAKE STIMULATION | 2 |
| LDL(OXIDIZED) UPTAKE INHIBITION | 5 |
| LEAF CLOSING EFFECT | 3 |
| LEAF MOVEMENT STIMULATION | 2 |
| LEAF OPENING EFFECT | 5 |
| LEARNING ENHANCEMENT | 91 |
| LECITHIN-CHOLESTEROL ACYLTRANSFERASE STIMULATION | 3 |
| LECTIN ACTIVITY | 41 |
| LEPTIN INHIBITION | 3 |
| LEUCINE AMINOPEPTIDASE INHIBITION | 71 |
| LEUCINE AMINOPEPTIDASE STIMULATION | 5 |
| LEUCINE INCORPORATION INHIBITION | 9 |
| LEUKOAGGLUTINATION ACTIVITY | 29 |
| LEUKOCYTE LEVEL DECREASE | 1 |
| LEUKOCYTE MIGRATION INHIBITION | 89 |
| LEUKOCYTE MIGRATION STIMULATION | 3 |
| LEUKOCYTE PROLIFERATION INHIBITION | 19 |
| LEUKOCYTOSIS ACTIVITY | 9 |
| LEUKOPENIC ACTIVITY | 78 |
| LEUKOTRIENE A-4 HYDROLASE INHIBITION | 6 |
| LEUKOTRIENE ANTAGONIST ACTIVITY | 1 |
| LEUKOTRIENE B-4 INHIBITION | 209 |
| LEUKOTRIENE B4 RECEPTOR BINDING ACTIVITY | 110 |
| LEUKOTRIENE B4 RELEASE ENHANCEMENT | 18 |
| LEUKOTRIENE C-4 INHIBITION | 83 |
| LEUKOTRIENE C-4 RELEASE STIMULATION | 1 |
| LEUKOTRIENE D-4 INHIBITION | 18 |
| LEUKOTRIENE D-4 RECEPTOR ANTAGONISM | 0 |
| LEUKOTRIENE E-4 INHIBITION | 9 |
| LEUKOTRIENE F4 PRODUCTION INHIBITION | 0 |
| LEUKOTRIENE RECEPTOR BINDING EFFECT | 13 |
| LEUKOTRIENE RELEASE INHIBITION | 24 |
| LEUKOTRIENE SYNTHESIS INHIBITION | 101 |
| LH LEVELS DECREASED | 15 |
| LH-LIKE ACTIVITY | 1 |
| LH-RELEASE INHIBITION | 117 |
| LH-RELEASE STIMULATION | 58 |
| LH-STIMULATED CYCLIC AMP INDUCTION INHIBITION | 3 |
| LH-STIMULATED CYCLIC AMP INDUCTION STIMULATION | 2 |
| LH-SYNTHESIS INHIBITION | 21 |
| LH-SYNTHESIS STIMULATION | 24 |
| LIGNAN LEVEL INCREASE | 5 |
| LIPASE INHIBITION | 128 |
| LIPASE RELEASE STIMULATION | 2 |
| LIPASE(PANCREATIC) INHIBITION | 65 |
| LIPID ABSORPTION INHIBITION | 1 |
| LIPID METABOLISM EFFECTS | 170 |
| LIPID METABOLISM INHIBITION | 2 |
| LIPID MOBILIZATION INHIBITION INDUCED BY EPINEPHRINE | 2 |
| LIPID PEROXIDASE INHIBITION | 227 |
| LIPID PEROXIDASE STIMULATION | 12 |
| LIPID PEROXIDE FORMATION INHIBITION | 2974 |
| LIPID PEROXIDE FORMATION STIMULATION | 93 |
| LIPID PROFILE ALTERATION | 60 |
| LIPID PYROPHOSPHATE INHIBITION | 9 |
| LIPID SECRETION INHIBITION | 3 |
| LIPID SYNTHESIS INHIBITION | 65 |
| LIPID SYNTHESIS STIMULATION | 73 |
| LIPOGENESIS INHIBITION | 35 |
| LIPOGENESIS STIMULATION | 12 |
| LIPOLYSIS INHIBITION | 16 |
| LIPOLYSIS STIMULATION | 21 |
| LIPOLYTIC EFFECT | 169 |
| LIPOPOLYSACCHARIDE DEGRADATION ACTIVITY | 1 |
| LIPOPOLYSACCHARIDE SYNTHESIS INHIBITION | 2 |
| LIPOPROTEIN LIPASE INHIBITION(ADIPOSE) | 19 |
| LIPOPROTEIN LIPASE STIMULATION | 15 |
| LIPOPROTEIN LIPASE STIMULATION(ADIPOSE) | 7 |
| LIPOPROTEIN LIPASE(LIVER)INDUCTION | 4 |
| LIPOPROTEIN LIPASE(LIVER)INHIBITION | 3 |
| LIPOPROTEIN LIPASE(PLASMA)INDUCTION | 4 |
| LIPOPROTEIN LIPASE(PLASMA)INHIBITION | 0 |
| LIPOPROTEIN MODIFICATION | 17 |
| LIPOPROTEIN(A) LEVEL INHIBITION | 2 |
| LIPOXYGENASE INHIBITION | 503 |
| LIPOXYGENASE STIMULATION | 13 |
| LIPOXYGENASE(PLATELET)INHIBITION | 34 |
| LIPOXYGENASE,12: INHIBITION | 62 |
| LIPOXYGENASE,15: INHIBITION | 100 |
| LIPOXYGENASE,5: INHIBITION | 564 |
| LIVER CATALASE INHIBITION | 10 |
| LIVER EFFECTS(UNSPECIFIED) | 1262 |
| LIVER GLYCOGEN DECREASE | 25 |
| LIVER GLYCOGEN INCREASE | 18 |
| LIVER REGENERATION EFFECTS | 10 |
| LIVER REGENERATION STIMULATION | 60 |
| LOCOMOTOR ACTIVITY DECREASE | 235 |
| LOCOMOTOR ACTIVITY RHYTHM DECREASE | 10 |
| LOCOMOTOR ACTIVITY STIMULATION | 39 |
| LONG TERM POTENTIATION SUPPRESSION | 1 |
| LONG TERM POTENTIATION SUPPRESSION INHIBITION | 1 |
| LONGEVITY PROLONGATION | 36 |
| LOW DENSITY LIPOPROTEIN RECEPTOR DEGRADATION INHIBITION | 4 |
| LOW DENSITY LIPOPROTEIN RECEPTOR SIALYLATION | 3 |
| LUCIFERASE INHIBITION | 11 |
| LUCIFERASE STIMULATION | 17 |
| LUNG PROBLEMS(UNSPECIFIED) | 205 |
| LUPUS EFFECTS CLAIMED | 6 |
| LUSITROPY(RELAXATION) DECREASED | 0 |
| LUSITROPY(RELAXATION) INCREASED | 1 |
| LUTEAL SUPPRESSANT EFFECT | 34 |
| LUTEOLYTIC EFFECT | 18 |
| LUTEOTROPIC EFFECT | 41 |
| LYMPH FLOW INCREASE | 4 |
| LYMPHOBLAST TRANSFORMATION INDUCTION | 1 |
| LYMPHOCYTE ACTIVATING FACTOR INDUCTION | 8 |
| LYMPHOCYTE ACTIVATION | 49 |
| LYMPHOCYTE BLASTOGENESIS INHIBITION | 123 |
| LYMPHOCYTE BLASTOGENESIS STIMULANT | 76 |
| LYMPHOCYTE CAPPING INHIBITION | 13 |
| LYMPHOCYTE DIFFERENTIATION INDUCTION | 7 |
| LYMPHOCYTE KINASE LCK (P56-LCK) INHIBITION | 3 |
| LYMPHOCYTE PROLIFERATION INHIBITION | 318 |
| LYMPHOCYTE PROLIFERATION STIMULATION | 168 |
| LYMPHOCYTE STIMULATION | 128 |
| LYMPHOCYTE SUPPRESSION | 87 |
| LYMPHOCYTE TRANSFORMATION INDUCTION | 59 |
| LYMPHOCYTE TRANSFORMATION INHIBITION | 51 |
| LYMPHOCYTE(B) STIMULATION | 21 |
| LYMPHOCYTE(B) SUPPRESSION | 49 |
| LYMPHOKINE-ACTIVATED KILLER CELLS ENHANCEMENT | 20 |
| LYSO PAF:ACETYL-COA ACETYLTRANSFERASE INHIBITION | 15 |
| LYSOPHOSPHOLIPASE A INHIBITION | 1 |
| LYSOPHOSPHOLIPASE INHIBITION | 2 |
| LYSOSOMAL ACIDIFICATION INHIBITION | 8 |
| LYSOSOMAL ENZYME SECRETION | 7 |
| LYSOSOMAL MEMBRANE STABILIZATION EFFECT | 49 |
| LYSOSOMAL PROTEASE INHIBITION | 0 |
| LYSOSOMAL PROTEASE STIMULATION | 2 |
| LYSOSOMAL PROTEIN DEGRADATION INHIBITION | 1 |
| LYSOZYMAL ENZYME INHIBITION | 41 |
| LYSOZYME INDUCTION | 78 |
| LYSOZYME RELEASE INHIBITION | 59 |
| LYSYL OXIDASE INHIBITION | 7 |
| LYSYL OXIDASE STIMULATION | 6 |
| M-RNA DIRECTED POLYPHENYLALANINE SYNTHESIS INHIBITION | 16 |
| M-RNA INHIBITION | 9 |
| M-RNA POLYMERASE INHIBITION | 11 |
| M-RNA STIMULATION | 0 |
| M-RNA(L-HISTIDINE DECARBOXYLASE) EXPRESSION INHIBITION | 1 |
| MACROGLOBULIN(ALPHA-2)INHIBITION | 3 |
| MACROPHAGE ACTIVATION | 96 |
| MACROPHAGE ACTIVATION INHIBITION | 29 |
| MACROPHAGE ADHESION MOLECULE-1 INHIBITION | 1 |
| MACROPHAGE CHEMOATTRACTANT PROTEIN-1 INHIBITION | 1 |
| MACROPHAGE CYTOTOXICITY ENHANCEMENT | 117 |
| MACROPHAGE CYTOTOXICITY INHIBITION | 28 |
| MACROPHAGE INFLAMMATORY PROTEIN 1-ALPHA INHIBITION | 2 |
| MACROPHAGE INFLAMMATORY PROTEIN 1-BETA INHIBITION | 2 |
| MACROPHAGE INFLAMMATORY PROTEIN-1-BETA BINDING INHIBITION | 1 |
| MACROPHAGE INFLAMMATORY PROTEIN-2 REDUCTION | 3 |
| MACROPHAGE MIGRATION INHIBITION | 15 |
| MACROPHAGE MIGRATION STIMULATION | 50 |
| MACROPHAGE SCAVENGER RECEPTOR INHIBITION | 1 |
| MAGNESIUM (MG++) LEVELS INCREASED | 1 |
| MAJOR HISTOCOMPATIBILITY PROTEIN BINDING INHIBITION | 1 |
| MALARIA SYMPTOM MIMICKING ACTIVITY | 1 |
| MALATE DEHYDROGENASE INHIBITION | 34 |
| MALATE DEHYDROGENASE STIMULATION | 15 |
| MALATE OXIDASE INHIBITION | 7 |
| MALATE OXIDASE STIMULATION | 0 |
| MALATE SYNTHASE INHIBITION | 9 |
| MALIC ENZYME INHIBITION | 14 |
| MALIC ENZYME STIMULATION | 5 |
| MALIGNANT CELL DIFFERENTIATION INHIBITION | 0 |
| MALIGNANT CELL TRANSFORMATION | 2 |
| MALONDIALDEHYDE INHIBITION | 241 |
| MALONDIALDEHYDE STIMULATION | 13 |
| MALONDIALDEHYDE-DNA ADDUCTS INHIBITION | 2 |
| MALTASE INHIBITION | 137 |
| MALTASE STIMULATION | 12 |
| MAMMARY GLAND GROWTH INCREASE | 2 |
| MAMMARY GLAND STRUCTURE DEVELOPMENT ALTERATION | 5 |
| MANNOPROTEIN SYNTHETASE INHIBITION | 3 |
| MANNOSE UPTAKE INHIBITION | 1 |
| MANNOSIDASE I INHIBITION | 10 |
| MANNOSIDASE II INHIBITION | 22 |
| MAST CELL DEGRANULATING EFFECT | 43 |
| MAST CELL MEMBRANE STABILIZING EFFECT | 25 |
| MATING BEHAVIOR STIMULATION(MAMMALIAN) | 3 |
| MATING INHIBITION | 1 |
| MATING INHIBITION(MAMMALIAN) | 23 |
| MATING TUBE FORMATION INDUCTION | 0 |
| MATRIX METALLOPROTEINASE 2 (MMP-2) INHIBITORY ACTIVITY | 3 |
| MEAN PLATELET VOLUME INCREASE | 1 |
| MEIOSIS INHIBITION | 2 |
| MEIOSIS STIMULATION | 3 |
| MEIOTIC CHROMOSOME NON-DISJUNCTION EFFECT | 1 |
| MEIOTIC MATURATION INDUCTION | 1 |
| MELANIN DEGRADATION STIMULATION | 1 |
| MELANIN FORMATION INHIBITION | 287 |
| MELANIN FORMATION STIMULATION | 35 |
| MELATONIN LEVEL DECREASE | 1 |
| MELATONIN LEVEL INCREASE | 42 |
| MELATONIN RECEPTOR BINDING ACTIVITY | 4 |
| MEMBRANE ALTERING EFFECT | 29 |
| MEMBRANE BINDING EFFECT | 45 |
| MEMBRANE DEPOLARIZATION | 44 |
| MEMBRANE DEPOLARIZATION INHIBITION | 2 |
| MEMBRANE DETERGENT EFFECT | 2 |
| MEMBRANE DISRUPTION EFFECT | 82 |
| MEMBRANE EFFECTS | 130 |
| MEMBRANE EXPRESSION SUPPRESSION | 15 |
| MEMBRANE FLUIDITY DECREASED | 19 |
| MEMBRANE FLUIDITY INCREASED | 45 |
| MEMBRANE FUSION INHIBITION | 1 |
| MEMBRANE PERMEABILITY DECREASE | 35 |
| MEMBRANE PERMEABILITY ENHANCEMENT | 90 |
| MEMBRANE POTENTIAL SHIFT | 19 |
| MEMBRANE STABILIZATION EFFECT | 91 |
| MEMORY ENHANCEMENT EFFECT | 273 |
| MEMORY RETENTION IMPAIRMENT | 48 |
| MEMORY RETENTION IMPROVEMENT | 165 |
| MENOPAUSE SYMPTOMS RELIEF | 288 |
| MENSTRUATION INDUCTION EFFECT | 4903 |
| MENSTRUATION INHIBITION EFFECT | 70 |
| MESANGIAL CELL PROLIFERATION INHIBITION | 1 |
| METABOLISM INHIBITION | 96 |
| METABOLISM INHIBITION(INTRACELLULAR) | 46 |
| METABOLISM OF | 1139 |
| METABOLISM STIMULATION | 17 |
| METAL COMPLEXING EFFECT | 8 |
| METAL-INDUCIBLE PROTEIN SYNTHESIS ACTIVITY | 1 |
| METALLO-LACTAMASE INHIBITION | 6 |
| METALLOPROTEASE INHIBITION | 51 |
| METALLOPROTEINASE STIMULATION | 2 |
| METALLOTHIONEIN INCREASED | 7 |
| METALLOTHIONEIN INDUCTION | 11 |
| METALLOTHIONEIN LEVEL DECREASE | 1 |
| METALLOTHIONEIN MRNA EXPRESSION INHIBITION | 1 |
| METAMORPHOSIS INDUCTION | 24 |
| METAMORPHOSIS SUPPRESSION ACTIVITY | 5 |
| METAPLASIA INDUCTION | 9 |
| METASTASIS INHIBITION | 298 |
| METASTASIS STIMULATION | 10 |
| METHANE MONOXYGENASE INHIBITION | 1 |
| METHEMOGLOBIN GENERATION ACTIVITY | 12 |
| METHEMOGLOBIN INHIBITION | 2 |
| METHIONINE AMINOPEPTIDASE INHIBITION | 10 |
| METHOXYHYDROXYPHENYLGLYCOL INDUCTION | 3 |
| METHOXYRESOFURIN-O-DEMETHYLASE(MROD) STIMULATION | 13 |
| METHOXYRESORUFIN O-DEMETHYLASE(MROD) INHIBITION | 47 |
| METHOXYRESORUFIN-O-DEALKYLASE STIMULATION | 0 |
| METHYLTRANSFERASE INHIBITION | 6 |
| MEVALONATE-NADP-OXIDOREDUCTASE INHIBITION | 2 |
| MEVALONATE-NADP-OXIDOREDUCTASE STIMULATION | 0 |
| MHC CLASS II PROTEIN-INDUCTION INHIBITION | 3 |
| MICROBIAL GROWTH ACCELERATOR | 4 |
| MICROCEREBRAL CIRCULATORY ACTIVITY | 5 |
| MICROFILAMENT DISRUPTION | 12 |
| MICRONUCLEATION INDUCTION | 78 |
| MICRONUCLEATION INHIBITION | 7 |
| MICROSOMAL DEGRANULATION EFFECT | 4 |
| MICROSOMAL ETHANOL OXIDIZING SYSTEM STIMULATION | 2 |
| MICROSOMAL HYDROXYLATION STIMULATION | 4 |
| MICROSOMAL METABOLIZING SYSTEM INDUCTION | 49 |
| MICROSOMAL METABOLIZING SYSTEM INHIBITION | 138 |
| MICROSOMAL N-DEMETHYLASE INDUCTION | 7 |
| MICROSOMAL N-DEMETHYLASE INHIBITION | 8 |
| MICROTUBULE ASSEMBLY INHIBITION | 136 |
| MICROTUBULE DEPOLYMERIZATION | 45 |
| MICROTUBULE DISASSEMBLY ACTIVITY | 1 |
| MICROTUBULE DISASSEMBLY INHIBITION | 82 |
| MICROTUBULE EFFECTS | 64 |
| MICROTUBULE INDUCTION EFFECT | 18 |
| MINERAL BALANCE EFFECT | 2 |
| MINERAL METABOLISM EFFECTS | 7 |
| MINERALOCORTICOID TYPE ACTIVITY | 14 |
| MINIATURE ENDPLATE POTENTIAL AMPLITUDE INHIBITION | 0 |
| MIOTIC ACTIVITY | 24 |
| MIRACIDIAL ACTIVITY | 34 |
| MISCELLANEOUS EFFECTS | 3805 |
| MITOCHONDRIAL INACTIVATION | 23 |
| MITOCHONDRIAL RESPIRATION INHIBITION | 7 |
| MITOCHONDRIAL RESPIRATION STIMULATION | 6 |
| MITOCHONDRIAL RESPIRATORY CHAIN COMPLEX I INHIBITION | 12 |
| MITOCHONDRIAL SWELLING INCREASED | 11 |
| MITOCHONDRIAL SWELLING INHIBITION | 14 |
| MITOGEN ACTIVATED PROTEIN KINASE(MAPKAPK-2) INHIBITION | 4 |
| MITOGEN AND STRESS ACTIVATED KINASE INHIBITION | 1 |
| MITOGEN-ACTIVATED PROTEIN KINASE INHIBITION | 34 |
| MITOGEN-ACTIVATED PROTEIN KINASE STIMULATION | 10 |
| MITOGENIC ACTIVITY | 1116 |
| MITOTIC ACTIVITY | 8 |
| MITOTIC PROTEIN MONOCLONAL-2 STIMULATION | 1 |
| MIXED FUNCTION OXIDASE ACTIVITY | 19 |
| MIXED FUNCTION OXIDASE INHIBITION | 11 |
| MMP INHIBITION | 6 |
| MOBILITY INHIBITION | 3 |
| MOLAR PREGNANCY TREATMENT | 1 |
| MOLLUSC REPELLENT ACTIVITY | 10 |
| MOLLUSCICIDAL ACTIVITY | 5392 |
| MONOAMINE OXIDASE ACTIVITY INCREASE | 39 |
| MONOAMINE OXIDASE INHIBITION | 274 |
| MONOAMINE OXIDASE INHIBITION(TYPE A) | 202 |
| MONOAMINE OXIDASE INHIBITION(TYPE B) | 184 |
| MONOAMINE UPTAKE INHIBITION | 1 |
| MONOCHLOROMONOGLUTATHIONYL-CHLORAMBUCIL EXPORT INHIBITION | 5 |
| MONOCYTE CHEMOKINETIC ACTIVITY(MEDIATOR) RELEASE INHIBITION | 2 |
| MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITION | 3 |
| MONOCYTE CHEMOTACTIC PROTEIN-1 GENE EXPRESSION INHIBITION | 3 |
| MONOCYTE CHEMOTACTIC PROTEIN-2 BINDING INHIBITION | 1 |
| MONOCYTE STIMULATION | 6 |
| MONOOXYGENASE INDUCTION | 24 |
| MONOOXYGENASE INHIBITION | 31 |
| MONOOXYGENASE(FLAVIN-CONTAINING) INHIBITION | 4 |
| MONOPHENOLASE INHIBITION | 1 |
| MORPHINE-6-DEHYDROGENASE INHIBITION | 10 |
| MORPHOGENESIS INHIBITION | 1 |
| MORPHOGENESIS REGULATION | 20 |
| MORPHOLOGICAL STUDIES | 23 |
| MOTILIN STIMULATION | 1 |
| MOTOR COORDINATION IMPAIRMENT | 6 |
| MOULT INHIBITION(CRUSTACEAN) | 4 |
| MOULTING ACTIVITY(ANIMAL) | 2 |
| MOULTING ACTIVITY(INSECT) | 464 |
| MOULTING INHIBITION(INSECT) | 6 |
| MU OPIOID RECEPTOR BINDING | 2 |
| MUCIN RELEASE STIMULATION | 7 |
| MUCOLYTIC EFFECT | 14 |
| MUCOPOLYSACCHARIDE INCREASE | 1 |
| MUCOPOLYSACCHARIDE REDUCTION | 0 |
| MUCOSAL MOISTURIZING EFFECT | 1 |
| MULTIDRUG RESISTANCE ENHANCEMENT | 77 |
| MULTIDRUG RESISTANCE INHIBITION | 429 |
| MULTIDRUG-RESISTANCE EFFLUX PUMP INHIBITION | 18 |
| MULTIDRUG-RESISTANT TRANSPORTER EXPRESSION STIMULATION | 5 |
| MURAMIDASE INHIBITION | 1 |
| MUREIN POLYMERASE INHIBITION | 3 |
| MURINE LEUKEMIA VIRUS INTEGRASE INHIBITION | 1 |
| MUSCARINIC AGONIST ACTIVITY | 33 |
| MUSCARINIC ANTAGONIST ACTIVITY | 98 |
| MUSCARINIC ANTIANTAGONIST ACTIVITY | 3 |
| MUSCARINIC RECEPTOR BINDING ACTIVITY | 83 |
| MUSCARINIC RECEPTOR BINDING INHIBITION | 0 |
| MUSCARINIC RECEPTOR INCREASE | 9 |
| MUSCLE EFFECTS(UNSPECIFIED) | 164 |
| MUTAGENIC ACTIVITY | 7051 |
| MYDRIATIC ACTIVITY | 46 |
| MYELOPEROXIDASE INHIBITION | 136 |
| MYELOPEROXIDASE STIMULATION | 13 |
| MYELOSUPPRESSION ACTIVITY | 1 |
| MYO-INOSITOL LEVEL INCREASE | 1 |
| MYOCARDIAL ANTIINFLAMMATORY ACTIVITY | 3 |
| MYOCARDIAL CIRCULATION ENHANCEMENT | 8 |
| MYOCARDIAL DEPRESSANT ACTIVITY | 83 |
| MYOCARDIAL DEPRESSANT FACTOR INHIBITION | 5 |
| MYOCARDIAL INFARCTION TREATMENT | 22 |
| MYOCARDIAL ISCHEMIC IMPROVEMENT | 36 |
| MYOCARDIAL OXYGEN CONSUMPTION DECREASED | 13 |
| MYOCARDIAL OXYGEN CONSUMPTION INCREASED | 12 |
| MYOCARDIAL STIMULANT | 25 |
| MYOCARDIAL UPTAKE OF 86-RB ENHANCED | 40 |
| MYODEGENERATION EFFECT | 4 |
| MYOFIBRILLOGENESIS EFFECT | 0 |
| MYONEURAL TRANSMITTER IN PERIPLANETA AMERICANA | 1 |
| MYOSIN INHIBITION | 1 |
| MYOSIN K,EDTA-ATP-ASE INHIBITION | 0 |
| MYOSIN K,EDTA-ATP-ASE STIMULATION | 2 |
| MYOSIN LIGHT CHAIN KINASE INHIBITION | 71 |
| MYROSINASE INHIBITION | 4 |
| N-ACETYL-NEURAMINIDASE INHIBITION | 1 |
| N-ACETYLTRANSFERASE INHIBITION | 18 |
| N-ACETYLTRANSFERASE STIMULATION | 3 |
| N-LINKED OLIGOSACCHARIDE NEURONAL PROTEIN INHIBITION | 1 |
| N-METHYL-D-ASPARTATE AGONIST ACTIVITY | 1 |
| N-METHYL-D-ASPARTATE ANTAGONIST ACTIVITY | 23 |
| N-METHYL-D-ASPARTATE MODULATORY ACTIVITY | 11 |
| N-METHYL-D-ASPARTATE(NMDA) RECEPTOR INHIBITION | 4 |
| N-NITROSAMINE INHIBITION | 5 |
| N-NITROSODIMETHYLAMINE N-DEMETHYLATION INHIBITION | 2 |
| N-NITROSOMORPHOLINE FORMATION INHIBITION | 1 |
| N-NITROSOPROLINE FORMATION INHIBITION | 2 |
| NA PUMP INHIBITION | 14 |
| NA+ CURRENT INHIBITION | 12 |
| NA+ LEAKAGE | 3 |
| NA+ PHOSPHATASE INHIBITION | 7 |
| NA+ UPTAKE INCREASED | 4 |
| NA+/H+ EXCHANGE INHIBITION | 13 |
| NA+/H+ EXCHANGE STIMULATION | 1 |
| NAD ISOCITRATE DEHYDROGENASE INHIBITION | 3 |
| NAD MALATE DEHYDROGENASE INHIBITION | 5 |
| NAD SYNTHESIS STIMULATION | 1 |
| NAD(P)H FORMATION STIMULATION | 3 |
| NAD(P)H-O2-OXIDOREDUCTASE COFACTOR INDUCTION | 1 |
| NAD(P)H:QUINONE ACCEPTOR OXIDOREDUCTASE INHIBITION | 17 |
| NAD(P)H:QUINONE REDUCTASE STIMULATION | 47 |
| NAD+/NADH INCREASE | 1 |
| NAD-DEHYDROGENASE INHIBITION | 10 |
| NAD-OXIDASE INHIBITION | 5 |
| NADH DEHYDROGENASE INHIBITION | 211 |
| NADH DEHYDROGENASE STIMULATION | 2 |
| NADH OXIDASE INHIBITION | 189 |
| NADH OXIDASE STIMULATION | 9 |
| NADH REDUCTASE INHIBITION | 8 |
| NADH REDUCTASE STIMULATION | 14 |
| NADH SUCCINO-OXIDASE INHIBITION | 7 |
| NADH-COENZYME Q OXIDOREDUCTASE INHIBITION | 19 |
| NADH:UBIQUINONE OXIDOREDUCTASE INHIBITION | 62 |
| NADP+ ISOCITRATE DEHYDROGENASE INHIBITION | 3 |
| NADP+ MALIC ENZYME INHIBITION | 11 |
| NADPH CYTOCHROME P450 REDUCTASE INHIBITION | 15 |
| NADPH CYTOCHROME P450 REDUCTASE STIMULATION | 24 |
| NADPH OXIDASE INHIBITION | 13 |
| NADPH OXIDASE STIMULATION | 1 |
| NADPH TRANSHYDROGENASE INHIBITION | 3 |
| NADPH-CYTOCHROME B-5 REDUCTASE STIMULATION | 1 |
| NADPH-CYTOCHROME C REDUCTASE INHIBITION | 51 |
| NADPH-CYTOCHROME C REDUCTASE STIMULATION | 50 |
| NADPH-CYTOCHROME C-5'-NUCLEOTIDASE INHIBITION | 2 |
| NADPH-CYTOCHROME C-5'-NUCLEOTIDASE STIMULATION | 2 |
| NADPH-DIAPHORASE INHIBITION | 6 |
| NARCOTIC ACTIVITY | 197 |
| NARCOTIC ANTAGONIST ACTIVITY | 78 |
| NARCOTIC TOLERANCE INHIBITION | 20 |
| NARCOTIC WITHDRAWAL EFFECTS INHIBITION | 43 |
| NARCOTIC WITHDRAWAL STIMULATION | 1 |
| NARGARSE INHIBITION | 1 |
| NARINGINASE INHIBITION | 1 |
| NATRIURETIC ACTIVITY | 30 |
| NATURAL ENDOGENOUS REVERSE TRANSCRIPTION INHIBITION | 1 |
| NATURAL KILLER CELL ENHANCEMENT | 229 |
| NATURAL KILLER CELL INHIBITION | 50 |
| NAUSEA-INDUCING EFFECT | 6 |
| NECROTIC EFFECT | 83 |
| NEGATIVE GEOTROPIC EFFECT | 2 |
| NEMATOCIDAL ACTIVITY | 894 |
| NEMATODE ATTRACTANT EFFECT | 11 |
| NEMATODE HATCHING STIMULANT | 7 |
| NEMATOSTATIC ACTIVITY | 6 |
| NEOPTERIN INHIBITION | 0 |
| NEOPTERIN STIMULATION | 6 |
| NEOVASCULARIZATION INHIBITION | 3 |
| NEPHROTOXIC ACTIVITY | 265 |
| NERVE CONDUCTION INHIBITION | 4 |
| NERVE FIBER DECREASE | 1 |
| NERVE FIBER INDUCTION | 10 |
| NERVE GROWTH FACTOR EFFECT | 38 |
| NERVE GROWTH FACTOR INHIBITION | 0 |
| NERVE GROWTH FACTOR STIMULATION | 102 |
| NERVE REGENERATION | 10 |
| NEURAL PLASTICITY ENHANCEMENT EFFECT | 1 |
| NEURAL TRANSMISSION INHIBITION | 34 |
| NEURAL TRANSMISSION STIMULATION | 7 |
| NEURAL TRANSPORT INHIBITION | 1 |
| NEURAMINIDASE INHIBITION | 111 |
| NEURITE SPROUTING INHIBITION | 19 |
| NEURITE SPROUTING STIMULATION | 79 |
| NEURITOGENIC ACTIVITY | 105 |
| NEURODEPRESSANT ACTIVITY | 16 |
| NEUROEXCITATORY ACTIVITY | 22 |
| NEUROKININ A-2 RECEPTOR ANTAGONIST | 3 |
| NEUROKININ NK1 RECEPTOR ANTAGONIST | 22 |
| NEUROKININ NK2 RECEPTOR ANTAGONIST | 13 |
| NEUROLEPTIC ACTIVITY | 80 |
| NEUROLEPTIC INHIBITION | 3 |
| NEUROMUSCULAR BLOCKING ACTIVITY | 482 |
| NEUROMUSCULAR STIMULANT | 53 |
| NEUROMUSCULAR TOXICITY | 50 |
| NEURON BRANCHING STIMULATION | 1 |
| NEURON INHIBITION | 11 |
| NEURON SPROUTING STIMULATION | 25 |
| NEUROPEPTIDE LEVEL INCREASE | 9 |
| NEUROPEPTIDE LEVEL REDUCTION | 17 |
| NEUROPEPTIDE Y BINDING INHIBITION | 18 |
| NEUROPEPTIDE Y LEVEL DECREASE | 3 |
| NEUROPROTECTANT EFFECT | 311 |
| NEUROTENSIN BINDING INHIBITION | 10 |
| NEUROTOXIC ACTIVITY | 343 |
| NEUROTROPHIC ACTIVITY | 18 |
| NEUROTROPIC EFFECT | 3 |
| NEUTRAL CHOLESTERYL ESTERASE INHIBITION | 1 |
| NEUTROPENIA ANTAGONIST | 7 |
| NEUTROPENIC EFFECT | 12 |
| NEUTROPHIL MATURATION INHIBITION | 2 |
| NEUTROPHIL MIGRATION INHIBITION | 2 |
| NEUTROPHIL RECRUITMENT INHIBITION | 1 |
| NEUTROPHIL RECRUITMENT STIMULATION | 2 |
| NFAT TRANSCRIPTION FACTOR INDUCTION | 0 |
| NFAT TRANSCRIPTION FACTOR INHIBITION | 9 |
| NICOTINAMIDASE INHIBITION | 2 |
| NICOTINIC AGONIST ACTIVITY | 45 |
| NICOTINIC ANTAGONIST ACTIVITY | 85 |
| NICOTINIC RECEPTOR BINDING ACTIVITY | 48 |
| NICOTINIC RECEPTOR INDUCTION | 1 |
| NIFEDIPINE OXIDASE INHIBITION | 15 |
| NIFEDIPINE OXIDATION INHIBITION | 2 |
| NITRATE FORMATION INHIBITION | 1 |
| NITRATE REDUCTASE INDUCTION | 4 |
| NITRATE REDUCTASE INHIBITION | 6 |
| NITRERGIC ACTIVITY | 1 |
| NITRIC ACID SYNTHASE INDUCTION | 3 |
| NITRIC ACID SYNTHASE INHIBITION | 67 |
| NITRIC OXIDE RELEASE INHIBITION | 390 |
| NITRIC OXIDE RELEASE STIMULATION | 49 |
| NITRIC OXIDE SCAVENGING ACTIVITY | 89 |
| NITRIC OXIDE STIMULATION | 79 |
| NITRIC OXIDE SUPPRESSION | 196 |
| NITRIC OXIDE SYNTHASE INHIBITION | 200 |
| NITRIC OXIDE SYNTHASE STIMULATION | 37 |
| NITRIC OXIDE SYNTHESIS INHIBITION | 532 |
| NITRIC OXIDE SYNTHESIS STIMULATION | 62 |
| NITRIC OXIDE SYNTHETASE RECEPTOR BINDING | 1 |
| NITRITE FORMATION INHIBITION | 25 |
| NITRITE FORMATION STIMULATION | 1 |
| NITROGEN UPTAKE INHIBITION | 5 |
| NITROSAMINE SYNTHESIS INHIBITION | 1 |
| NITROSATION INHIBITION | 34 |
| NITROSODIMETHYLAMINE-N-DEMETHYLASE INHIBITION | 18 |
| NITROSODIMETHYLAMINE-N-DEMETHYLASE(NDMAD) STIMULATION | 6 |
| NMDA RECEPTOR BINDING STIMULATION | 2 |
| NO-SYNTHASE INHIBITION | 66 |
| NOCICEPTIVE EFFECT | 27 |
| NOCICEPTIVE RESPONSE REDUCTION | 848 |
| NON-ESTERIFIED FATTY ACID INHIBITION | 1 |
| NON-POLY(A)-CONTAINING RNA SYNTHESIS INHIBITION | 2 |
| NON-SPECIFIC RESISTANCE DEPRESSION | 17 |
| NON-SPECIFIC RESISTANCE STIMULATION | 158 |
| NONHISTONE PHOSPHORYLATION INHIBITION | 2 |
| NOREPINEPHRINE ANTAGONIST ACTIVITY | 2 |
| NOREPINEPHRINE LEVEL INCREASE | 30 |
| NOREPINEPHRINE LEVELS DECREASED | 23 |
| NOREPINEPHRINE RELEASE INHIBITION | 23 |
| NOREPINEPHRINE RELEASE STIMULATION | 29 |
| NOREPINEPHRINE UPTAKE INHIBITION | 41 |
| NOS INDUCTION INHIBITION | 4 |
| NOSCAPINE BINDING SITE INTERACTION | 5 |
| NUCLEAR ABERRATION REDUCTION | 16 |
| NUCLEAR FACTOR KAPPA-BETA ACTIVATION | 9 |
| NUCLEAR FACTOR KAPPA-BETA ALTERATION ACTIVITY | 1 |
| NUCLEAR FACTOR KAPPA-BETA BINDING INHIBITION | 66 |
| NUCLEAR FACTOR KAPPA-BETA DNA BINDING STIMULATION | 4 |
| NUCLEAR FACTOR KAPPA-BETA INHIBITION | 243 |
| NUCLEAR FACTOR KAPPA-BETA INHIBITOR DEGRADATION INHIBITION | 3 |
| NUCLEAR FACTOR KAPPA-BETA MEDIATED SIGNAL TRANSDUCTION INHIB | 10 |
| NUCLEAR FACTOR KAPPA-BETA STIMULATION | 8 |
| NUCLEAR FACTOR OF ACTIVATED T CELLS INHIBITION | 15 |
| NUCLEAR FACTOR-AT INHIBITION | 10 |
| NUCLEIC ACID INHIBITION | 28 |
| NUCLEOLUS SEGREGATION INDUCTION | 5 |
| NUCLEOSIDE TRANSPORT INHIBITION | 12 |
| NUCLEOSIDE TRANSPORTER MODULATION | 1 |
| NUCLEOSIDE UPTAKE STIMULATION | 4 |
| NUCLEOTIDASE INDUCTION | 8 |
| NUCLEOTIDASE INHIBITION | 89 |
| NUCLEOTIDE TRIPHOSPHATASE INHIBITION | 2 |
| NUMBING EFFECT | 21 |
| NUTRITIONAL VALUE | 40 |
| NYCTINASTIC EFFECT | 15 |
| O-6-METHYL-GUANINE-DNA-TRANSMETHYLASE ACTIVATION | 1 |
| O-ACETYLTRANSFERASE INHIBITION | 2 |
| O-DEALKYLATION INHIBITION | 1 |
| OBSTRUCTIVE BOWEL DISEASE IMPROVEMENT | 3 |
| OCTANOYL-CO-A DEHYDROGENASE STIMULATION | 2 |
| OCULAR OUTFLOW STIMULATION | 0 |
| OCULAR PRESSURE REDUCER | 12 |
| OCULAR PROTECTION ACTIVITY | 3 |
| OCULAR TOXICITY | 16 |
| ODONTOGENESIS INHIBITION | 1 |
| ODOR EFFECT | 49 |
| OLFACTORY EFFECT | 8 |
| OLIGOSACCHARIDE PROCESSING INHIBITION | 6 |
| ONCOGENE DOWN-REGULATION ACTIVITY | 3 |
| ONCOGENE EXPRESSION ENHANCEMENT | 14 |
| ONCOGENE EXPRESSION INHIBITION | 43 |
| OOCYTE MATURATION INDUCTION | 9 |
| OOCYTE MATURATION INHIBITION | 6 |
| OPHTHALMOLOGICAL EFFECTS | 3 |
| OPIATE AGONIST ACTIVITY | 1 |
| OPIATE ANTAGONIST | 29 |
| OPIATE POTENTIATION | 15 |
| OPIATE RECEPTOR BINDING ACTIVITY | 60 |
| OPIATE RECEPTOR BINDING INHIBITION | 135 |
| OPIATE RECEPTOR BINDING STIMULATION | 29 |
| ORGAN REGENERATION EFFECT | 0 |
| ORGAN WEIGHT INCREASE | 1 |
| ORGAN WEIGHT LOSS | 4 |
| ORNITHINE CARBAMYL TRANSFERASE INHIBITION | 6 |
| ORNITHINE CARBAMYL TRANSFERASE STIMULATION | 4 |
| ORNITHINE DECARBOXYLASE INDUCTION | 164 |
| ORNITHINE DECARBOXYLASE INDUCTION INHIBITION | 59 |
| ORNITHINE DECARBOXYLASE INHIBITION | 529 |
| OROTIDINE-5'-PHOSPHATE DECARBOXYLASE INHIBITION | 13 |
| OSTEOBLAST FUNCTION ENHANCEMENT | 7 |
| OSTEOCALCIN STIMULATION | 2 |
| OSTEOCLAST FORMATION INHIBITION | 18 |
| OTOTOXIC ACTIVITY | 10 |
| OVICIDAL ACTIVITY | 142 |
| OVIPOSITION INHIBITION | 41 |
| OVIPOSITION STIMULATION | 25 |
| OVULATION INDUCTION EFFECT | 24 |
| OVULATION INHIBITION EFFECT | 238 |
| OXIDATION EFFECT | 1 |
| OXIDATION-REDUCTION NORMALIZATION ACTIVITY | 1 |
| OXIDATIVE BURST INDUCTION | 43 |
| OXIDATIVE BURST INHIBITION | 37 |
| OXIDATIVE METABOLISM RATE OF NNK DECREASED | 0 |
| OXIDATIVE METABOLISM RATE OF NNK INCREASED | 0 |
| OXIDATIVE PHOSPHORYLATION INHIBITION | 59 |
| OXIDATIVE PHOSPHORYLATION STIMULATION | 6 |
| OXIDATIVE PHOSPHORYLATION UNCOUPLING EFFECT | 41 |
| OXOSTEROID(11-) REDUCTASE INHIBITION | 1 |
| OXYGEN CONSUMPTION DECREASE | 108 |
| OXYGEN CONSUMPTION INCREASE | 20 |
| OXYGEN DELIVERY INCREASE | 4 |
| OXYGEN RADICAL FORMATION INDUCTION | 46 |
| OXYGEN RADICAL INHIBITION | 121 |
| OXYGEN SATURATION DECREASE | 4 |
| OXYGEN STATUS IMPROVEMENT | 2 |
| OXYTOCIN BINDING INHIBITION | 3 |
| OXYTOCIN RELEASE INDUCTION | 4 |
| OXYURICIDAL ACTIVITY | 10 |
| P-GLYCOPROTEIN BINDING ACTIVITY | 17 |
| P-GLYCOPROTEIN BINDING INHIBITION ACTIVITY | 6 |
| P-GLYCOPROTEIN REVERSAL ACTIVITY | 5 |
| P-GLYCOPROTEIN TRANSPORT INHIBITION | 6 |
| P-HYDROXYPHENYLPYRUVATE-DIOXYGENASE INHIBITION | 32 |
| P-NITROANISOLE O-DEMETHYLASE INHIBITION | 3 |
| P-NITROPHENOL HYDROXYLASE INHIBITION | 12 |
| P-NITROPHENOL HYDROXYLASE STIMULATION | 8 |
| P-SELECTIN RECEPTOR INHIBITION | 3 |
| P38 INHIBITION | 1 |
| PALMITOYL PROTEIN THIOESTERASE 1 INHIBITION | 2 |
| PALMITOYL-CO-A DEHYDROGENASE STIMULATION | 4 |
| PANCREATIC SECRETION STIMULATION | 24 |
| PANCREATIC TOXICITY | 5 |
| PANCREATIN INHIBITION | 34 |
| PANIC ATTACK INDUCTION | 1 |
| PAPAIN INHIBITION | 116 |
| PARA-AMINOHIPPURATE INDUCTION | 0 |
| PARA-AMINOHIPPURATE INHIBITION | 1 |
| PARA-AMINOHIPPURATE TRANSPORT ACTIVITY | 2 |
| PARA-AMINOHIPPURATE UPTAKE INHIBITION | 5 |
| PARA-NITROPHENOL HYDROXYLASE INHIBITION | 13 |
| PARA-NITROPHENYL PHOSPHATASE(K+) INHIBITION | 6 |
| PARADOXICAL SLEEP ENHANCEMENT | 2 |
| PARALYZING ACTIVITY | 13 |
| PARALYZING EFFECT(INSECT) | 18 |
| PARANITROANISOLE-O-DEMETHYLASE INDUCTION | 18 |
| PARANITROANISOLE-O-DEMETHYLASE INHIBITION | 1 |
| PARASITE AGGLUTINATION EFFECT | 14 |
| PARASITIC INSECTICIDAL ACTIVITY | 35 |
| PARASYMPATHOLYTIC ACTIVITY | 110 |
| PARASYMPATHOMIMETIC ACTIVITY | 73 |
| PARATHORMONE RELEASE INHIBITION | 1 |
| PARATHYROID HORMONE INDUCTION | 6 |
| PARATHYROID HORMONE INHIBITION | 0 |
| PARTIAL THROMBOPLASTIN TIME INCREASE | 8 |
| PASSIVE CUTANEOUS ANAPHYLAXIS INHIBITION | 95 |
| PASSIVE SENSITIZATION INDUCTION | 2 |
| PDB BINDING INHIBITION | 5 |
| PDGF RECEPTOR KINASE INHIBITION | 1 |
| PECTIN LYASE INHIBITION | 4 |
| PECTIN METHYLESTERASE INHIBITION | 2 |
| PECTINESTERASE INHIBITION | 1 |
| PENICILLINASE INHIBITION | 39 |
| PENILE SIZE INCREASE | 14 |
| PENIS ERECTILE STIMULANT | 48 |
| PENTOXYRESORUFIN DEPENTYLATION ACTIVITY | 4 |
| PENTOXYRESORUFIN O-DEALKYLASE INHIBITION | 5 |
| PENTOXYRESORUFIN-O-DEALKYLASE(PROD) STIMULATION | 39 |
| PENTOXYRESORULIN-O-DEALKYLASE INHIBITION | 17 |
| PEP CARBOXYLASE INHIBITION | 9 |
| PEPSIN BINDING | 9 |
| PEPSIN INHIBITION | 94 |
| PEPSIN SECRETION INHIBITION | 42 |
| PEPSINOGEN ACTIVATION INHIBITION | 2 |
| PEPTIDE RECEPTOR BINDING INHIBITION | 10 |
| PEPTIDE TRANSPORT INHIBITION | 1 |
| PEPTIDOGLYCAN SYNTHESIS INHIBITION | 34 |
| PEPTIDOLEUKOTRIENE RELEASE INHIBITION | 1 |
| PEPTIDYL TRANSFERASE INHIBITION | 7 |
| PEPTIDYL TRANSFERASE STIMULATION | 6 |
| PEPTIDYL-PROLYL CIS/TRANS ISOMERASE INHIBITION | 6 |
| PEPTIDYL-PROLYL ISOMERASE STIMULATION | 1 |
| PEPTIDYLDIPEPTIDE HYDROLASE INHIBITION | 2 |
| PEPTIDYLGLUTAMYLPEPTIDE HYDROLYSIS INHIBITION | 5 |
| PERCUTANEOUS ABSORPTION ENHANCEMENT | 26 |
| PERFUME EFFECT | 2 |
| PERICARDIAL EFFUSION TREATMENT | 1 |
| PERIODONTAL REGENERATION EFFECT | 1 |
| PERIPHERAL GLUCOSE UPTAKE STIMULATION | 1 |
| PERITONEAL DIALYSIS ENHANCEMENT | 1 |
| PEROXIDASE ACTIVITY | 51 |
| PEROXIDASE INHIBITION | 14 |
| PEROXIDASE STIMULATION | 19 |
| PEROXIDE FORMATION INHIBITION | 117 |
| PEROXIDE FORMATION STIMULATION | 15 |
| PEROXISOMAL ENZYME INDUCTION | 2 |
| PEROXISOMAL FATTY ACYL-COENZYME A OXIDASE INDUCTION | 1 |
| PEROXISOME CONTENT DECREASE | 2 |
| PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ACTIVATION | 18 |
| PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA ACTIVATION | 2 |
| PH LOWERING EFFECT | 1 |
| PHAGE INDUCTION | 13 |
| PHAGOCYTOSIS CAPACITY DECREASED | 18 |
| PHAGOCYTOSIS CAPACITY INCREASED | 88 |
| PHAGOCYTOSIS INHIBITION | 133 |
| PHAGOCYTOSIS RATE DECREASED | 26 |
| PHAGOCYTOSIS RATE INCREASED | 117 |
| PHAGOCYTOSIS STIMULATION | 490 |
| PHAGOSOME-LYSOSOME FUSION INHIBITION | 4 |
| PHARMACOKINETIC ALTERATION | 326 |
| PHARMACOKINETIC STUDY OF | 1672 |
| PHASE II ENZYME INDUCTION | 5 |
| PHENOL OXIDASE STIMULATION | 2 |
| PHENOLOXIDASE INHIBITION | 2 |
| PHENOLSULFOTRANSFERASE(PST) INHIBITION | 18 |
| PHENOLSULFOTRANSFERASE(PST) STIMULATION | 1 |
| PHENYLALANINE AMMONIA LYASE ACTIVATION | 3 |
| PHENYLALANINE AMMONIA LYASE INDUCTION | 3 |
| PHENYLALANINE AMMONIA LYASE INHIBITION | 77 |
| PHENYLALANINE HYDROXYLASE INHIBITION | 2 |
| PHEROMONE ACTIVITY(UNSPEC) | 5 |
| PHEROMONE(AGGREGATION) | 4 |
| PHEROMONE(ALGAL SEX ATRTRACTANT) | 28 |
| PHEROMONE(ANIMAL ADRENOCORTICAL ACTIVATOR) | 1 |
| PHEROMONE(ANIMAL AGGRESSION INDUCER) | 0 |
| PHEROMONE(ANIMAL AGGRESSION INHIBITOR) | 0 |
| PHEROMONE(ANIMAL ALARM) | 11 |
| PHEROMONE(ANIMAL ESTRUS INDUCER) | 0 |
| PHEROMONE(ANIMAL ESTRUS INHIBITOR) | 2 |
| PHEROMONE(ANIMAL REPELLENT) | 18 |
| PHEROMONE(ANIMAL SEX ATTRACTANT) | 74 |
| PHEROMONE(ANIMAL-TRAIL BREAKING-ALARM) | 4 |
| PHEROMONE(ANTIAGGREGATIVE) | 1 |
| PHEROMONE(BROOD) | 2 |
| PHEROMONE(COMMUNICATION DISRUPTION) | 1 |
| PHEROMONE(FISH ATTRACTANT)ACTIVITY | 2 |
| PHEROMONE(IMPRINTING) | 4 |
| PHEROMONE(INSECT AGGRESSION INDUCER) | 4 |
| PHEROMONE(INSECT ALARM) | 19 |
| PHEROMONE(INSECT ATTRACTANT INHIBITION) | 3 |
| PHEROMONE(INSECT CONTACT COURTING) | 3 |
| PHEROMONE(INSECT RECRUITMENT) | 1 |
| PHEROMONE(INSECT SEX ATTRACTANT) | 1641 |
| PHEROMONE(INSECT STIMULANT) | 2 |
| PHEROMONE(INSECT TRAIL) | 22 |
| PHEROMONE(KAIROMONE) | 31 |
| PHEROMONE(POPULATION AGGREGATION) | 7 |
| PHEROMONE(PRIMING) | 1 |
| PHEROMONE(PUBERTY ACCELERATOR) | 1 |
| PHEROMONE(SIGNALLING) | 1430 |
| PHEROMONE(SNAIL ATTRACTANT) | 0 |
| PHEROMONE(YEAST-MATING) | 6 |
| PHLOGISTIC ACTIVITY | 31 |
| PHORBOL 12,13-DIBUTYRATE BINDING INHIBITION | 14 |
| PHORBOL ESTER ANTAGONIST | 190 |
| PHORBOL ESTER RECEPTOR BINDING | 18 |
| PHORBOL ESTER RECEPTOR BINDING INHIBITION | 4 |
| PHORBOL ESTER RECEPTOR MODULATION | 3 |
| PHOSPHATASE INHIBITION | 13 |
| PHOSPHATIDIC ACID FORMATION INHIBITION | 2 |
| PHOSPHATIDYL-GLYCEROL SYNTHESIS STIMULATION | 1 |
| PHOSPHATIDYLATE PHOSPHOHYDROLASE INHIBITION | 10 |
| PHOSPHATIDYLCHOLINE FORMATION INHIBITION | 12 |
| PHOSPHATIDYLCHOLINE FORMATION STIMULATION | 2 |
| PHOSPHATIDYLCHOLINE HYDROLYSIS INHIBITION | 1 |
| PHOSPHATIDYLETHANOLAMINE SYNTHESIS INHIBITION | 7 |
| PHOSPHATIDYLINOSITOL 3-KINASE INHIBITION | 28 |
| PHOSPHATIDYLINOSITOL KINASE INHIBITION | 36 |
| PHOSPHATIDYLINOSITOL KINASE STIMULATION | 3 |
| PHOSPHATIDYLINOSITOL SYNTHESIS INHIBITION | 1 |
| PHOSPHATIDYLINOSITOL SYNTHESIS STIMULATION | 1 |
| PHOSPHATIDYLINOSITOL TURNOVER INHIBITION | 11 |
| PHOSPHATIDYLINOSITOL-4-PHOSPHATE KINASE ACTIVATION | 1 |
| PHOSPHATIDYLINOSITOL-4-PHOSPHATE KINASE INHIBITION | 5 |
| PHOSPHATIDYLINOSITOL-PHOSPHOLIPASE STIMULATION | 2 |
| PHOSPHATIDYLSERINE SYNTHESIS INHIBITION | 4 |
| PHOSPHATIDYLSERINE SYNTHESIS STIMULATION | 5 |
| PHOSPHOCREATINE LEVEL INCREASE | 2 |
| PHOSPHODIESTERASE INHIBITION | 454 |
| PHOSPHODIESTERASE STIMULATION | 15 |
| PHOSPHOENOLPYRUVATE CARBOXYKINASE INHIBITION | 6 |
| PHOSPHOENOLPYRUVATE CREATINE KINASE INHIBITION | 0 |
| PHOSPHOFRUCTOKINASE INHIBITION | 30 |
| PHOSPHOFRUCTOKINASE STIMULATION | 11 |
| PHOSPHOGLUCOISOMERASE STIMULATION | 0 |
| PHOSPHOGLUCOMUTASE INHIBITION | 4 |
| PHOSPHOGLUCONATE DEHYDROGENASE INHIBITION | 3 |
| PHOSPHOGLUCONATE DEHYDROGENASE STIMULATION | 5 |
| PHOSPHOGLUCOSE ISOMERASE INHIBITION | 6 |
| PHOSPHOGLYCERATE(3)-KINASE-1 INHIBITION | 2 |
| PHOSPHOGLYCERATE(3)-KINASE-2 INHIBITION | 1 |
| PHOSPHOHEXOSE ISOMERASE ACTIVATION | 2 |
| PHOSPHOINOSITIDE BREAKDOWN | 11 |
| PHOSPHOINOSITIDE BREAKDOWN INHIBITION | 28 |
| PHOSPHOINOSITIDE KINASE INHIBITION | 23 |
| PHOSPHOINOSITIDE PRODUCTION INHIBITION | 2 |
| PHOSPHOINOSITIDE TURNOVER INHIBITION | 3 |
| PHOSPHOKINASE A INHIBITION | 1 |
| PHOSPHOKINASE A STIMULATION | 1 |
| PHOSPHOKINASE C INHIBITION | 49 |
| PHOSPHOKINASE C STIMULATION | 9 |
| PHOSPHOLIPASE A2 ACTIVATION | 1 |
| PHOSPHOLIPASE A2 ANTAGONIST | 17 |
| PHOSPHOLIPASE A2 INHIBITION | 481 |
| PHOSPHOLIPASE ACTIVITY | 7 |
| PHOSPHOLIPASE C INHIBITION | 81 |
| PHOSPHOLIPASE D INHIBITION | 21 |
| PHOSPHOLIPASE D STIMULATION | 5 |
| PHOSPHOLIPASE INHIBITION | 52 |
| PHOSPHOLIPASE STIMULATION | 28 |
| PHOSPHOLIPID LEVEL INCREASE | 4 |
| PHOSPHOPROTEIN FORMATION INHIBITION | 7 |
| PHOSPHORIBOSYL PYROPHOSPHATE AMINOTRANSFERASE INHIBITION | 16 |
| PHOSPHORYLASE INHIBITION | 16 |
| PHOSPHORYLASE KINASE INHIBITION | 24 |
| PHOSPHORYLASE KINASE STIMULATION | 1 |
| PHOSPHORYLASE STIMULATION | 14 |
| PHOSPHORYLATION INHIBITION | 47 |
| PHOSPHORYLATION OF HISTONE PROTEIN INHIBITION | 4 |
| PHOSPHORYLATION OF NONHISTONE PROTEIN STIMULATION | 6 |
| PHOSPHORYLATION STIMULATION | 6 |
| PHOSPHORYLATION UNCOUPLING EFFECT | 22 |
| PHOSPHOTRANSFERASE INHIBITION | 2 |
| PHOSPHOTRANSFERASE STIMULATION | 4 |
| PHOSPHOTYROSINE INHIBITION | 5 |
| PHOTODERMATITIS EFFECT | 7 |
| PHOTOPHOSPHORYLATION INHIBITION | 16 |
| PHOTOPHOSPHORYLATION STIMULATION | 7 |
| PHOTOPHOSPHORYLATION UNCOUPLING EFFECT | 2 |
| PHOTOSENSITIVITY INHIBITION | 4 |
| PHOTOSENSITIZER ACTIVITY | 209 |
| PHOTOSYNTHESIS INHIBITION | 34 |
| PHOTOSYSTEM II INHIBITION | 2 |
| PHOTOTOXICITY | 472 |
| PHOTOTOXICITY INHIBITION | 9 |
| PHYSICAL CHEMICAL STUDY | 32 |
| PHYTOALEXIN | 38 |
| PHYTOALEXIN INDUCTION | 1 |
| PHYTOCHROME KILLER ACTIVITY | 0 |
| PHYTOHEMAGGLUTININ | 28 |
| PHYTOTOXIC EFFECT | 879 |
| PHYTOTOXIN INITIATION | 1 |
| PIGMENT(COLORING AGENT)USE | 16 |
| PINOCYTOSIS INHIBITION | 1 |
| PINOCYTOSIS STIMULATION | 1 |
| PINOLINE BINDING ACTIVITY | 6 |
| PIP CARBOXYLASE INDUCTION | 0 |
| PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE RECEPTOR AGON | 2 |
| PITUITARY REGRESSIVE EFFECT | 1 |
| PLANT ABSCISSION INDUCTION | 11 |
| PLANT ALKALOID FORMATION INHIBITOR | 1 |
| PLANT ALKALOID FORMATION STIMULANT | 4 |
| PLANT ANTI-ABCISSION EFFECT | 1 |
| PLANT ANTITUMOR EFFECT | 47 |
| PLANT BIOSYNTHESIS INHIBITOR | 43 |
| PLANT BRANCH PRODUCTION INCREASE | 0 |
| PLANT CALLUS FORMATION INHIBITOR | 9 |
| PLANT CALLUS FORMATION STIMULANT | 11 |
| PLANT CARBOHYDRATE METABOLISM EFFECT | 2 |
| PLANT CAROTENOID SYNTHESIS STIMULANT | 1 |
| PLANT CELL ELONGATION INHIBITION | 1 |
| PLANT CHLOROPHYLL SYNTHESIS STIMULANT | 2 |
| PLANT CHLOROPLAST COUPLING FACTOR I INHIBITION | 2 |
| PLANT CHLOROSIS INDUCTION | 21 |
| PLANT CROWN GALL TUMOR INHIBITION | 10 |
| PLANT DEFOLIANT EFFECT | 0 |
| PLANT DISEASE RESISTANCE SUPPRESSOR | 1 |
| PLANT DISEASE VECTOR INHIBITION | 2 |
| PLANT DNA SYNTHESIS STIMULANT | 1 |
| PLANT EFFECTS(UNSPECIFIED) | 45 |
| PLANT ELECTRON TRANSFER INHIBITION | 1 |
| PLANT ENZYME INDUCTION | 12 |
| PLANT ENZYME INHIBITOR | 6 |
| PLANT FASCIATION INDUCTION | 2 |
| PLANT FLOWER INDUCTION | 11 |
| PLANT FLOWER INHIBITION | 1 |
| PLANT FRUIT RIPENING INHIBITION | 2 |
| PLANT GERMINATION INHIBITION | 1227 |
| PLANT GERMINATION STIMULANT | 186 |
| PLANT GREEN ISLAND INDUCTION | 55 |
| PLANT GROWTH INHIBITOR(UNSPEC) | 893 |
| PLANT GROWTH PROMOTER(UNSPEC) | 226 |
| PLANT GROWTH REGULATOR ACTIVITY | 1 |
| PLANT HOST RECOGNITION EFFECT | 2 |
| PLANT HYPERSENSITIVE RESPONSE ELICITOR | 6 |
| PLANT HYPOCOTYL GROWTH INHIBITION | 62 |
| PLANT HYPOCOTYL GROWTH STIMULANT | 8 |
| PLANT INDIRECT DEFENSE INDUCTION | 13 |
| PLANT KAURENE BIOSYNTHESIS INHIBITION | 6 |
| PLANT LEAF GROWTH INHIBITION | 26 |
| PLANT LEAF MOVEMENT STIMULATION | 7 |
| PLANT MATURATION ACCELERATOR | 1 |
| PLANT MUTAGEN | 9 |
| PLANT NECROSIS INDUCTION | 227 |
| PLANT NECROSIS INHIBITION | 1 |
| PLANT NODULE WEIGHT INCREASE | 2 |
| PLANT PATHOTOXIN | 7 |
| PLANT POLLEN GROWTH INHIBITION | 8 |
| PLANT POLLEN TUBE ELONGATION INHIBITION | 30 |
| PLANT POLLEN TUBE ELONGATION STIMULATION | 5 |
| PLANT PROTEIN SYNTHESIS INHIBITION | 5 |
| PLANT PROTEIN SYNTHESIS STIMULANT | 2 |
| PLANT RADICLE ELONGATION INHIBITION | 81 |
| PLANT RADICLE ELONGATION STIMULATION | 39 |
| PLANT RESTITUTION INHIBITOR | 3 |
| PLANT ROOT ELONGATION INHIBITION | 104 |
| PLANT ROOT GROWTH INHIBITION | 814 |
| PLANT ROOT GROWTH STIMULANT | 290 |
| PLANT ROOT MALFORMATION INDUCTION | 8 |
| PLANT SENESCENCE INHIBITION | 1 |
| PLANT SENESCENCE PROMOTING ACTIVITY | 2 |
| PLANT SHOOT FORMATION STIMULANT | 20 |
| PLANT SHOOT GROWTH INHIBITOR | 266 |
| PLANT SHOOT GROWTH STIMULATION | 78 |
| PLANT STOMATAL CLOSURE INDUCER | 4 |
| PLANT TUBER INDUCTION | 10 |
| PLANT TUMOR-INDUCTION EFFECT | 1 |
| PLANT WATER TRANSPORT INHIBITION | 3 |
| PLANT WILT INHIBITOR | 13 |
| PLANT WILT STIMULANT | 12 |
| PLANT WOUND HEALING INHIBITION | 1 |
| PLANT WOUND-HEALING ACTIVITY | 2 |
| PLAQUE FORMATION SUPPRESSANT | 448 |
| PLAQUE FORMING CELL STIMULATION | 37 |
| PLAQUE-FORMING CELL SUPPRESSION | 32 |
| PLASMA BILIRUBIN DECREASE | 124 |
| PLASMA BILIRUBIN INCREASE | 37 |
| PLASMA EXTENDER | 2 |
| PLASMA EXUDATION INHIBITION | 9 |
| PLASMA KININ INHIBITION | 3 |
| PLASMA PROTEIN CONCENTRATION INCREASED | 16 |
| PLASMA PROTEIN EFFECT | 5 |
| PLASMA RENIN STIMULANT | 2 |
| PLASMID REMOVAL ACTIVITY | 8 |
| PLASMIN ACTIVITY INCREASE | 5 |
| PLASMIN INHIBITION | 238 |
| PLASMINOGEN ACTIVATION STIMULATION | 51 |
| PLASMINOGEN ACTIVATOR INHIBITION | 13 |
| PLASMINOGEN ACTIVATOR INHIBITOR FORMATION INHIBITION | 1 |
| PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITION | 30 |
| PLASMINOGEN BINDING STIMULATION | 6 |
| PLASMINOGEN INHIBITION | 96 |
| PLATELET ACTIVATING FACTOR ACETYLTRANSFERASE INHIBITION | 11 |
| PLATELET ACTIVATING FACTOR BINDING INHIBITION | 365 |
| PLATELET ACTIVATING FACTOR INHIBITION | 146 |
| PLATELET ACTIVATING FACTOR RECEPTOR BINDING INHIBITION | 54 |
| PLATELET ACTIVATING FACTOR STIMULATION | 30 |
| PLATELET ACTIVATION INHIBITION | 11 |
| PLATELET ADHESION INHIBITION | 67 |
| PLATELET AGGREGATING FACTOR ANTAGONISM | 0 |
| PLATELET AGGREGATING FACTOR INDUCTION INHIBITION | 16 |
| PLATELET AGGREGATING FACTOR RECEPTOR ANTAGONIST ACTIVITY | 14 |
| PLATELET AGGREGATION INHIBITION | 6243 |
| PLATELET AGGREGATION STIMULATION | 267 |
| PLATELET ATP RELEASE INHIBITION | 30 |
| PLATELET ATP RELEASE STIMULATION | 4 |
| PLATELET SECRETORY INHIBITION | 2 |
| PLATELET SECRETORY STIMULATION | 8 |
| PLATELET STIMULANT | 26 |
| PLATELET STRIP RELAXANT ACTIVITY | 4 |
| PLATELET-DERIVED GROWTH FACTOR A PRODUCTION INHIBITION | 0 |
| PLATELET-DERIVED GROWTH FACTOR B PRODUCTION INHIBITION | 3 |
| PLATELET-DERIVED GROWTH FACTOR B PRODUCTION STIMULATION | 0 |
| PNEUMOTOXICITY | 82 |
| POLY(A)-CONTAINING RNA SYNTHESIS INHIBITION | 3 |
| POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITION | 40 |
| POLY(ADP-RIBOSE) POLYMERASE CLEAVAGE STIMULATION | 2 |
| POLY(ADP-RIBOSE) POLYMERASE INHIBITION | 13 |
| POLY(ADP-RIBOSE) SYNTHETASE INHIBITION | 44 |
| POLYAMINE BIOSYNTHESIS INHIBITION | 14 |
| POLYAMINE LEVEL DECREASE | 5 |
| POLYAMINE OXIDASE INHIBITION | 1 |
| POLYAMINE SYNTHESIS STIMULATION | 4 |
| POLYCYSTIC KIDNEY DISEASE INHIBITION | 3 |
| POLYCYTHEMIC EFFECT | 2 |
| POLYGALACTURONASE INHIBITION | 31 |
| POLYGLYCOHYDROLASE INHIBITION | 1 |
| POLYMERASE-BETA LYASE INHIBITION | 6 |
| POLYMORPHONUCLEAR LEUKOCYTE ACTIVATION | 9 |
| POLYMORPHONUCLEAR LEUKOCYTE ACTIVATION INHIBITOR | 208 |
| POLYMORPHONUCLEAR LEUKOCYTE MOTILITY ENHANCEMENT | 4 |
| POLYNUCLEOTIDE KINASE INHIBITION | 4 |
| POLYPEPTIDE CHAIN INITIATION FACTOR I INHIBITION | 3 |
| POLYPHENOL OXIDASE ACTIVITY | 2 |
| POLYPHENOL OXIDASE INDUCTION | 3 |
| POLYPHENOL OXIDASE INHIBITION | 10 |
| POLYPHENOLASE INHIBITION | 2 |
| POLYPHENYLALANINE SYNTHESIS INHIBITION | 2 |
| POLYPLOIDY INDUCTION | 5 |
| POLYSACCHARIDE SYNTHESIS INHIBITION | 4 |
| POLYURIDINE-DIRECTED POLYPHENYLALANINE SYNTHESIS INHIBITION | 36 |
| POPULATION SPIKE AMPLITUDE DECREASE | 3 |
| POPULATION SPIKE AMPLITUDE INCREASE | 4 |
| PORPHYRIN SYNTHESIS INHIBITION | 16 |
| POSITIVE REINFORCEMENT EFFECT | 7 |
| POTASSIUM CHANNEL ACTIVATION | 33 |
| POTASSIUM CHANNEL BLOCKING ACTIVITY | 105 |
| POTASSIUM TRANSPORT INHIBITION | 14 |
| POTASSIUM TRANSPORT STIMULATION | 4 |
| POTASSIUM UPTAKE INHIBITION | 2 |
| PPAR-GAMMA (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR) LIGAND BINDING ACTIVITY | 21 |
| PRECIPITIN AGGLUTINANT | 10 |
| PREGNANE X RECEPTOR STIMULATION | 1 |
| PREKALLIKREIN DECREASE | 4 |
| PREKALLIKREININ ACTIVATION | 1 |
| PREMENSTRUAL SYNDROME TREATMENT | 59 |
| PRESSOR RESPONSE INHIBITION | 11 |
| PRESYNAPTIC INHIBITION | 2 |
| PRO-MATRIX METALLOPROTEINASE 1 INHIBITION | 4 |
| PRO-MATRIX METALLOPROTEINASE 3 INHIBITION | 2 |
| PROACROSIN INHIBITION | 3 |
| PROBING STIMULATION(INSECT) | 3 |
| PROCASPASE-8 CLEAVAGE STIMULATION | 1 |
| PROCASPASE-9 CLEAVAGE STIMULATION | 1 |
| PROCOLLAGEN ALPHA-1(I) EXPRESSION INHIBITION | 1 |
| PROGESTAGENIC EFFECT | 295 |
| PROGESTERONE 11-ALPHA-HYDROXYLASE INHIBITION | 2 |
| PROGESTERONE RECEPTOR AGONIST ACTIVITY | 3 |
| PROGESTERONE RECEPTOR BINDING ACTIVITY | 28 |
| PROGESTERONE RECEPTOR BINDING INHIBITION | 9 |
| PROGESTERONE RECEPTOR STIMULATION | 2 |
| PROGESTERONE SECRETION INHIBITION | 5 |
| PROGESTERONE SECRETION STIMULATION | 15 |
| PROGESTERONE SYNTHESIS INHIBITION | 16 |
| PROINSULIN BIOSYNTHESIS INHIBITION | 1 |
| PROLACTIN INHIBITION | 183 |
| PROLACTIN STIMULATION | 84 |
| PROLIDASE INHIBITION | 1 |
| PROLINE HYDROXYLASE INHIBITION | 14 |
| PROLINE HYDROXYLASE STIMULATION | 1 |
| PROLONGATION OF LIFESPAN | 9 |
| PROLYL ENDOPEPTIDASE INHIBITION | 260 |
| PROLYLIMINOPEPTIDASE INHIBITION | 1 |
| PRONASE INHIBITION | 3 |
| PROOXIDANT ACTIVITY | 57 |
| PROPERDIN INDUCTION | 1 |
| PROPHAGE INDUCTION | 336 |
| PROPHAGE INDUCTION IN A LYSOGENIC ORGANISM | 13 |
| PROPROTEIN CONVERTASE INHIBITION | 0 |
| PROSTACYCLIN RELEASE INHIBITION | 8 |
| PROSTACYCLIN SYNTHESIS STIMULATION | 6 |
| PROSTAGLANDIN DEHYDROGENASE INHIBITION | 11 |
| PROSTAGLANDIN E-2 RELEASE STIMULATION | 27 |
| PROSTAGLANDIN E2 INHIBITION | 271 |
| PROSTAGLANDIN ENDOPEROXIDE SYNTHASE INHIBITION | 17 |
| PROSTAGLANDIN F-1-ALPHA-6-KETO RELEASE INHIBITION | 1 |
| PROSTAGLANDIN F-1-ALPHA-6-KETO RELEASE STIMULATION | 5 |
| PROSTAGLANDIN F-1-ALPHA-6-KETO SYNTHESIS INHIBITION | 4 |
| PROSTAGLANDIN I-2 SECRETION STIMULATION | 4 |
| PROSTAGLANDIN INDUCTION | 139 |
| PROSTAGLANDIN INHIBITION | 214 |
| PROSTAGLANDIN RECEPTOR BINDING DECREASE | 2 |
| PROSTAGLANDIN RELEASE INHIBITION | 2 |
| PROSTAGLANDIN SYNTHESIS INHIBITION | 260 |
| PROSTAGLANDIN SYNTHESIS STIMULATION | 61 |
| PROSTAGLANDIN SYNTHETASE INHIBITION | 316 |
| PROSTAGLANDIN SYNTHETASE STIMULATION | 22 |
| PROSTAGLANDIN-H-SYNTHASE 1 INHIBITION | 5 |
| PROSTAGLANDIN-H-SYNTHASE 2 INHIBITION | 5 |
| PROSTAGLANDOYL E2-CO-A OXIDASE STIMULATION | 2 |
| PROSTATIC BUD FORMATION INHIBITION | 2 |
| PROSTATIC HYPERPLASIA INDUCTION | 1 |
| PROSTATIC SECRETION INCREASED | 5 |
| PROTEASE ACTIVITY | 23 |
| PROTEASE INHIBITION | 204 |
| PROTEASE STIMULATION | 9 |
| PROTEASE(HEPATITIS C VIRUS) INHIBITION | 153 |
| PROTEASE(HIV) INHIBITION | 833 |
| PROTEASOME INHIBITION | 16 |
| PROTECTIVE ACTIVITY | 82 |
| PROTEIN AGGREGATION STIMULATION | 1 |
| PROTEIN BINDING | 93 |
| PROTEIN DEGRADATION | 9 |
| PROTEIN DEGRADATION INHIBITION | 11 |
| PROTEIN DOWNREGULATION ACTIVITY | 23 |
| PROTEIN DOWNREGULATION INHIBITION | 1 |
| PROTEIN EXPRESSION INHIBITION | 177 |
| PROTEIN EXPRESSION STIMULATION | 166 |
| PROTEIN FARNESYLATION INHIBITION | 2 |
| PROTEIN GLYCATION (ADVANCED GLYCATION ENDPRODUCTS) INHIBITION | 68 |
| PROTEIN GLYCOSYLATION INHIBITION | 16 |
| PROTEIN KINASE A ACTIVATION | 2 |
| PROTEIN KINASE A TYPE I INHIBITION | 23 |
| PROTEIN KINASE A TYPE II INHIBITION | 5 |
| PROTEIN KINASE ACTIVATION | 26 |
| PROTEIN KINASE C ACTIVATION | 153 |
| PROTEIN KINASE C AGONIZING EFFECT | 47 |
| PROTEIN KINASE C BINDING EFFECT | 16 |
| PROTEIN KINASE C INHIBITION | 515 |
| PROTEIN KINASE C ISOZYME REDISTRIBUTION | 4 |
| PROTEIN KINASE C TRANSLOCATION | 41 |
| PROTEIN KINASE C TRANSLOCATION INHIBITION | 1 |
| PROTEIN KINASE INHIBITION | 325 |
| PROTEIN KINASE STIMULATION | 20 |
| PROTEIN METHYLTRANSFERASE INHIBITION | 1 |
| PROTEIN PHOSPHATASE INHIBITION | 87 |
| PROTEIN PHOSPHATASE STIMULATION | 1 |
| PROTEIN PHOSPHORYLATION DECREASE | 5 |
| PROTEIN PHOSPHORYLATION INCREASED | 15 |
| PROTEIN PHOSPHORYLATION INHIBITION | 22 |
| PROTEIN PHOSPHORYLATION STIMULATION | 13 |
| PROTEIN PHOTOAGGREGATION INHIBITION | 2 |
| PROTEIN PRENYLATION INHIBITION | 3 |
| PROTEIN SECRETION INHIBITION | 18 |
| PROTEIN SECRETION STIMULATION | 13 |
| PROTEIN STABILIZATION TO HEAT DENATURATION | 8 |
| PROTEIN SYNTHESIS INHIBITION | 2168 |
| PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS | 26 |
| PROTEIN SYNTHESIS INHIBITION PREVENTION | 3 |
| PROTEIN SYNTHESIS INHIBITION(ENDOGENOUS) | 20 |
| PROTEIN SYNTHESIS INHIBITION(EUKARYOTIC) | 1 |
| PROTEIN SYNTHESIS STIMULATION | 232 |
| PROTEIN TRANSPORT(INTRACELLULAR) INHIBITION | 21 |
| PROTEIN TYROSINE KINASE INHIBITION | 193 |
| PROTEIN TYROSINE KINASE STIMULATION | 3 |
| PROTEIN TYROSINE PHOSPHATASE INHIBITION | 33 |
| PROTEIN TYROSINE PHOSPHATASE INHIBITION | 1 |
| PROTEIN TYROSINE PHOSPHORYLATION INHIBITION | 29 |
| PROTEIN UP-REGULATION STIMULATION | 12 |
| PROTEIN-DNA BINDING INHIBITION | 4 |
| PROTEIN-RNA BINDING INHIBITION | 2 |
| PROTEINASE INHIBITION | 35 |
| PROTEINASE(HIV) INHIBITION | 27 |
| PROTEOGLYCAN RELEASE INHIBITION | 1 |
| PROTEOGLYCAN RESORPTION INHIBITION | 2 |
| PROTEOGLYCAN SYNTHESIS STIMULATION | 3 |
| PROTEOHETEROGLYCAN SYNTHESIS INHIBITION | 4 |
| PROTEOLYSIS INHIBITION | 3 |
| PROTEOLYTIC ACTIVITY | 82 |
| PROTEOMIC ANALYSIS | 1 |
| PROTHROMBIN LEVEL DECREASED | 3 |
| PROTHROMBIN TIME DECREASED | 47 |
| PROTHROMBIN TIME INCREASED | 67 |
| PROTOCOLLAGEN PROLINE HYDROXYLASE INHIBITION | 1 |
| PROTON PUMP INHIBITION | 5 |
| PROTOPECTINASE INHIBITION | 21 |
| PSA(PROSTATE SPECIFIC ANTIGEN) EXPRESSION INHIBITION | 3 |
| PSA(PROSTATE-SPECIFIC ANTIGEN) PRODUCTION INHIBITION | 25 |
| PSEUDOCHOLINESTERASE INHIBITION | 2 |
| PSORIASIS TREATMENT | 79 |
| PSYCHOTROPIC ACTIVITY | 92 |
| PTH SECRETION STIMULATION | 1 |
| PUBERTY DELAYING ACTIVITY | 4 |
| PULLULANASE INHIBITION | 1 |
| PULMONARY ANTIHYPERTENSION ACTIVITY | 10 |
| PULMONARY EDEMA PROTECTION | 14 |
| PULMONARY FIBROSIS TREATMENT | 1 |
| PULMONARY HYPERTENSION STIMULATION | 2 |
| PUNGENT TASTE | 39 |
| PURIFICATION PROCEDURES FOR PLANT EXTRACTS | 1 |
| PURINE SYNTHESIS INHIBITION | 16 |
| PUSTULANT ACTIVITY | 1 |
| PUTRESCINE INHIBITION | 1 |
| PYRETIC ACTIVITY | 66 |
| PYRIDOXAL KINASE LEVEL INCREASE | 1 |
| PYRIDOXAL-5'-PHOSPHATE LEVEL DECREASE | 1 |
| PYROGLUTAMYL PEPTIDASE INHIBITION | 6 |
| PYROPHOSPHATASE STIMULATION | 3 |
| PYRUVATE DECARBOXYLASE INHIBITION | 1 |
| PYRUVATE DEHYDROGENASE INHIBITION | 7 |
| PYRUVATE DEHYDROGENASE STIMULATION | 4 |
| PYRUVATE INHIBITION | 3 |
| PYRUVATE KINASE INHIBITION | 15 |
| PYRUVATE KINASE STIMULATION | 7 |
| PYRUVATE OXIDASE INHIBITION | 1 |
| Q-H2-OXIDIZING ENZYME INHIBITION | 1 |
| Q-REDUCING ENZYME INHIBITION | 1 |
| QUINONE REDUCTASE INDUCTION | 826 |
| QUINONE REDUCTASE INHIBITION | 58 |
| R-RNA POLYMERASE INHIBITION | 8 |
| R-RNA TRANSCRIPTION INHIBITION | 1 |
| RACHITOGENIC ACTIVITY | 1 |
| RADICAL FORMATION EFFECT | 87 |
| RADICAL SCAVENGING EFFECT | 3276 |
| RADIOMIMETIC ACTIVITY | 6 |
| RADIOPROTECTIVE EFFECT | 226 |
| RADIOSENSITIZING EFFECT | 39 |
| RAS FUNCTION INHIBITION | 9 |
| RBC ANTIADHESANT | 3 |
| RBC DEFORMABILITY INCREASE | 11 |
| RBC STIMULANT ACTIVITY | 13 |
| RBC SYNTHESIS ANTAGONIST | 10 |
| REACTIVE OXYGEN SPECIES GENERATION INHIBITION | 130 |
| REACTIVE OXYGEN SPECIES GENERATION STIMULATION | 18 |
| RECEPTOR BINDING STIMULANT | 94 |
| RECEPTOR BINDING(2-DEOXY-D-GLUCOSE) DECREASED | 1 |
| RECEPTOR BINDING(ALPHA-BUNGAROTOXIN) INHIBITION | 24 |
| RECEPTOR BINDING(ANDROGEN) DECREASED | 29 |
| RECEPTOR BINDING(ARGININE VASOPRESSIN) DECREASED | 15 |
| RECEPTOR BINDING(BENZODIAZEPINE) DECREASED | 65 |
| RECEPTOR BINDING(BETA-1-ADRENO) INHIBITION | 1 |
| RECEPTOR BINDING(BETA-2-ADRENO) INHIBITION | 1 |
| RECEPTOR BINDING(CHLORIDE) ACTIVITY | 3 |
| RECEPTOR BINDING(DOPAMINE) DECREASED | 68 |
| RECEPTOR BINDING(ENDOTHELIAL) DECREASED | 53 |
| RECEPTOR BINDING(ESTROGEN) DECREASED | 16 |
| RECEPTOR BINDING(ETHYLKETOCYCLOAZOCINE) DECREASED | 2 |
| RECEPTOR BINDING(GLUCOCORTICOID) DECREASED | 5 |
| RECEPTOR BINDING(GLUTAMATE) DECREASED | 14 |
| RECEPTOR BINDING(GLYCINE) ACTIVITY | 7 |
| RECEPTOR BINDING(LEUCINE) DECREASED | 1 |
| RECEPTOR BINDING(MINERALOCORTICOID) DECREASED | 3 |
| RECEPTOR BINDING(NALOXONE) DECREASED | 4 |
| RECEPTOR BINDING(NICOTINE) INHIBITION | 1 |
| RECEPTOR BINDING(NOREPI) DECREASED | 1 |
| RECEPTOR BINDING(PROGESTIN) DECREASED | 2 |
| RECEPTOR REGULATING EFFECT(UNSPECIFIED) | 32 |
| RECEPTOR(LOW-DENSITY LIPOPROTEIN) STABILIZING EFFECT | 2 |
| RECOMBINATION INDUCTION | 7 |
| RECURRENT APHTHOUS STOMATITIS (CANKER SORE) TREATMENT | 9 |
| REDUCING AGENT ACTIVITY | 21 |
| REDUCTASE,5-ALPHA STIMULATION | 1 |
| REDUCTASE,5-ALPHA(TYPE I) INHIBITION | 9 |
| REDUCTASE,5-ALPHA(TYPE II) INHIBITION | 3 |
| REDUCTASE,5-ALPHA: INHIBITION | 288 |
| REDUCTASE,5-BETA: INHIBITION | 18 |
| REMINERALIZATION ACTIVITY | 1 |
| RENAL CIRCULATION ENHANCEMENT | 2 |
| RENAL FUNCTION DECREASE | 18 |
| RENAL FUNCTION IMPROVEMENT | 132 |
| RENAL LITHIASIS INHIBITION | 9 |
| RENAL TUBULAR DAMAGING ACTIVITY | 7 |
| RENIN ACTIVITY STIMULATION | 2 |
| RENIN INHIBITION | 33 |
| REPELLENT ACTIVITY(ANIMAL) | 95 |
| REPELLENT ACTIVITY(MOLLUSC) | 13 |
| RESIN PRODUCTION STIMULANT | 1 |
| RESPIRATION ACTIVATION(WBC) | 4 |
| RESPIRATION IMPROVEMENT | 0 |
| RESPIRATION INHIBITION | 76 |
| RESPIRATION INHIBITION(CELLULAR)-STATE 3 | 41 |
| RESPIRATION INHIBITION(CELLULAR)-STATE 4 | 9 |
| RESPIRATION(CELLULAR) STIMULATION-STATE 4 | 11 |
| RESPIRATION(CELLULAR)INHIBITION | 242 |
| RESPIRATION(CELLULAR)STIMULANT | 38 |
| RESPIRATORY BURST INHIBITION | 35 |
| RESPIRATORY BURST(HUMAN NEUTROPHIL) REGULATION | 10 |
| RESPIRATORY BURST(MACROPHAGE) STIMULATION | 6 |
| RESPIRATORY DEPRESSANT | 295 |
| RESPIRATORY GLYCOCONJUGATE SECRETION INCREASE | 1 |
| RESPIRATORY STIMULANT EFFECT | 286 |
| RESPIRATORY SYSTEM IMPROVEMENT | 2 |
| RESPIRATORY SYSTEM TOXICITY | 62 |
| RESTRICTION ENZYME INHIBITION | 4 |
| RETICULOENDOTHELIAL SYSTEM ACTIVATION | 89 |
| RETINAL PERIPHLEBITIS TREATMENT | 1 |
| RETINOIC ACID BINDING PROTEIN 2 EXPRESSION STIMULATION | 1 |
| RETINOIC ACID SYNTHESIS INHIBITION | 1 |
| RETINOIC ACID X RECEPTOR BINDING ACTIVITY | 1 |
| RETINOID X RECEPTOR(RXR) LIGAND ACTIVITY | 1 |
| RETINOL LEVEL DECREASE | 4 |
| REV-TRANSPORT INHIBITION | 2 |
| REVERSE TRANSCRIPTASE INHIBITION | 2130 |
| REVERSE TRANSCRIPTASE STIMULATION | 1 |
| REVIEW OF ALL MAJOR ASPECTS OF HERBAL TEAS | 1 |
| REVIEW OF CHEMISTRY OF MEDICINAL PLANTS | 0 |
| RHINOVIRUS 3C-PROTEASE INHIBITION | 1 |
| RIBONUCLEASE ACTIVITY | 4 |
| RIBONUCLEASE INHIBITION | 45 |
| RIBONUCLEOTIDE REDUCTASE INHIBITION | 20 |
| RIBOSOME CONFORMATIONAL CHANGE | 2 |
| RIBOSOME INACTIVATION | 127 |
| RNA BINDING | 33 |
| RNA BINDING INHIBITION | 4 |
| RNA DEPENDENT DNA POLYMERASE INHIBITION | 57 |
| RNA LEVEL DECREASE | 6 |
| RNA LEVEL INCREASE | 10 |
| RNA N-GLYCOSIDASE ACTIVITY | 1 |
| RNA POLYMERASE I INHIBITION | 11 |
| RNA POLYMERASE I STIMULATION | 6 |
| RNA POLYMERASE II INHIBITION | 50 |
| RNA POLYMERASE II STIMULATION | 7 |
| RNA POLYMERASE III INHIBITION | 6 |
| RNA POLYMERASE III STIMULATION | 7 |
| RNA POLYMERASE INHIBITION | 98 |
| RNA POLYMERASE INHIBITION(HORMONE-SENSITIVE) | 1 |
| RNA POLYMERASE INHIBITION(RIBOSOMAL) | 3 |
| RNA POLYMERASE STIMULATION | 14 |
| RNA REVERSE TRANSCRIPTASE INHIBITION | 68 |
| RNA SCISSION EFFECT | 2 |
| RNA SYNTHESIS INHIBITION | 1081 |
| RNA SYNTHESIS STIMULATION | 149 |
| RNA(MESSENGER)POLYMERASE INHIBITION | 6 |
| RNA(TRANSFER)POLYMERASE INDUCTION | 4 |
| RNA(TRANSFER)POLYMERASE INHIBITION | 4 |
| RNA-METHYLTRANSFERASE INHIBITION | 3 |
| RNASE ACTIVITY | 22 |
| RNASE H INHIBITION | 33 |
| RNASE INHIBITION | 8 |
| ROBERANT EFFECT | 2 |
| RODENTICIDE ACTIVITY | 33 |
| RUBEFACIENT EFFECT | 82 |
| RYANODINE RECEPTOR BLOCKING | 1 |
| S'-NUCLEOTIDASE STIMULATION | 1 |
| S-ADENOSYL-L-METHIONINE METHYL TRANSFERASE INHIBITION | 1 |
| S-ADENOSYLMETHIONINE DECARBOXYLASE STIMULATION | 4 |
| SAIALOGLYCOPROTEIN RECEPTOR DECREASE | 2 |
| SALIDASE INHIBITION | 2 |
| SALIDIURETIC EFFECT | 23 |
| SALIVARY SECRETION INCREASE | 17 |
| SCHIZONTOCIDAL ACTIVITY | 17 |
| SCLEROSING EFFECT | 45 |
| SEBACEOUS SECRETION INHIBITION | 21 |
| SEBACEOUS SECRETION STIMULATION | 3 |
| SECRETAGOGUE ACTIVITY | 5 |
| SECRETED ALKALINE PHOSPHATASE EXPRESSION INHIBITION | 1 |
| SECRETED ASPARTIC PROTEASE INHIBITION | 7 |
| SECRETIN INDUCTION | 2 |
| SECRETOLYTIC EFFECT | 7 |
| SECTORAL DARKENING EFFECT | 1 |
| SEED GERMINATION INHIBITION | 147 |
| SEED GERMINATION STIMULATION | 1 |
| SEMEN COAGULATION | 552 |
| SENSITIZATION(SKIN) | 331 |
| SENSORY NEURON-SPECIFIC RECEPTOR (SNSR) AGONIST ACTIVITY | 1 |
| SERINE CARBOXYPEPTIDASE INHIBITION | 1 |
| SERINE HYDROXYMETHYLTRANSFERASE INHIBITION | 1 |
| SERINE KINASE INHIBITION | 2 |
| SERINEPALMITOYL TRANSFERASE INHIBITION | 7 |
| SEROTONIN (5-HT) AGONIST ACTIVITY | 35 |
| SEROTONIN (5-HT) ANTAGONIST ACTIVITY | 126 |
| SEROTONIN (5-HT) DEPLETION | 20 |
| SEROTONIN (5-HT) LEVEL INCREASE | 38 |
| SEROTONIN (5-HT) RECEPTOR BINDING ACTIVITY | 94 |
| SEROTONIN (5-HT) RECEPTOR BINDING DECREASED | 48 |
| SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT | 162 |
| SEROTONIN (5-HT) RECEPTOR UPREGULATION | 3 |
| SEROTONIN (5-HT) RELEASE INHIBITION | 134 |
| SEROTONIN (5-HT) RELEASING EFFECT | 67 |
| SEROTONIN (5-HT) SECRETION INHIBITION | 174 |
| SEROTONIN (5-HT) SYNTHESIS STIMULATION | 1 |
| SEROTONIN (5-HT) UPTAKE INHIBITION | 56 |
| SEROTONIN (5-HT) UPTAKE STIMULATION | 5 |
| SERTOLI CELL FUNCTION INHIBITION | 3 |
| SERUM ALBUMIN DECREASE | 1 |
| SERUM GLOBULIN DECREASE | 3 |
| SERUM HDL ELEVATING EFFECT | 41 |
| SERUM HDL LOWERING EFFECT | 8 |
| SERUM LDL ELEVATING EFFECT | 1 |
| SERUM LDL LOWERING EFFECT | 37 |
| SERUM UREA INCREASE | 1 |
| SERUM UREA INHIBITION | 4 |
| SESQUITERPENE CYCLASE INHIBITION | 1 |
| SETTLING OF SWIMMING LARVAE | 5 |
| SEX DETERMINANT FOR OFFSPRING | 17 |
| SEX HORMONE BINDING GLOBULIN BINDING ACTIVITY | 9 |
| SEX HORMONE BINDING GLOBULIN BINDING INHIBITION | 7 |
| SEX HORMONE BINDING GLOBULIN LEVEL INCREASE | 8 |
| SEXUAL BEHAVIOR MODIFICATION | 70 |
| SIALAGOGUE EFFECT | 74 |
| SIALIC ACID (SERUM) LOWERING EFFECT | 1 |
| SIALIC ACID SYNTHESIS INHIBITION | 13 |
| SIALIDASE INHIBITION | 72 |
| SIALYL LEWIS X(SLEX) INHIBITION | 2 |
| SIALYLTRANSFERASE INHIBITION | 1 |
| SIGMA RECEPTOR AGONIST ACTIVITY | 3 |
| SIGMA RECEPTOR BINDING | 0 |
| SIGNAL TRANSDUCTION MODULATION | 16 |
| SIGNAL-REGULATED KINASE PHOSPHORYLATION INHIBITION | 0 |
| SISTER CHROMATID EXCHANGE INHIBITION | 90 |
| SISTER CHROMATID EXCHANGE STIMULATION | 221 |
| SKELETAL MUSCLE RELAXANT ACTIVITY(UNSPECIFIED) | 199 |
| SKELETAL MUSCLE RELAXANT EFFECT(CENTRAL) | 121 |
| SKELETAL MUSCLE RELAXANT EFFECT(PERIPHERAL) | 306 |
| SKELETAL MUSCLE STIMULANT ACTIVITY | 326 |
| SKELETAL MUSCLE TOXICITY | 8 |
| SKIN DEPIGMENTATION EFFECT | 148 |
| SKIN DESQUAMATION ACTIVITY | 1 |
| SKIN ELASTICITY INCREASE | 4 |
| SKIN IMPROVEMENT EFFECT | 343 |
| SKIN METABOLISM ACCELERATION | 2 |
| SKIN MOISTURIZING EFFECT | 28 |
| SKIN PERMEATION ABILITY | 7 |
| SKIN PIGMENTATION EFFECT | 106 |
| SLEEP EFFECTS | 72 |
| SLEEP TIME INCREASED | 180 |
| SLEEP(SPONTANEOUS) POTENTIATION | 31 |
| SLEEPING TIME DECREASED | 61 |
| SLOW REACTING SUBSTANCE OF ANAPHYLAXIS ANTAGONIST | 70 |
| SLOWLY ADAPTING PULMONARY STRETCH RECEPTOR STIMULATION | 1 |
| SMALL G PROTEIN ISOPRENYLATION ACTIVITY | 3 |
| SMOKING DETERRENT | 42 |
| SMOOTH MUSCLE CELL MIGRATION INHIBITION | 14 |
| SMOOTH MUSCLE PHOSPHATASE INHIBITION | 1 |
| SMOOTH MUSCLE RELAXANT ACTIVITY | 2914 |
| SMOOTH MUSCLE RESTED-STATE CONTRACTION REDUCTION | 4 |
| SMOOTH MUSCLE STIMULANT ACTIVITY | 1849 |
| SOBERIZING ACTIVITY | 1 |
| SODIUM CHANNEL AGONIST ACTIVITY | 19 |
| SODIUM CHANNEL BINDING EFFECT | 10 |
| SODIUM CHANNEL BLOCKING EFFECT | 58 |
| SODIUM CHLORIDE INFLUX INHIBITION | 2 |
| SODIUM CONTENT INCREASE | 15 |
| SODIUM DEPLETION EFFECT | 6 |
| SODIUM PREFERENCE INHIBITION | 1 |
| SODIUM TRANSPORT INHIBITION | 12 |
| SODIUM TRANSPORT STIMULATION | 11 |
| SODIUM UPTAKE INHIBITION | 1 |
| SODIUM-POTASSIUM-CHLORIDE COTRANSPORT FLUX INHIBITION | 1 |
| SOLUBILIZATION STUDY | 46 |
| SOLUBLE AMINOPEPTIDASE INHIBITION | 2 |
| SOMATOSTATIN INDUCTION | 7 |
| SOMATOSTATIN INHIBITION | 6 |
| SOMATOSTATIN RECEPTOR BINDING ACTIVITY | 11 |
| SORBITOL ACCUMULATION INHIBITION | 9 |
| SORBITOL-DEHYDROGENASE INHIBITION | 29 |
| SORBITOL-DEHYDROGENASE STIMULATION | 23 |
| SPASMOGENIC ACTIVITY | 526 |
| SPASMOLYTIC ACTIVITY | 3390 |
| SPERM AGGLUTINATION | 54 |
| SPERM ATTRACTANT | 5 |
| SPERM COUNT DECREASE | 12 |
| SPERM MOTILITY DECREASE | 47 |
| SPERM MOTILITY INCREASED | 82 |
| SPERMATOGENESIS DISRUPTION EFFECTS IN INVERTEBRATES | 1 |
| SPERMATOGENIC EFFECT | 95 |
| SPERMICIDAL EFFECT | 1409 |
| SPERMIDINE LEVELS INCREASED | 4 |
| SPERMIDINE SYNTHASE INHIBITION | 2 |
| SPERMIDINE/SPERMINE N-ACETYLTRANSFERASE ACTIVITY STIMULATION | 3 |
| SPERMINE SYNTHASE INHIBITION | 1 |
| SPERMINE SYNTHESIS STIMULATION | 2 |
| SPHINGOMYELIN CYCLE ACTIVATION | 2 |
| SPHINGOMYELINASE INHIBITION | 38 |
| SPHINGOSINE KINASE INHIBITION | 7 |
| SPHINGOSINE(SPHINGANINE)-N-ACETYLTRANSFERASE INHIBITION | 10 |
| SPHINGOSINE-1-PHOSPHATE(SPP) FORMATION INHIBITION | 1 |
| SPLENOMEGALIC ACTIVITY | 20 |
| SPONTANEOUS ACTIVITY REDUCTION | 565 |
| SPONTANEOUS ACTIVITY STIMULATION | 142 |
| SPONTANEOUS CYTOTOXICITY SUPPRESSION | 3 |
| SPORE ATTRACTANT EFFECT | 5 |
| SPORE GERMINATION INHIBITOR | 164 |
| SPORE GERMINATION STIMULANT | 153 |
| SQUALENE EPOXIDASE INHIBITION | 22 |
| SQUALENE SYNTHASE INHIBITION | 48 |
| SRC PROTEIN KINASE INHIBITION | 1 |
| SRS-A RELEASE INHIBITION | 2 |
| STABILITY STUDY | 62 |
| STARCH DEGRADATION INHIBITION | 1 |
| STARCH DIGESTION INHIBITION | 1 |
| STAT(SIGNAL TRANSDUCERS/ACTIVATORS OF TRANSCRIP) INHIBITION | 5 |
| STATHMOKINETIC EFFECT | 3 |
| STEM CELL FACTOR RELEASE STIMULATION | 0 |
| STENOSIS RECURRENCE TREATMENT | 2 |
| STERILANT ACTIVITY(INSECT) | 4 |
| STERILITY INDUCTION IN TROGODERMA GRANARIUM | 1 |
| STERNUTATORY EFFECT | 17 |
| STEROID ANTAGONIST ACTIVITY | 5 |
| STEROID BINDING INHIBITION | 1 |
| STEROID HORMONE BINDING GLOBULIN BINDING INHIBITION | 10 |
| STEROID(3-ALPHA,20-BETA-HYDROXY) DEHYDROGENASE INHIBITION | 4 |
| STEROIDOGENESIS INHIBITION | 33 |
| STEROIDOGENIC ACTIVITY | 13 |
| STEROL EXCRETION INCREASE | 5 |
| STEROL SYNTHESIS INHIBITION | 4 |
| STILBENE OXIDASE INHIBITION | 8 |
| STINGING BEHAVIOR INDUCTION | 2 |
| STOMACH EMPTYING TIME DECREASED | 4 |
| STOOL SOFTENING ACTIVITY | 1 |
| STORAGE-PACKAGING STUDIES OF PLANT MATERIAL | 8 |
| STROKE VOLUME DECREASED | 1 |
| STROMAL CELL-DERIVED FACTOR-1-ALPHA BINDING INHIBITION | 1 |
| STROMELYSIN INHIBITION | 9 |
| STUDIES ON VARIETAL DIFFERENCES OF MEDICINAL PLANTS | 1 |
| SUBSTANCE P EXPRESSION INHIBITION. | 5 |
| SUBSTANCE P LEVELS DECREASED | 13 |
| SUBSTANCE P RECEPTOR BINDING | 43 |
| SUBSTANCE P STIMULATION | 3 |
| SUBTILISIN INHIBITION | 14 |
| SUCCINATE DEHYDROGENASE INHIBITION | 50 |
| SUCCINATE DEHYDROGENASE INHIBITION(STATE 3) | 24 |
| SUCCINATE DEHYDROGENASE INHIBITION(STATE 4) | 22 |
| SUCCINATE DEHYDROGENASE STIMULATION | 83 |
| SUCCINATE OXIDASE INDUCTION | 10 |
| SUCCINATE OXIDASE INHIBITION | 75 |
| SUCCINATE-CYTOCHROME C REDUCTASE INDUCTION | 0 |
| SUCCINATE-CYTOCHROME C REDUCTASE INHIBITION | 15 |
| SUCCINIC SEMIALDEHYDE DEHYDROGENASE INHIBITION | 3 |
| SUCCINIC SEMIALDEHYDE REDUCTASE INHIBITION | 3 |
| SUCCINYL CO-A SYNTHETASE INHIBITION | 3 |
| SUCRASE INHIBITION | 159 |
| SUCRASE STIMULATION | 8 |
| SUCRASE-ISOMALTASE BIOSYNTHESIS STIMULATION | 1 |
| SUDDEN INFANT DEATH SYNDROME RELATED ACTIVITY | 1 |
| SULFATASE INHIBITION | 14 |
| SULFATION INHIBITION | 11 |
| SULFHYDRYL-CONTAINING COMPOUNDS DECREASED | 8 |
| SULFHYDRYL-CONTAINING COMPOUNDS INCREASED | 32 |
| SULFOCONJUGATION INHIBITION | 1 |
| SULFOCONJUGATION STIMULATION | 0 |
| SULFONYLUREA RECEPTOR BINDING ACTIVITY | 30 |
| SULFONYLUREA RECEPTOR BINDING INHIBITION | 0 |
| SULFONYLUREA RECEPTOR BLOCKING EFFECT | 15 |
| SULFOTRANSFERASE INHIBITION | 31 |
| SULFOTRANSFERASE STIMULATION | 8 |
| SUNSCREEN EFFECT | 70 |
| SUPEROXIDE DISMUTASE INHIBITION | 91 |
| SUPEROXIDE DISMUTASE STIMULATION | 340 |
| SUPEROXIDE INHIBITION | 196 |
| SUPEROXIDE PRODUCTION INHIBITION | 333 |
| SUPEROXIDE RADICAL SCAVENGING ACTIVITY | 651 |
| SUPEROXIDE SCAVENGING ACTIVITY INCREASE | 611 |
| SUPEROXIDE STIMULATION | 165 |
| SUPERPRECIPITATION RATE INCREASE | 3 |
| SURFACE ACTIVE ACTIVITY | 5 |
| SURFACE PROTEIN EXPRESSION INHIBITION | 5 |
| SURFACE PROTEIN EXPRESSION STIMULATION | 5 |
| SWEETENING EFFECT | 830 |
| SYMPATHOLYTIC ACTIVITY | 5 |
| SYMPATHOMIMETIC ACTIVITY | 69 |
| SYNAPTIC TRANSMISSION MODULATION | 4 |
| SYNAPTOSOMAL PERMEABILITY INCREASE | 2 |
| SYNCYTIA INDUCTION | 3 |
| SYNCYTIA INHIBITION | 175 |
| T-CELL ACTIVATION MARKER(CD25) EXPRESSION INHIBITION | 1 |
| T-CELL RECEPTOR EXPRESSION ENHANCEMENT | 1 |
| T-CELL STIMULATION | 27 |
| T-CYTOTOXIC LYMPHOCYTE INHIBITION | 8 |
| T-HELPER CELL PROLIFERATION | 2 |
| T-HELPER LYMPHOCYTE STIMULATION | 5 |
| T-LYMPHOCYTE CYTOTOXICITY ENHANCEMENT | 11 |
| T-LYMPHOCYTE CYTOTOXICITY SUPPRESSION | 5 |
| T-LYMPHOCYTE STIMULATION | 59 |
| T-LYMPHOCYTE SUPPRESSION | 114 |
| T-RNA METHYLASE INHIBITION | 2 |
| T-RNA POLYMERASE INHIBITION | 8 |
| T-SUPPRESSOR LYMPHOCYTE INHIBITION | 5 |
| TACHYCARDIA ACTIVITY | 81 |
| TACHYKININ RECEPTOR ANTAGONIST | 30 |
| TAENICIDE ACTIVITY | 93 |
| TAENIFUGE ACTIVITY | 138 |
| TANNASE STIMULATION | 2 |
| TARDIVE DYSKINESIA INDUCING ACTIVITY | 1 |
| TARDIVE DYSKINESIA INHIBITION | 2 |
| TASTE AVERSION(CONDITIONED) | 13 |
| TASTE MODIFYING EFFECT | 46 |
| TAURINE TRANSPORT STIMULATION | 1 |
| TBA VALUE DECREASED | 2 |
| TELOMERASE INHIBITION | 37 |
| TELOMERE SHORTENING EFFECT | 2 |
| TEMPERATURE(EXTREME) RESISTANCE | 5 |
| TERATOGENIC ACTIVITY | 692 |
| TERMINAL DEOXYNUCLEOTIDYLTRANSFERASE INHIBITION | 6 |
| TESTOSTERONE AGONIST ACTIVITY | 1 |
| TESTOSTERONE ANTAGONIST ACTIVITY | 1 |
| TESTOSTERONE HYDROLASE INHIBITION | 3 |
| TESTOSTERONE HYDROXYLASE INHIBITION | 9 |
| TESTOSTERONE HYDROXYLATION INHIBITION | 27 |
| TESTOSTERONE HYDROXYLATION STIMULATION | 8 |
| TESTOSTERONE LEVEL DECREASED | 115 |
| TESTOSTERONE LEVEL INCREASED | 91 |
| TESTOSTERONE OXIDATION INHIBITION | 2 |
| TESTOSTERONE RELEASE INHIBITION | 28 |
| TESTOSTERONE RELEASE STIMULATION | 11 |
| TESTOSTERONE SYNTHESIS INHIBITION | 23 |
| TESTOSTERONE(5-ALPHA-DIHYDRO) BINDING INHIBITION | 12 |
| TESTOSTERONE-5-ALPHA-REDUCTASE INHIBITION | 296 |
| TETRAHYDROCANNABINOL(DELTA-9)-11-HYDROXYLASE INHIBITION | 1 |
| THERMITASE INHIBITION | 3 |
| THERMOGENIC ACTIVITY | 37 |
| THERMOLYSIN INHIBITION | 44 |
| THERMOTOLERANCE INHIBITION | 1 |
| THIAMINASE ACTIVITY | 15 |
| THIAZOLE ADENINE DINUCLEOTIDE INHIBITION | 1 |
| THIOBARBITURATE REACTING SUBSTANCE INHIBITION | 14 |
| THIOGLUCOSIDASE INHIBITION | 14 |
| THIOL CONTENT DECREASE | 8 |
| THIOL INHIBITION | 2 |
| THIOL-PROTEASE INHIBITION | 17 |
| THIOREDOXIN REDUCTASE INHIBITION | 3 |
| THIOREDOXIN REDUCTASE STIMULATION | 2 |
| THIRST-QUENCHING EFFECT | 49 |
| THROMBIN BINDING INHIBITION | 1 |
| THROMBIN INHIBITION | 161 |
| THROMBIN RECEPTOR ANTAGONIST ACTIVITY | 2 |
| THROMBIN TIME INCREASE | 2 |
| THROMBIN-LIKE ACTIVITY | 5 |
| THROMBOCYTOPENIA INHIBITION | 4 |
| THROMBOCYTOPENIC ACTIVITY | 18 |
| THROMBOCYTOPOIETIC ACTIVITY | 17 |
| THROMBOPLASTIN TIME INCREASE | 4 |
| THROMBOSPONDIN RELEASE INHIBITION | 1 |
| THROMBOXAN B2 RELEASE INHIBITION | 37 |
| THROMBOXANE A2 INHIBITION | 54 |
| THROMBOXANE A2 SYNTHESIS INHIBITION | 37 |
| THROMBOXANE B-2 SYNTHESIS INDUCTION | 25 |
| THROMBOXANE B-2 SYNTHESIS INHIBITION | 341 |
| THROMBOXANE B2 RELEASE ENHANCEMENT | 7 |
| THROMBOXANE RECEPTOR BINDING | 4 |
| THROMBOXIN B2 FORMATION INDUCTION | 1 |
| THROMBUS FORMATION INHIBITION | 26 |
| THYMIDINE INCORPORATION INDUCTION | 3 |
| THYMIDINE INCORPORATION INHIBITION | 69 |
| THYMIDINE KINASE INDUCTION | 3 |
| THYMIDINE KINASE INHIBITION | 26 |
| THYMIDINE TRANSPORT RATE DECREASED | 2 |
| THYMIDINE TRANSPORT RATE INCREASED | 0 |
| THYMIDINE UPTAKE INHIBITION | 20 |
| THYMIDINE UPTAKE STIMULATION | 6 |
| THYMIDYLATE DIPHOSPHATE KINASE INHIBITION | 10 |
| THYMIDYLATE MONOPHOSPHATE KINASE INDUCTION | 2 |
| THYMIDYLATE MONOPHOSPHATE KINASE INHIBITION | 9 |
| THYMIDYLATE SYNTHETASE INHIBITION | 25 |
| THYMUS ATROPHY EFFECT | 7 |
| THYMUS HYPERTROPHY EFFECT | 3 |
| THYMUS INVOLUTION EFFECT | 32 |
| THYROGENIC ACTIVITY | 4 |
| THYROID AGONIST ACTIVITY | 21 |
| THYROID HORMONE RECEPTOR ANTAGONIST | 1 |
| THYROID PEROXIDASE INHIBITION | 7 |
| THYROID TYPE 1 DEIODINASE(D1) INHIBITION | 8 |
| THYROTOXIC EFFECT | 19 |
| THYROTROPIN RECEPTOR BINDING INHIBITION | 6 |
| THYROTROPIN RELEASING HORMONE STIMULATION | 2 |
| THYROXINE LEVEL DECREASE | 15 |
| THYROXINE LEVEL INCREASE | 27 |
| TIC SUPPRESSION | 1 |
| TISSUE CULTURE GROWTH CONDITIONS FOR | 6 |
| TISSUE FACTOR ACTIVITY INHIBITION | 16 |
| TISSUE FACTOR EXPRESSION INHIBITION | 2 |
| TISSUE INHIBITOR OF METALLOPROTEINASE 1 STIMULATION | 1 |
| TISSUE INHIBITOR OF METALLOPROTEINASE 2 STIMULATION | 1 |
| TISSUE INHIBITOR OF METALLOPROTEINASES-1(TIMP-1) INHIBITION | 1 |
| TISSUE PLASMINOGEN ACTIVATOR INHIBITION | 21 |
| TISSUE TYPE PLASMINOGEN ACTIVATOR STIMULATION | 3 |
| TMPD OXIDASE INHIBITION | 3 |
| TNF SECRETION INDUCTION | 21 |
| TNF-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) INDUCTION | 0 |
| TNF-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) RESISTANCE INHIBITION | 2 |
| TOBACCO DETERRENT | 1 |
| TOBACCO SUBSTITUTE | 8 |
| TOLERABILITY STUDY | 4 |
| TOLERANCE INHIBITION | 21 |
| TOOTH EXTRACTION | 20 |
| TOPOISOMERASE I ACTIVITY | 2 |
| TOPOISOMERASE I INDUCTION | 14 |
| TOPOISOMERASE I INHIBITION | 303 |
| TOPOISOMERASE I(MAMMALIAN)-MEDIATED DNA CLEAVAGE INDUCTION | 10 |
| TOPOISOMERASE II CATALYTIC INHIBITION ACTIVITY | 9 |
| TOPOISOMERASE II INDUCTION | 37 |
| TOPOISOMERASE II INHIBITION | 434 |
| TOPOISOMERASE II-MEDIATED DNA CLEAVAGE INDUCTION | 5 |
| TOTAL SERUM PROTEIN DECREASE | 1 |
| TOXIC EFFECT(GENERAL) | 8744 |
| TOXIC EFFECT(UNSPEC) | 472 |
| TOXICITY ASSESSMENT(QUANTITATIVE) | 11035 |
| TOXOPLASMACIDAL ACTIVITY | 3 |
| TRACHEAL CILIA MOVEMENT STIMULATION | 2 |
| TRANQUILIZING EFFECT | 490 |
| TRANSCRIPTION FACTOR ACTIVATION ACTIVITY | 9 |
| TRANSCRIPTION FACTOR INHIBITION | 2 |
| TRANSCRIPTION INHIBITION | 108 |
| TRANSCRIPTION STIMULATION | 2 |
| TRANSFERRIN EXPRESSION STIMULATION | 1 |
| TRANSFERRIN INDUCTION | 4 |
| TRANSFERRIN INHIBITION | 3 |
| TRANSFERRIN RECEPTOR DECREASE | 2 |
| TRANSFORMATION INHIBITION | 64 |
| TRANSFORMING GROWTH FACTOR BETA-1 BINDING EFFECT | 5 |
| TRANSFORMING GROWTH FACTOR BETA-1 EXPRESSION STIMULATION | 2 |
| TRANSFORMING GROWTH FACTOR BETA-1 PRODUCTION | 8 |
| TRANSFORMING GROWTH FACTOR RECEPTOR EXPRESSION | 2 |
| TRANSFORMING GROWTH FACTOR-ALPHA EXPRESSION INHIBITION | 2 |
| TRANSFORMING GROWTH FACTOR-BETA RELEASE INHIBITION | 8 |
| TRANSGLUTAMINASE STIMULATION | 2 |
| TRANSGLYCOSYLASE INHIBITION | 1 |
| TRANSHYDROGENASE INHIBITION | 10 |
| TRANSKETOLASE INHIBITION | 4 |
| TRANSLATION INHIBITION | 2 |
| TRANSMEMBRANE POTENTIAL DECREASE | 12 |
| TRANSMEMBRANE POTENTIAL INCREASE | 7 |
| TRANSPEPTIDASE INHIBITION | 7 |
| TRANSPORT INHIBITION | 60 |
| TRANSPORT STIMULATION | 12 |
| TRANSPORTER RECEPTOR BINDING INHIBITION | 9 |
| TREHALASE INHIBITION | 133 |
| TREHALOSE SYNTHESIS STIMULATION | 2 |
| TREMORIGENIC ACTIVITY | 75 |
| TRIACYLGLYCEROL LEVEL INHIBITION | 4 |
| TRIACYLGLYCEROL SYNTHESIS INHIBITION | 13 |
| TRICHOTHECENE TOXIN BIOSYNTHESIS INHIBITION | 32 |
| TRIIODOTHYRONINE LEVEL DECREASE | 1 |
| TRIIODOTHYRONINE(T3) LEVEL DECREASE | 14 |
| TRIIODOTHYRONINE(T3) LEVEL INCREASE | 6 |
| TRP CHANNEL ANTAGONISM | 1 |
| TRPV1 EXPRESSION INHIBITION. | 5 |
| TRYPANOTHIONE REDUCTASE INHIBITION | 2 |
| TRYPANOTHIONE REDUCTASE STIMULATION | 0 |
| TRYPSIN INHIBITION | 639 |
| TRYPTAMINE RECEPTOR BINDING EFFECT. | 7 |
| TRYPTOPHAN HYDROXYLASE INHIBITION | 6 |
| TRYPTOPHAN HYDROXYLASE STIMULATION | 3 |
| TRYPTOPHAN OXYGENASE INHIBITION | 2 |
| TRYPTOPHAN PYRROLASE INHIBITION | 7 |
| TRYPTOPHAN PYRROLASE STIMULATION | 15 |
| TRYPTOPHAN-2-3-DIOXYGENASE INHIBITION | 1 |
| TSH INHIBITION | 41 |
| TSH STIMULATION | 12 |
| TUBULIN AGGREGATION EFFECT | 9 |
| TUBULIN BINDING EFFECT | 95 |
| TUBULIN BINDING INHIBITION | 82 |
| TUBULIN DECREASE ACTIVITY | 3 |
| TUBULIN DESTABILIZING EFFECT | 11 |
| TUBULIN POLYMERIZATION ENHANCEMENT | 47 |
| TUBULIN POLYMERIZATION INHIBITION | 237 |
| TUBULIN STABILIZING EFFECT | 6 |
| TUMOR BLOOD FLOW DECREASED | 13 |
| TUMOR CELL AGGLUTINATION | 8 |
| TUMOR INITIATING EFFECT | 15 |
| TUMOR INITIATION INHIBITION | 25 |
| TUMOR NECROSING FACTOR INDUCTION | 202 |
| TUMOR NECROSING FACTOR INHIBITION | 450 |
| TUMOR NECROSING FACTOR RECEPTOR EXPRESSION INHIBITION | 1 |
| TUMOR NECROSING FACTOR RELEASE STIMULATION | 50 |
| TUMOR NECROSING FACTOR SECRETION INHIBITION | 72 |
| TUMOR NECROSING FACTOR SYNTHESIS INHIBITION | 75 |
| TUMOR NECROSING FACTOR-ALPHA GENE EXPRESSION INHIBITION | 11 |
| TUMOR NECROSING FACTOR-ALPHA GENE EXPRESSION STIMULATION | 6 |
| TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION | 140 |
| TUMOR NECROSING FACTOR-ALPHA STIMULATION | 10 |
| TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) RESISTANCE INHIBITION | 1 |
| TUMOR NEOVASCULAR DAMAGE INDUCTION | 3 |
| TUMOR NEUTRALIZING ACTIVITY | 5 |
| TUMOR PROMOTING EFFECT | 344 |
| TUMOR PROMOTION INHIBITION | 540 |
| TUMOR STIMULANT EFFECT | 25 |
| TURGAL STIMULANT ACTIVITY | 17 |
| TUSSIVE ACTIVITY | 3 |
| TYRAMINE OXIDASE INHIBITION | 2 |
| TYROSINASE INHIBITION | 1621 |
| TYROSINASE STIMULATION | 16 |
| TYROSINE AMINOTRANSFERASE INDUCTION | 44 |
| TYROSINE AMINOTRANSFERASE INHIBITION | 8 |
| TYROSINE AMMONIA LYASE INDUCTION | 3 |
| TYROSINE DIMERIZATION INHIBITION | 1 |
| TYROSINE HYDROXYLASE INHIBITION | 55 |
| TYROSINE HYDROXYLASE STIMULATION | 5 |
| TYROSINE KINASE INHIBITION | 297 |
| TYROSINE NITRATION INHIBITION | 23 |
| TYROSINE PHOSPHATASE INHIBITION | 10 |
| TYROSINE PHOSPHATASE INHIBITION(CD-45 PROTEIN) | 8 |
| TYROSINE PHOSPHORYLATION INHIBITION | 45 |
| TYROSINE PHOSPHORYLATION STIMULATION | 12 |
| TYROSINE PROTEIN KINASE C INHIBITION | 2 |
| TYROSINE PROTEIN KINASE INHIBITION | 65 |
| TYROSINE PROTEIN KINASE STIMULATION | 4 |
| TYROSINE TRANSAMINASE INDUCTION | 5 |
| TYROSINE UPTAKE ENHANCEMENT | 2 |
| TYROSYL T-RNA SYNTHETASE INHIBITION | 1 |
| UBIQUINOL-1 OXIDASE INHIBITION | 4 |
| UBIQUINONE SYNTHESIS INHIBITION | 1 |
| UBIQUITIN-ACTIVATING ENZYME(E1) INHIBITION | 1 |
| UDP-GLUCOSE DEHYDROGENASE INHIBITION | 5 |
| UDP-GLUCURONYL TRANSFERASE INHIBITION | 17 |
| UDP-GLUCURONYL TRANSFERASE STIMULATION | 81 |
| UDP-N-ACETYLMURAMIC ACID SYNTHESIS INHIBITION | 4 |
| ULCEROGENIC ACTIVITY | 149 |
| UNSCHEDULED DNA SYNTHESIS ENHANCEMENT | 8 |
| UNSCHEDULED DNA SYNTHESIS INHIBITION | 3 |
| UREASE INHIBITION | 109 |
| UREOGENESIS STIMULATION | 0 |
| UREOLYTIC ACTIVITY | 1 |
| URETERAL STONE REMOVAL | 17 |
| URIC ACID DECREASE | 16 |
| URIC ACID INCREASE | 10 |
| URICASE(HEPATIC)INHIBITION | 1 |
| URICOSURIC ACTIVITY | 39 |
| URIDINE DIPHOSPHATE GLUCURONYL TRANSFERASE INHIBITION | 2 |
| URIDINE DIPHOSPHATE GLUCURONYLTRANSFERASE INDUCTION | 15 |
| URIDINE INCORPORATION INHIBITION | 6 |
| URIDINE KINASE INHIBITION | 2 |
| URIDINE TRANSPORT RATE DECREASED | 2 |
| URIDINE TRANSPORT RATE INCREASED | 0 |
| URIDINE UPTAKE INHIBITION | 4 |
| URIDINE UPTAKE STIMULATION | 3 |
| URODYNAMIC IMPROVEMENT | 2 |
| UROKINASE INHIBITION | 4 |
| UROKINASE SECRETION STIMULATION | 8 |
| UROKINASE-TYPE PLASMINOGEN INHIBITION | 1 |
| UROLITHIATIC ACTIVITY | 1 |
| URONIC ACID DECREASE | 2 |
| URTICARIANT ACTIVITY | 22 |
| UTERINE RELAXATION EFFECT | 1645 |
| UTERINE STIMULANT EFFECT | 3695 |
| UTP-ASE INHIBITION | 3 |
| UV ABSORBENT EFFECT | 21 |
| V-SRC INHIBITION | 1 |
| VACUOLATING ACTIVITY | 7 |
| VACUOLE FORMATION REDUCTION | 5 |
| VANILLOID RECEPTOR AGONIST | 4 |
| VANILLOID RECEPTOR BINDING | 5 |
| VARIATIONS OF CHEM CONSTITS IN CULTIVATED PLANTS | 14 |
| VARIATIONS OF CHEM CONSTITS IN WILD PLANTS | 1 |
| VAS DEFERENS OCCLUSION EFFECT | 3 |
| VASCULAR CELL ADHESION MOLECULE-1 INHIBITION | 78 |
| VASCULAR CELL ADHESION MOLECULE-1 TRANSCRIPTION STIMULATION | 1 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION INHIBITION | 8 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION STIMULATION | 3 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION | 6 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULATION | 1 |
| VASCULAR HYPERTROPHY INHIBITION | 5 |
| VASCULAR PERMEABILITY DECREASED | 168 |
| VASCULAR PERMEABILITY INCREASED | 31 |
| VASOACTIVE INTESTINAL PEPTIDE INHIBITION | 6 |
| VASOCONSTRICTION INHIBITION ACTIVITY | 124 |
| VASOCONSTRICTOR ACTIVITY | 291 |
| VASODILATION ANTAGONIST ACTIVITY | 8 |
| VASODILATOR ACTIVITY | 754 |
| VASOINTESTINAL PEPTIDE RECEPTOR BINDING ACTIVITY | 4 |
| VASOPRESSIN ANTAGONIST | 8 |
| VASOPRESSIN RECEPTOR V1 BINDING ACTIVITY | 17 |
| VASORELAXATION ACTIVITY | 229 |
| VASORELAXATION INHIBITION ACTIVITY | 41 |
| VENOM POISONING | 11 |
| VENOTONIC ACTIVITY | 67 |
| VENOUS INSUFFICIENCY IMPROVEMENT | 24 |
| VENOUS INSUFFICIENCY SYMPTOMATIC TREATMENT | 30 |
| VERBAL FLUENCY IMPROVEMENT | 2 |
| VERMICIDE ACTIVITY | 17 |
| VERMIFUGE ACTIVITY | 605 |
| VESICANT ACTIVITY | 58 |
| VESICULAR-ARBUSCULAR MYCORRHIZA STIMULATION | 2 |
| VESSEL WALL PROTECTION EFFECT | 7 |
| VESTIBULAR COMPENSATION INCREASE | 9 |
| VIRAL ADSORPTION INHIBITION | 29 |
| VIRAL ADSORPTION STIMULATION | 1 |
| VIRAL GENE INDUCTION(ENDOGENOUS) | 4 |
| VIRAL INFECTION STIMULATION | 3 |
| VIRAL INFECTIVITY INHIBITION | 88 |
| VIRAL PROMOTOR GENE STIMULATION | 0 |
| VIRAL STIMULANT | 114 |
| VIRULENCE GENE INDUCING ACTIVITY | 2 |
| VIRUS FOCUS FORMATION INHIBITION | 10 |
| VIRUS INDUCTION INHIBITION | 42 |
| VIRUS-CELL FUSION INHIBITION (SYNCITIA FORMATION INHIBITION) | 12 |
| VISION IMPROVEMENT | 11 |
| VISUAL ATTENTION INHIBITION | 1 |
| VISUAL EFFECTS | 9 |
| VITAMIN A CONCENTRATIONS DECREASED | 6 |
| VITAMIN ACTIVITY | 162 |
| VITAMIN C LEVEL INCREASE | 7 |
| VITAMIN D HYDROXYLASE INHIBITION | 2 |
| VITAMIN D RECEPTOR EXPRESSION INHIBITION | 6 |
| VITAMIN E CONSUMPTION ACTIVITY | 1 |
| VOLTAGE-GATED CALCIUM CHANNEL ANTAGONISM | 0 |
| VOLTAGE-GATED POTASSIUM CHANNEL ANTAGONISM | 0 |
| VOLTAGE-GATED SODIUM CHANNEL ANTAGONISM | 15 |
| VON WILLEBRAND'S FACTOR BINDING INHIBITION | 4 |
| VON WILLEBRAND'S FACTOR SECRETION INHIBITION | 2 |
| WATER CONSUMPTION DECREASE | 2 |
| WATER CONSUMPTION INCREASE | 6 |
| WBC STIMULANT | 140 |
| WBC-MACROPHAGE STIMULANT | 73 |
| WEAK AND ACHING BACK | 7 |
| WEIGHT GAIN INHIBITION | 91 |
| WEIGHT INCREASE | 141 |
| WEIGHT LOSS | 402 |
| WITHDRAWAL ACTIVITY | 1 |
| WOUND HEALING ACCELERATION | 3158 |
| WOUND HEALING INHIBITION | 35 |
| WOUNDED CELL RECOVERY EFFECT | 7 |
| XANTHINE DEHYDROGENASE INHIBITION | 2 |
| XANTHINE DEHYDROGENASE STIMULATION | 0 |
| XANTHINE LEVEL DECREASE | 1 |
| XANTHINE OXIDASE INHIBITION | 1051 |
| XANTHINE OXIDASE STIMULATION | 10 |
| XENOBIOTIC METABOLISM INHIBITION | 2 |
| xxx | 0 |
| XYLANASE INHIBITION | 6 |
| Y-1 RECEPTOR INHIBITION | 97 |
| YEAST SEX HORMONAL EFFECT | 4 |
| YEAST STIMULANT | 7 |
| YIELDS FROM CULTIVATED MEDICINAL PLANTS | 2 |